var title_f24_33_25104="Occl superotemporal branch";
var content_f24_33_25104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occlusion of the superotemporal branch retinal vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 369px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFxAXIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VAzRj3FA6GkoAXHuKMe4pKKAFx7ijHuKSigBce4ox7ikooAXHuKMe4pKKAFx7ijHuKSigBce4ox7ikooAXHuKMe4pKKAFx7ijHuKStrSPDGt6uR/Z2mXUykZD7Nqn/gRwKmU4wV5OxcISm7QV2Y2PcUY9xXpWm/B/Xrj5r6eyslxn5nLt9ML/jXTaf8ABfT1VDf6tcyt/EIY1QH6E5rjnmWGh9q/od9PKMXU15Leuh4fj3FGPcV9HWnwq8J24Bktrm5PX99cHn/vnbV9fAHhWOP91o1uCe7M7fzY1zvOaF7JP+vmdcOH8RLdpff/AJHzFj3FGPcV9IReHNDsbkh9G05k6fPbq38xW4vhrw3PDkaHpWD6WkY/kKKubQp2fK7Gy4cq/wA6/E+U8e9GPevqT/hCPC9yhaTRLPk/wKU4/Aiqd18L/CVwmF05oD/einfP6kip/tugnaSf4f5kS4dxC2kn9/8AkfM+PejHuK9+u/gvocv/AB6X9/bkdQxWQfyFcxqXwX1KIMdO1O0ueflWRTGSP1FdEM0w09Oa3qclTJcXD7N/RnlGPcUY9xXUav4B8S6XuNxpU0kYON8H7wH/AL5yf0rmZEeNykilXU4KsMEV2wqQqK8Hc86pRqUnapFr1G49xRj3FJRVmYuPcUY9xSUUALj3FGPcUlFAC49xRj3FJRQAuPcUY9xSUUALj3FGPcUlFAC49xRj3FJRQAuPcUY460lL2NACUUUUAKOhpKUdDSUAFFFFABRRRQAUUUUAFFFFABRRS4oASitjw94c1PX5/L022LqDhpW+VE+rV6loPw007TtsuqSf2hOOdnKxD8Op/H8q562Kp0dJPXsdmGwNbEaxWndnlWiaBqmty7NLsprjBwXAwi/VjwPzr0XQPhIW2ya7f7R/zxtRk/i5H6Y/GvQ1laCBYreNIok4VEXaq/QClj1BkI3A+9eXXx1aa/d6Hv4bJaMNanvP8CHQ/CehaPKRZ6fD5o5Esg3v+ZrpYpcKEzgDsKx4rpZ5jtPJHSrKSkMM149eU5P33qe7Spxpq0FZGkz5GfemrIQKriUFT70kj4B5HFcPO9jpRKZ8k880z7QT07VU3EsSRgZ4pC5HTjvWwLQtXMKTwYbh+xrGju5bCRkcnYePpWmHJHoDzVa+t1uIj2PY1tQrJPknsy7XNKC6UxqUOQRVqKcbRzXG2N01lcGCYnYTge1bkU4OMEVGIoOHoyFvZmuZueDweDS+aB1NZwm9T1phnPTqa54pmrRqicEj2qlqejaVq8O3UrC2uB6yRgkfQ9RVZZ+i+tWknA71d5Qs0zOUIzVpK555r3wf0y43Po91NZSdkf8Aep+vzD8z9K8z8ReA9f0IM9xZme3Xkz22ZEH14yPxAr6T87GDmpUmU4r0qGbV6fxe8vP/ADPFxWR4errFcr8v8j4+xSV9NeJ/AGgeIA8klv8AZbtsn7RbAKSf9peh/n71414t+HWs6BvmjT7dYrz50AOVH+0vUfqK9zDZlRxGmz8z5zF5PiMN71uaPdfqjiqKWkr0DygooooAKKKKACiiigAooooAKXsaSl7GgBKKKKAFHQ0lKOhpKACiiigAooooAKKKKACiitrwx4cv/EN55Nkm2JT+8mf7kY9/U+1TKSiry2KhCVSXLFXZlW8EtzOkNvG8sznCogySfYV6R4X+H0abLjX23P1Fqh4H+8w6/QfnXb+HfC+neHrUraKXuGGJLh/vt7D0Ht/OtMKjIfUV5dbHc2kNj6LCZQoe9W1fbp/wR1i1vbQJDbxpFCgwqIMAfhU08wUA54x1rNnjxkLwRVWWWSMYbPFcDgpO6Z7MVy6GsLkBAMcGpHWORMYwaw4bnJTByM8irMl0FkUg8YrOdJ30OmC0HypJBKskZOBWjbXgukA6OODVNLhJo+eg6ioJIzBIJITleuRWUo+0XLLc3STRtLIVGKRpeefSqlpeRzDEnyuPWpyNxAz9MVxShyytJDWmhOCWBIPSguM/MKgJaNCRk5xxT3PylW496nl6lpkpPygg/hTnbEYBPWqck6pHz19qZHKZ4xknrT9m7XewlJpkGr2wmjDpw6j86h0i+BPkznDjgE96vuTjB544rD1OAo6zxcEHPHau2jJVYeyl8g57s6QPz1psrnAxWfp96s8Kgn94OCKtM/UZrllBwlZlSndDxKcnPBp0c56Z9zVXluh57UxXOc1XKmjDme5qCfI681Kk4x1rJVyxyKnD4HHX1qORI13jc2VnyBk809ZA82DyAKyY5+fpU1tN95v7x4pJONwpvm0ZzvjL4b6VrwkuLILYag3O+Nfkc/7S/wBRz9a8O8SeHdS8OXv2bVLcxk/ckXlJB6q3f+Y719Qwy5wM0mp6fZaxp8lnqNulxbv1Rh39Qex9xXpYTM50fdnqjysxyOliLzp+7L8H6nyPRXoXxA+HF34fMt9phe60scnvJCP9r1H+1+dee19JRrQrR54O6Pi8RhqmGn7OqrMKKKK1MAooooAKKKKACl7GkpexoASiiigBR0NJSjoaSgAooooAKKKKACiiuy8B+D31yVby+Vk0tGxxwZiP4R7ep/Ae0VKkaceaRrRozrTUILUg8G+EbjXpBcT74dOU8yY5k9Qv+PavXrOCHS7aK1sYUht06Kv+eT71eRYbaBIoY1jhRQqogwFHoKhmXehAHPb3rxa2KdV67H1mCwMMNHTV9WTM29Qc8Gq7FlPB4NKG2xDPf+dV9zSEkZwDg1ypnpxRJv8AMYNnleopWiEqkgfKKiVWjIHc09ZfKXA5U9aiTtsDjYyLtXs7gkKSh5pGcyMrK2M1eZhNlHGeentVd7LaBsJ2+g7V0RqL7W5aWhZtjgdcHNWEuAtwVY/KegrHkW4jY+WNw96ak028M68+9J0ubW5pex0BsVlTMbbT6VCVurU5yxC1Uh1CVSdycDuKtf2irxkE7XPZu9czjVi7PVG2pZi1XbH+8XnvxUq3sUhB3YPvVB2idF3AZ6EimNaoykq2O9R7Km9WrDsi3ORIXIx1qa0Ubc55z0rKCS277gxI961LW5j8vDjEh6GnVi+S0dSGnElkODg5qN4Q65bn2p6ne2GJwKUg5O3jFcalyvQSWph6hayWUq3FuTtB5FaNpci6hDr17juKtTBXjKMODwRXPMJNKuywy0DH9K64S+sRs/iX4mnJzI3gDjr9KiPMrAdxmpoJUnjQoQQRxim4Dys47fLXOpNNpkun2CFgrVMOVGTzUWNo96RZMDB71Ld3dBF3VhzuVRiOvSrEcmFWqVwcRsT0yKcsoBq2rrQpWiasMvOO9XoZSFrDil75PFW4pyMc4rGSZXObatlcHGD1ryT4k/DQSCTVPDUIV/vTWSDg+pj9/wDZ/L0r02O4ztBNWo5Nwwa6MLiZ4eXNE5cZhKOMp8lRf5o+RCCCQQQR1Bpte6fFD4ejU0l1fRIgt+BumgUYE/8AtL/te3f69fDWBUkMCCOCD2r6zDYmGJhzR+aPgcbgqmDqck9uj7jaKKK6DjCiiigApexpKXsaAEooooAUdDSUo6GkoAKKKKACiitXw3o02t6nHaw5VPvSyY4Re5pSairsqEHOSjHdmh4L8Ntrl55k+5bCI/vGHBc/3R/X0r26zWOG2jhiRUiRQqqowFA6AVS0+yttPsorW1jCQRrhR/Mn3PWrYcCvDxWI9q/I+vwGDjh4eb3GXrlVBHIqO1l3EA9frUsieZGy4x3BqtHGYGy/Izge1cyacbdT1FEs3Kkx/J160xCIk5H3uakLfJ71C4Y4J61ipaWZdrMkQ5+ZsGqt44428ZPNTFtuSWwM1WuZE2fMR60Q+IJbFUybG+ZgPenC8HTOeaxLi6UznjK5p6okgLLIEx712Okt2XCJoSXrb9seSTVdtRyAdpNUAGJYMfmz1pUGSUYY57iqUUjb2aZs29x5kYO2rKxLJgnP0qpp0fkSMoIYeh61p4QsCpwcVzVJ8r0L5SE2RABVsD8aVYphwpLfrVxXBABYHPYUJOhJUkgA1h7afqVyFTzLhSQ8fANWvIMiZUYbrj1qTIY/KflPWpo3CMePl6c1nOs+i1LjBMp292Y/3b9R0PetCCVZVUdSKx9Uwk4ljOQ3OD6j/EZpGuGs5VmHMEnTHbNOdJVFzR0bG6SvdG+yDBPXFUbyBbmBkIwMfiKmt7lZV3I4YHkVKSpG4cr6Vxxcqb8zGo7bHM29zLpkrQzj5OoOelbcE0Txr5bD8+tMv7dJ428xNy9PpWY2ltD+8t5DtPQE8V3N06yu9GUpJo1pm9P51GXO7tWPLcXNnjzVLKT064/Gr9vcx3EYZSOOo75pSoOKutUYzi9yeVi7LGDwOTTqaisME/ePJoUnPNZ36IXKyaNiB7VYR849apg88dD29KmDEYHpUtXLULF2Nz61ft5M49ayY2zj0FXonwB61lJgo6m3C4K+3avKfi94DFwkuuaLEPPUbrqBB/rB3dR6+o79evX0mCbjHOavRNuUcAkitcLiZYealE58Zg4Yuk6c/wDhj48or0j4t+Df7IvH1bTY8afO/wC8jUcQuf5Ke3oePSvN6+xo1Y1oKcT89xWGnharpVN1/VwooorU5wpexpKXsaAEooooAUdDSUo6GkoAKKKKAJIY3mlSKJS8jsFVR1JPQV7X4R0KPQtLWNgpunw07jnJ9B7CuW+F2ghy2r3S5AyluD69C39B+NehTfJjmvLxlfmfs4n0GVYTlXtpbvYZ5uTgU8PzntVMswJOOO1S28vmY3DkVwTjpc96BeVsqMGopHwcMMk0gfBz3/nSkgMSxyTXLsdMSLMhPDY/pTiSUyWqKaZE5zz6VTnuSyHYeM9q0UHMpalyWbcQuR9ao6lKqwFiAarwz73KsvvzVe+kEnyZIx2xW0KXLIbj3MwsS5G0ZqWKCSTcFUjHWnRrgjuevSrMcxQ7jwO+0V0OXY6IFV1ZACDz6VIJyhX5RnFaMTw3EpwoPTqKmktUZ+SMYwMisnUto0axavqJZTecQNpUnvV+MSKwwVZTUEEZt4zsG7PUVds/MWItIqr+NclWe7RpZLYcE/dkng9gaY4DEc59qu5Rk5AqvKi7lC+vGK5oVbvUlPUbDGyocsdp5+lIs2VCE8Nxmpd58vjqeKqLIhlPHGPxzVK8rtlpPoT3MJaAjglfm6+lO0ZlnspIpVBCMRgjt2qyQDEhPPvWbbTfZ73GAQSVJHTI5H6GoTc4OPVC5XKLLUujoB5llI0bf3ewqrDfTWsnlXgIz/GOlb4wygrxVe7t451CSqGGcEkdazhiL+7U1X4mTfN8RHG6TR7lYMpHY0kYxGAecdfasi5027sN01izFR1Sp9L1eGUtHP8Au5PfjmtHSvFypu6/EmVFpXWqNF7dJFw4yPSucv7Y6dcrJCT5Z7Z610qybxwRjtis/WI1kt8jOQaeFqSjPlezJTa3J4pBJEkinOQCaQ4J/wAKraQWktEVv4R0q0CA2COe9KUeWTSLtoGR1607cAOKhDEcAUuePepM5TtoixC4DZPA61ailz0ORWdjL+mBUsTkEDHWlKNyYz1szZgf8K0YJOeprFjbPWr8LkYxWDNk9C5c2dvqEVxaXkQkt50KSIe4NfMvjnw1P4W1+awl3PAfnglIx5kZ6H6jofcV9MNKVZZF7VhfE7w4nifwq5jUG+tsy2zd890+jAfnivVy7FujNc3wvRni5zgli6XND4o7f5HzHRTmUqxVgQwOCCOQabX1R8IFL2NJS9jQAlFFFACjoaSlHQ0lABWhoenSatqlvZxZzI3zN/dXufyrPr1T4VaOILCXU5l/e3B2RZHIQHkj6n+VY4ir7KDkdWCw/wBYqqHTr6HY2cUVpaxW9uuyKJQigegomPmEg9qncAZC9agJJXpg968By1ufYxjZWKuDkjNJE23dxUhYA9fxpoQhgzHv+lPm01NY7kscm0Aufx9KWR1ZlZSPQiq12QyhVYgio412oeSc1HJpzG62ElaMM3t2qg0saMxwcNweKfK2WPPzZ61HP5YjDKwBHNdMVbQcWPJhwOfoPWqctwPOJBxg4HHUVPG0TfMccD61UuZUZxtAC9BgULc6Ei3FPHK4UHDAdAKsC3Q85zx+VZbz/MGiTaPp1rWtpj5QAAJPcDHNRNOOwkrD7RNjEbOM8YHfFWFdi+3nPUcdKSO4iSP5jtcHpmobi+iyG3/dI4B61j70nsbQTZoJE7LnOCO9MdpwNoUHnsf61Rh1OLDq5YZPBq0LyNowqMNx4xmsnCaeqNrNDY76WOVopFIU4Ck+tXrVVmlJPylePxrKE8sUzK6h0Y8GtWwLmNto3ZyTupVlyxbWhpbqiW4YwxsivuB6VStIJJJN44HIGe1Xmt/m3u2T9elSLAAdyHr09q51UUY2W7BSsEdswiwzn6VWubDzEzHnzF6gnrV5HIAVuPrU0QwM/ezySe9ZKrKLuZuUlqZGn6m0Li3uuB03ensa2FYbhhgV7e9VdTskuYi2Asqj7wHNZkRuLIlJfmjz8vv+NW4Rre9HR9i2ozV4aM6COUMcHgjoDVHUNJtbvdvURy9d6cfnTbW7juAHRs+qnrU28t8pyfTFZJSpy00ZinJPsc6632kyH/ltCD65Ip1xqcU1tjcwckYGOnIrfVSeZB83YkVn6hpUN1CzRIIZhyVHQ11wrwlJOa17oJVYPdEGjOWhZgeN7H6c1osRjNcnY3c+lXjwzIdhPKn+Yrqo5I5YxKjDawB+lPE03GfN0Zi5u9hjZ3Zz19KepCjLdBSEhsBRmgKzNkjHtWHqZJDNxZiTxmp4gAwzTPLy316VMke3nrSlJJE7F2Nhnmp1kOeDxVGNsNz+QqxFzgdqw5Lalc+hpQybwM4qxC27dHz5Y71ltKUAVfvNWrAoS198c1vD3FfuTFt6Hhnxo8OLpmuLqdmm2zviSwAwFlHX8+v515xX1b4m8PJ4l8L3untjzJF3Quf4ZByp/Pg+xNfK00TwzSRSqUkRirKeoI4Ir6fLsSqtPke8T4zOsJ9Xr88dpfn1I6XsaSl7GvRPHEooooAUdDSUo6GkoAt6XZSahqNvaQ/fmcID6ep/Ac173ZRw2trFbwDEUSBFHsBivM/hdpplvLnUXX5YF8uM/wC0euPoP/Qq9CMgGRk5rysdPnlyLofSZRS5KbqPd/kXiy5xmopO5FVWl4DDp3qeNw6/WvMnHl1PdjZjDggDbUUkqqMEnIqf1BHNVrtBIpA4anBq+o9hNqH5jzT2UbOKqwuV+WTqKR7xI1OG4HaqlGTdkUpFa7VVYtwCc9ay7ybcQo5P8q0XuIp3GTkHpms69xHKdo4xj6V1U+zNLa3H2hPHAOOoPpU7RxI/z9D2xVCGfb1z+FSx3aIeQWz60Si7myZbSVCwCxn5e54qZleRg8Z2AcHNVVnWRtwJz/dxgVoW8wc4HT1zWUrx1J5rMpTLJ5m1AWz12j3pfLmmb/VEg9M8YrUmQRqzIwBIyMjNUornGXM3P909KlS5ldHRTqNrQrPbTgkKnTnCnNPihmXJaPt19KUXZEzMGGPTpTpLxHi2EfMepA6im3J6WOtNixRvNPsc8dCetdFpkirCI1BJUYwetYNtbbpFkhJEYPPqTWtaK/2gjA55zXNiEpRsOVm7XNGUsUZUADe/FOt90aqrscgYJNAXuQfengZBJOB2rz29LE83REe5ScEjd2xUkchHHCj1qjGGNy7nAHQGrETSbT5lVKCRNXaxb84sQDtNS+UjQ7JAGUnHNVlQHGPlPr2q2M7QB7HI6VhLTY5zLvdNRRmAsnOcdP8A9VJb3MkDbLgHPqOtahjLA7jn+lU7uDcCMcetaxq8y5Z6mrn7vvFhJFkxjkdc1FOvlESIOAOR6iqbRT2h3qxKf3h/WrcU6XUZVvvdwP51Lhy+9HVHJJdVsVdV0wX8GePMAypx+hrnLC4ezuvKmBCE4IJ6Gu3gG63G1s7TtNYXiKwGftSDAPD11YSum/Yz2ewltY0Yk+XK9Mdae0Yxu9e1UNBuTLbmJjl4uOe4rUbI7HBrmqxcJuLJvYiCdyMClAxmpGXjtn2ppUiovchsRV5OasxMI8ntjrUUak4GM80tySWSJRy3J+lWlzOwJ2LNkhkdpD3OBmtGWRQUiB6cmmQhI41IGMCoLbEtwWPOTxRGXPJyeyKjodHZ4EKqOtfPPxz0AaV4s+3wJi21JTL7CQcOP1Df8Cr6BgYg4rkvjJoo1jwNdSooNxZEXSH2X74/75J/ECurLcR7LEJvZ6P5nDm2G+sYaVt1qvkfMdL2NBo7GvsT4MSiiigBR0NAoHQ1Z022N5qFtbj/AJayKn4E0N21Gk5OyPW/BFsLDw3axkAPMPOc4wct0z9BgfhWhcKUkzzj1o2qihI+AowKUHzEZHJOOhrw5v3nLufa0qahBQXQYrLtGDUsThWOG4qi0bq/yDp60PMo4JO6olDm2NosuNLl/lyaVpAo+Y81myXDFcj5QOpqm08s8gRGGOmTS9hc01ZozyLkkAsT6VSNoSCxfjsKsrGxjCk8HjI708QfJzwPemny7FR0MknY42ABvzFKts85yxx9RVtgiAA4A9elKrsXyv3M9T3rRy7F89tilLbxQrjkkdcmqO45yBzmt541YZGOe9U5rEb8g4B5+lKNRPcdOd9GZpZ2bP8AKrFpM6n7parRs045PTvWjCqRxgKF/CiVRW2NHJIlSbzIhtiIfHQ1Ta0RCWkG0Z6Z61Mz/MD6d81DJH5hHmElfc1klbY0pTsQXDQxNiJATjrnNQxgM+SCAfSrzwQr90Y+lSwwssjZ+6f4TTvodcaqSLcUBSNWDMDx3x+dTwTbZPldS+ec0R22IuJHz1GefwqqdqTNlypHOcZrGyknqEHdm6kwRQ+c56+gpI7pJFGePmx/9esKS5ZY2ZJecHjFR2t2VR2djnG1SOhrD6qmrlNpHQMYnmVN3zdeKtBSE+ZQOeMVz1hchLkB1ZBjnPc10UC+ZtwQV69eK5q9N02kRJN6k0a7uo/wNTGMBcg4B7Zp0YCptGP8KY4Ckk8k1xt3ZMYakJVt5A+72FOUEcYxn9DT1X+LsPenqdxyf1ptjqdiPAIKsuQf1rIubZ7SZXjbahPX+6ff2rbQ8kj8T2pk4V4yrKDuGCD3p06jg/I546Mh0596ZAHzdR71LeRb4iki/IRgiqdnIIJGBbjof6GtqVdyKwIKkfnU1fcndBNcuxw8W7TtR5BIU4PuK6hWD8r3HSsjxDbZkSZQcN8jVY0WQyWmX+8h2n8K7sRarSjW69TCTNAAHnHIobAXIx+NTImUOTio50JQIAMdc1wQ96VifMfGu1d/41BbfNI8z9zgVM6slvx1xjFULyWSGzBUYJ6GumjByTS6uwM1HnxETgZPAp1gWBZj0HFZVn5s8SAtkkZFX0tpQm0kitXSjTXK2Ck2bUV3HF/rHH0p0tw9/E8Ma/umG1s+hrMtLBCcyszAeprdslSP5QMD0FZx9nT1jqzS7eh8keIdNfR9cvtPkzut5WQZ7jPB/EYNZ/Y16X8fNM+x+MY7xFAjvYFYkd3X5T+m2vNOxr7LDVfa0oz7o/PcXR9hXnT7MSiiitznFHQ10fgG3E3iOJz0hRpPxxgfzrnB0Nd78LLbc2o3LY2hUjH4kk/yFY4iXLTbOvAw568V/Wh3G09RzSO4Uk4P0p7sq8LVdnV2I6V42+59hFaEE85K4QYNU3Vg+SQfU1feMAZxkniq7xqT0IrSLS2LRCyl14+5jBqSKJVXqMDnFKI8qQgx7U6EFfvDkdDSlLQpOxahZHOOnFKy4Bzz6e1QhVDbh8rdqgubhihCnHFYJOT90LkcwBcsBvI6CkZHkUE8D0ptu4bKAdB97samyNuBWrfLoNsZIwiQe3cmmCQsMkg/WlncMB8u4+9QllGTgnvjNCWgovqPJcg5XK9Bg1YhBC4JB+tVoQ8jHdkRkcEVfRFEPJ+nqaUnbQ0c7kUj+X1G73qCSc56gc561bMWVJfkHtUP2SInJyPQZoUl1KjLoJFKNyhjjvxWhav5yggk4OcVFCIgW3BcY5zT4ZY4ioXOD0ODWU3e9kdEdUXJC7EBAyj1GKrT2rbmd3LLj+7nHvUocn5lc/TpUsLykncR+dZJtbG8JcpW+ygxgKzDHoMCqE8OQAcD1KjGa3nilOcMNuOvc1Rlt2ClRyT15ranK473ZQtCVkCsx+Ug+9dbaHaqHGTjqRzXMtZmWcLGhAXgEd66azjbyVXByAO9cmNaaR0KKSLgk5znpQjFz8360ixDYN3NDbVOc5Xv6ivN06ESkktCzjCngCnxrknPGRk1UiuUcFYlZh0z2q1GjMQJDj/drKSa3MX5iLtTheW74qFbZ5DufjnpnpV9UWEcY54yO9SrFmTn0rP2ltjPlKcuniaHaAA/VWFUNOnkguWtboYUHH0rqIYiF6ZB6VWv9OE537QJQOD6+xqYYlawnsxxlH4ZGVrFpu0+UKOQNw/Csnw/jzbmMnjAYDNdBYyrIz202dwBHPpWA9vJpmqBpFJjBIOO6mu/DNypzoPfdCdBvTqbhjZRgdD3phgbqWyKuQmN4wycqeQQac4Ty/mO09hXFCo4uxCot6GfOCtu2eSBWbqlwklokad+1bUsJlhdjxGBWTpVj9puyzf6uM559a9LDzhGLnLoU6XLuaWl26wWcYYfPjJq8PmPTipFiB4A6U7yx34rzqldTk2yeQj24PFXLUHcKgIHQDOPWp4G5+6RirjPQlRszzj9obTvO8O6ffqgLW9wY2buFcf4qK8C7GvqT4sWi33w81dWBzEizr9VYH+Wa+W+xr6/JqnPh7Poz43PqfJiebul/kJRRRXrHiijvXp3w0i8vQJ5ScGWc/kFH+JrzEdDXrfgCLb4Ttv9uSRv/Hsf0rkxsrU/menlMb179kaVySOhrNeZkJ3dc+ta9zGOuOMdaoSIr9RiuCElY+l16CRXBYfL+VIjOZMuKr7fJO4HpUyzGU4VTk98UNdjaL0LQyp3DGfTNIzk4wKpyvJFIuWHJ5HbFW0IZQQawlG2oCSLvTGcHsaoXCAgKMkD9avuBt61X2DcT1OKqErCuVUjYdWxnipnDgdR6U4le/bsKdtJXJAAq3ITehSecbSMfX606EhcAjIouo1U5A460RODzg8VTs1oZ87vYmeRlTBHJNSwyDZhjyD3qLJfA4wacYRvGOcVGlrMuL1LBmUxgfMSR2qm16AxUK2fyqfGwkgYxwKmhjEjBnHIpaRVzpjJXKiSvwxQquT94U1L2dZHBKkZrXaVQAoAI9xTkh3j5FB3e3Ss3UXVHXCSIbIyTlSw3IepDVpJFz8uce9V4EePh2HXtxWjC3TB/SuapUs9DRNNkyRExHdwcduaj8uIkAjkDrUm4559KbwoZznGeeM1h7SRqrdBUUIc8HNTxybMlyMelVI3MrfKSg+mKtwxIG4H4msKn94mV3pcsiZnH7uPPuxxTTbPgGVt2e1SqvPXHfin+XnO5mOK53K2wp7WG2ygAgDGCcirkTEMeDxx9KrrGVkVi3JODzV6BdzHBGTWNR9SRwA2gtgLUlnN582ERiOgbsaS9hLweWp5PbpW74bsfl3FcKoxyK461WMKbkzKpPlVyxBbCGAGQDd6VBcR7ugrTuSWfCr34Iqu8Bc55De1eZGo78zOaM+rOS1uzeORbq1X94vLAd/eq1xqFndW+24hYOBz7H2rsTZSTyqFIBU/eUU278OQSKWliUvjO4DFehTx9OPKqm62a3O2ni6aSjU6bWPPbK4kjmeGyRyh6Fx/KteC3YHdO29zzjtSJbS/aXkB/dA4UVX1K7bAht8l24OK9iperJKn13Z6EvffLT07jr65a6P2W1/EjpWnptstpEqLz6nHequn2i2sABbLnlj61f8AMVFxySe1clepp7Gnt+ZyVWm+WGxMygdKjyFznpURkmk+UIB7ntTDBlszMxJ/KueMLaSZlZjjIm/CEsT6VbhEhGcBRVdIwrgjge1WkkJIGOK64zX2UQo9yr4gtftfhzVYD8xktZVAPqUOK+Q+xr7SiAf5WAweCPavjGddksq4xhiK+oyOfNGa9P1PluI4+9Tl6/oRUUUV7x8yKOhr2HwSwHhLTwDztf8A9GNXjw6GvX/BQC+E9PbP8L/+jGrix38Nep6uUfxn6fqjWlDHjtVOWMBuOnpVl5Vzx2qNiGIYDNeYm0fSIo3Sqe3NEPyJgKFAqy8Y68g0gUAdOlXzqxaukVLu3MgDZ5FJAjICCx/GrRcA4b8KqyqVHyvkE5FEW2rMbZI8gX7xyKhdycYOAaQRNJjqfWpkgG0jPIofLEzu2ORFXHrTZ2PAXgYqtcs6dfzotyx6tn0zRyfaJ5rkUhOOTimKvBDHAqaQYc5+tROCevStET0uPimBcKB2wKsqzK2QeKzoSVfdx7Cr0JMow3A70TjYqlJtakqTRsCScY65qxHMDFlQQP51XSFF5NW7dEKjgYHasJuKOqNiLbcO+47QvbnNX7QyqpDYA7Gk4HAAx1pQ6jjoRWMp8yskdEWSsC+OcmrEWUAyeTUEZLKdvFTqrEYJWueemhormhaFPvSDOMYqW4uY5TtZF2g8YHNZjCToHwvsKsohwB3/AJ0c8IxNFCV73JQAwO0jB6Z4qzblMgFgPr1qqBwDgEjuauQcL8nf2rgmaxSY5n3NtjIwO571LvdGGUyp6labsIcZ61ZCkN8o7daxk0N2I9wdkJOFB61bt5oRIR5g46CooAAckD6irCnMgBUMp9hWM2tiJElpK1xePwCqgAf/AFq7G0iNvp2FHzMOvua45bfypw9thSTyCMiuvjmvF01T5cLqoBJyR3ry8bry8uxxV09PUUDPY06NWc4UDHdif5VCrXLEh7dc9DiTj+VJm6DBQYUx2wTXDysyaNu0gVF4x68mpLzAjJwBx1zWPHJcBsm4U+qhOB+NUdY1F5LiKxVwC+NxHYVlDDyqTsmYRoSnPcxL6z8zz5I5NqkkkKKr6Za24VpY/mlHBLc4rYngSBW2E7cYcH09awrEMmoyxRY54ya+kp1XUoyUX/XmezSk505JPYsOm9ysShSDywq3b26JGcg7qelv5aY6nPPvVpPkjJJ4A44riqVb6RMJ1OiKGcP0P4VHgsT7cVNnkkmomHByetUmNCBBnJ/SpIhg+opi9cVPFwPeuinOSNUXLf7wNfHOsoI9Xv0H8Nw4/wDHjX2HD94Y618ea0wfV79h0a4c/wDjxr6vh/7b9D5biNe7T+ZRooor6Q+VFHQ16x4EfzPCdsv9xnX/AMeJ/rXk46GvT/hrOr+HZYyPminb8iAf8a5Mav3fzPTyl2r28jbuIypIWmROwIUq1WZ2DAt3qqJgH5zXm6tH06LAYchhUDA8lTkelSE7lOKY/Ckd6zSNLlKa5PmBGTrUgUEZNMkQEZwCaikEpAzgJ9ea2snoiWWlYD7pzUqMrDisR5GhdjVmyuw/B4yamdLS6IWpoPGrDDdKzy3lSHJ6Dk1cMoAGfyrMvCxDkdD1FOkm9GD93Uk81GGe2PypkzCMqByWqrFIu1iR+HrT3djErY+YHqe1actmVHlmrluOMNLz0x0qzseNQIx/Fz9Kq2cn7tCTlhk0r3jB9u36+1Q027IOVQZcO5hgcCrUORiqkD7gMDH1q3DlQPSsanY0iyymT15qRIRjBx9SKSNhkY9KsITnGDz3rjlJrY6IsVVC4A5x6VKo5AJPTrSoo4B70/A49q55SOiKuCrgg4GKnReeTTFXJBxUqA7gASc8HispMV76EqJ64qxEcuMkCoCAg5yTUir07cVky1cuRAljk5qY5UcHk/rUETjaDuGB6VIWd0GUO761hJamj1AN/DT93KnI68mq4EinLpwR25p+8nH7t2J7dAKTQmWJLxkkQBc5I79a9B0WVLiwVTjO3BzXmz4Ybj8rDgg9R6V0Xh28yqhXxn1NefjqHPTTXQ5MRT54nSXYxkqSRnBx61RdyO3Fa1rCDvbIIk5wezVRvYCg4Ge9eTTkr8py05K/KUftBXj16VzGq33keJUlY/Iu0Y/Ct6XKk5PJrnPEVmZ4jKn34+fqK9jARgqnvbNW+89LCcqnaWzVjdnlDHJPBH6VzSXJTVC8ZzhsDNPj1InS13H99jYfw71Z0exDQs0qg+Zzz1Arrp01hlL2nodFKKoRk5+hc+03oH+oBHbniq7a5skEN3E0QPftS3EU9i+VJkg7j0pZobe9t9vUHow6ipiqLs5x919VfQzkoWvbTui0JlZAVGV7GlJDHjmsGCWfS5PLmG+DsfStaCeK4XdG2f50quFdPVax7mfKkybv6VNHlveoQCDggNVmJl6dD70RXYvYswDkZ6CvjO5bfPMxOSzk59ea+wNYnNpoGp3IPMVrK457hCa+Ouxr6zIVpN+n6nyPEkrypx9f0Eooor6E+ZFHQ13/AMLJiy6lanphJB+o/qK4AdDXU/De58nxKkRJxPG0f49R/KsMTHmpSOzAT5MRF/L7z0x7cc1UktF3kkmtZ14ziqsiZFeEqjR9eo9SptC8LUUoyOOtTuOOtN2jpzihStqNJlPymBGDlfSibC4DcZq4FwwAHFJIoYfMv51XtdS0royLqIFPl5HrVBInLKQOfQVuSIMYxj2qLywmQozW8auhN0hsSksQ3YCiaFSp20B2BOR9KZJKw5IwKVncNDLnjEbnHU1GZMEA8jHerFw2MM68emapKyuwBOK3Wo0lHRF+1clwFPB9KuxxoWywyfes+MvAcrGSPWtG0ZnHzIVB9T1rGd1qjV2ZPGRnA/lVqPpyQBUSA5zip1+bnFc0nqZ2J4x3BOKuQ8S4J4xkVTj+VvlOPapxPyuRgg9fWuaab2N4KxeBCnjr7U+NcdearK6swJbBHvUsb/NXM0zoi7bk6vkkY4qVCQ2e/rVdH2sCcc8VLlgx5PNZtGqVkW0AkHBwx9Kf5IOWB59OoqGzfkY47dKvAkgg5xWMm4sdrkEEZR8svHer/G3ORjpUCryR6+9KVwMEe+Kyk7sS0LES9gPlqPgnjgj1qS3IyRu+X0NR3IAYlMnPftWa3sFiKYggyLncOMeo9KksZ2WQNHwoPIB/nVZhIpAHQ+poSJ8kttUjqR3rRxTVmS1c7jR9XjZdkjruHfNa0lwjx8OjAe/NebCBRICpkz6jite0JAC7iR2rya+Bhfmizmnh03c2L1oC5PmKAPesydlIOM7ccseBUiog4JJI79aw9fv5ZZxZQkEnGSB3rXD0XKSijalC7sjGvMNfkwf6oH+VdfpF/DPbgpjIGCvoazxZRWulukgBYjlu+a52Ceexujn74646MK9aUI42HLHeO3mdFaSqR06HcZ3ltxHzdqzrmAwkSQZX1HanWV0l1ErqeDwRnpVp+RjqK82PNRlZ/cYRbWxSheO6j2ygZPY9Kgl0ySFvNtGIx/DVxrVSSVOG9fWpYZGQYk6V1wquOtL5o0snsU7a/wDmCXK7HHfHFbMZBAxgg9CKqTW0dyp3AE+tRW6z2D4b5oTWsYU62sNH2/yE7mb8UbtbL4fay5YqZIfJXB6lyFx+RNfLHavoD4+6ksfhGztY2B+1XIJ9dqAn+ZFfP/Y19Zk9PkoXfVnxOf1ObEqPZCUUUV6x4Yo6Grui3ZsNWtLoHHlSqx+mef0qkOhoFJq6sxxk4tSXQ+g5DuUMv3TyDVWbJIA4zVHwpfi/8MWUxJLonlPzkkrx+v8AWrzRFuT+VfNShyyal0PuqVRVIKS6lV+G45Jo6cdKlePBy34UhGPek2aqJEMZNMY54px4OaYwyM55oGn0ImXJODUZXk4qycDHSox3qk7ENIiZQwzxUUg4II4HarCruycj0ppjye2KrmSE0ZNxblkJ75qK2047t7dBWzJHkEAUIgCgDmtVWaQEKR44/GrEak/d9KXHNSIhJ6YxWUpFxECYHI4qWPrgetL27YoXIfOOTWTdzSy6D15AHcVMi5U8Zz2qNfcc9eanUjAxWUmONhViQDpzUkIbcyHPy/rSjKj1PakdGGZFY7wPz9jWV77nVGzLEalmwQcjpVuPIx0BqnFIWRCO461ZRQfXH5VhLzLiyWMMrEg8HtV0viJecn6VXtsFQQBwBmreCyYB49BWE3rqOI1GkWTCjGO56VOUZzuZufaoN2TtFWo8lRk96yloPQFULyMsPU1K5DYX05ozgZAzxSRnH3gKybvqIVossQR05prxcYznngAVOAWBKkLnpzSj5U29anmZJAIWxgnGKlDeWAuT+NMmuQgCIuWPQVDJExQM0mXYdu1Fm/iCxZN26KxI4HfNY2ibrrU5bmT61Pqcfk2cjb2zjABo0CB0tN4YqzHpitoxjClKS66FJWi2aOtEmxIU9xn86z9SsvNt1lj5ZRnHqK0JopJo9hK7SOaihgdbNY2bLJnB9RWdKfs0rPVMlaIyvD8pFxsyTu6iunXknGK4uz8yO+Vozg7iBXW2kvmDB+Vx1BrfMafvqa6oHCxYZgenGKTaGG04NLkEEEfNmlQZIIrzU+XVCiwjDwvzlkPpV8Krx/3lNRRrn6elKytb5kQ5jHLKe1dlKXtX2f5lS1PAPj5eB/FVtYxtmO1twSPRnOSPyC15l2NbHi/VTrfibUtR/hnmZk/3Bwv6AVj9jX6Fhqbp0oxe9j84x1f2+InU7v8A4YSiiitzkFHQ0lKOhpKAPQPhVfDz7rTpGwrjz4x7jg/pj8q9CkGCfb1rwzQ9QfS9Wtb1ASYXyQO69CPxBNe6ZWWJJoWDxSKGVh3B5Brxcwp8tTm6M+pyevz0fZveP5FWQc0zHJPUVPKuDz3qFhwRXnnr2IXGccU0gcjtUrqCflpjcUXBorY5I9DxTWHzEVKVy+V/Ghlw2eMGtLkOLIUPJPr2peMkUoUBiv4inBfXrQ3qGozqD6U5QNowOadgdsYFIOM5qb3GkJsyfWnx/dyfpTwpyMcUwZ3MV+6aLl2sPOCcdKkGCg4yRzUYUnjvmrEa8ACs5OxUdyPgke3SpolOBzjNR4YEjAI71Ih9DhulTJ6DUdblkYxgdacp4O7ofWos8+lG7Ax2NY2OhNITDxLiKQbewYVaiuhgeYkinGMAZFQpw+4nk+1Wo1BX3qZNdTbmb0Y1HuFAKxKB33NVxbi5EW0xA/7rVBGRyrc1ahAK7QKxnbqgTsyNJ8ybZVZCePm6VpRyjZgMCBzxVQY3EMM5p0MEMgyAyH2OKymk9y9Ll55dse45ANNU/ICT1qnJbsMIJ5MH6cUiW7ltgmcgVHJG24rWZqRTrt2kYpstyifKvzSegqsliGG5pHIz61b8mKAjao5/WsWoJ9yeoyGEKTNIct71LD8zNlcZ6VIF3Ec5Yckdqe4Crk5Bz1qHO+4XMjxEwVI4wep6VoWi+TbxIBnArKuw17rQQYKodv8AU1uIo64xitKnu04xfqVLSKQ4MwckfdxgCmtkK38qk52kAc1BfMYLaSTIwEOa54q7SIWrsctYtnU48dN5rqZVORJH98eneuW0cGbUIlwMAFjXXRxuoGPmFejmL5ZxXZGtT3WOhfegbsatxgcZ6n9az7dtkkiYOOo4q2GzivLnB3sjPkdyyvByK5f4q62NE8DX8iNtuLkfZYcEg5fOSCOhC7j9RXTxAsMivBfj1rwv/EUGlQPmHT0/eY6GVsE/kNo+ua9nKML7avFPZav5HnZtifq+GlLq9F8zy80djSUvY192fnwlFFFACjoaSlHQ0lABXrXwy1X7dorWMrZns/u56mM9PyOR+VeS1reGNWfRdat7xclAdsij+JD1H+fSubF0fbU3Fb9DtwGJ+r1lJ7PRntrrzz1qs65bHNWg6TxpNCweN1DKw7g8g1FMuORXzux9mn2K6DPGcUyVcAc9e9Pxx7UyTBcZ6YoW5aYYQL8o/E1G4XJzmn7uMDFNIyCe9PYbehEwU8EZ9DSIAFIzyDUjDA9/SoGTIJBwR3qk7mZKF3HHNPQADoSTzSIx+z5cY4p69scY45qG+5SjYbMMR+44/wDr0qbCAFP3akC5Iz0psqHGVHKnt6VN09C4q+g7YpapVBxgYAFKgBUY5HXNCMfwrNs0jFIQgZwOgpHB2g/3ealznpxUbkFGHtSRoo2ZITkgsOPWkVd2MAkU442cGgZ4zSFZD4xkDg1OrADA601BtAPrSxsMkHtWb1NEPOcqVB9auWrZIGAKhQhgBjPsDUpUKc4IHWspa6FRT5ifYC2XOBShgMlc7fWmRksRuHGasnaIjwPasm7GraGAhmzk7R+tW4xghhz9KZGoBHH5VMvUBeorCciG7kyj5SwHHvTCQJOnA70M5CNk4IPaq6OSzDpmoUb6iSLcTgnd2zyTSXEpKs3QLUcbcFc/Kar6nIBabE4ZztBzRGF5IEtSpo53XMkpHOM8+prejk4AxzjpWZpMP7ku38R/MDitRV9xxxRiJJyYpvUkHHI69ayfEcvl6ZIOhYgcVqoOfQVgeKJRshjPc5IpYSHPWih0l76K3huImWWXGQoCiuthOARxzWF4dh2WG/BO9jWsrjJ7Grx79pWl5aBU1Ysg23KNng8E1aCjOOKgOHVgevaprY7jgn5h1rnhFyV10KS925W8R6tb+HvDt7qlyBtgjJVf77nhV/E4r5IvbqW9vJ7q5cvPM7SSMepYnJNeq/HrxQLzUIdAs3zBaHzLgj+KUjhfwH6n2ryOvt8kwro0PaT3l+XQ+FzzGe3r+zi9I/n1Cl7Gkpexr2jxBKKKKAFHQ0lKOhpKAClFJRQB6d8MNc86BtIuW/eRgvASeq91/Dr9M+ldtKNvXkV4FZ3MtndxXNs5SaJg6sOxFe4+H9Wi17R47yIKsmdssefuP3H07ivEzDD8kvaLZ/mfUZRjfaQ9jPdben/AJDHjoBUbKCvTqfyq9IhBBAqBkIY7cGvM5j2ynIvlt7Y5p4wV6deafKp2HcBk0yDJ4xyvBqt1c0ihpXk45HWm7dxxjipyCQeKZjg44qbicbFeH5i8ZOQvFTx42gdx1qEqY7gN2bipHDZ3Jj3FVLUTWhMPT0pVG4k49qgEpHBQjFTCVVUnDD6is3FoqEWNx5Umwfdb7uO3tUuM5ANQCQtiR0baPu/404SoTuJ2+xFDTN+V3JDx37VG4OAF4zTmljLD5gaRcb1PbkUI0cdSeNcn3/nSck9akjAORnHpTlX5ucYrO4nG1hwX5FGcU0ctxketTqAVBzSomHwT71ncLO4sLtGTxzjvU6gtF854qF/nYE5AFSqWaMgHIA6d6hmjdtB8bAvgZ/PNWRkDJ61VtlC/MTV1SGG0cAjNZT0ITuEUhOQfwq7GwbOOvrVUR7OFIJ9amgYAkmsJ67BG/UkdQQcctUaKN2COnNPIIG5ep6iowScn8MVK2KAMUfJY7feqN9J59zHCgyAcfjS3t4IfkTl24PtU2k2jMvnZ5/hJ61skoLnZcbJczNaJViRVAwAMcU/5Sf1NV/mxyxJ70sUeSQGIJrja6tmNiycBc1y/iQk3ijrtTpXRkuEI+XIFczqpM2pSZJ6Ba7Mtj++v2NaK3Z0WiKI9OgB54zWisW7pjFQWUYW3jjA6KKtooXJzxXm1p803IzeruMMQzx0Fc/481+PwpoE2oZU3TfurdD/HIRxx6DqfpXQzSxwQyTzuscMalndjgKAMkmvmX4k+LH8V6+00ZZdOt8x2sZ4wvdiPVsZ+mB2r2MlwUsTVu/hW/wDkebmuYfU6Puv3nov8/kctcTSXM8k87tJLKxd3bqzE5JNRUtJX3p+ft31YUvY0lL2NACUUUUAKOhpKUdDSUAFFFFABW74R16TQdUWbBe2kws8fqvqPcVhUVM4KcXGWzLpVJUpqcHqj6KhliurdLi3kWSCRdyOvcU11+UY5Oa8p8A+KTpM4sr5ydPlbhj/yxY9/oe/5+ufXVUOqsCCp5BHcV8xisPLDys9uh9tgsZHFU+aO/VFKRScDBzVcqVuQB3GT7VpMMNjH0qqeJmLdxxXNGW53xIh35xmo2HJI6VOcDAUjJpCvJzjii5W6KRXfcAEnaq8CpNvz0Y33AK/dUEE1KUyMitJS2JauiPgZprOXITPDcn6VMVB9veooIg5aQjJJwPpUq27FHQlUlwCThRwBTiBkk9OnNPjjAXHp2oWLbnuc1F0dUI31IDGjkfIv5UGCNiMjaw5BHarGznJxTsAFeKOdjm7OyZWR3hG2T7p6N2q6uxgMnrzxUWcfKwBB7Ughxh4WxjnaeaTsw5r6MnBIIVc1Jz07ioHkkRPmj59RUkEquvytgnrWbT3KgnuWMccnNTCMBQTkZ70QKpGWPHpmnTEZwxAjHNYt3dgabkQOP3mVztJ5q3HwAwJAHSs+a9jAZYvnz3HamfbXKlSAQeDg1TpykhezkbSyE8nBz0qRmAPI6+lYtve7GywP40l1qhH+qXJJ+92qPYSbsjSFOUtDZeYbeuB6ms261Eg+XbHcTwW9DWagu744yxHtwK29P0wQbXlw0g9uBTcIUvid32NXGNPfVkNhYvKxknyBnnPVq3YsJwRx2xTUHIGB+dTAAHJ5rjq1HN6nNJ33DG5gV6mnAZ5A5pi8E8c5zT1c7SO9YMkJCRhvWubiX7RqvHO5xXQTMUjZiRgA8Vk6FEX1BG+rGvQwXuwnU7I6aStBs6aJGXg49Km2MCBxTkXJya83+L3j1dBgbSdIl/4m0q/vJFP/AB7qf/ZiOnp19K8/CYepi6ypU1q/6uefisVTw1N1KmyOa+NfjYTyP4d0mbMMbf6ZIh+8w/5Zj2B6+/HY14/SkkkknJPc02v0jCYWGEpKlD/h2fn+Mxc8XVdWf/DIKKKK6TlCl7GkpexoASiiigBR0NJSjoaSgAooooAKKKKACu/+H/jIaeU0zVnJsicRTHrCfQ/7P8vpXAUVlWowrwcJm+GxM8NUVSmz6TMWeQ2QRkEdCKhmhDHkZ968r8DeNn0kJYamWk0/oj9Wh/xX27dvSvXY3iuYI5raRZYZBuV0OQw+tfL4nDVMNK0tu59tgsbSxcLw0fVdjIuLcJHvT7w5pkzbljBOA55rUeItuBHHSqk1ijDlmBHTmojNP4juihkcQVQABigqMkEZHpUISe3ByNyep7VZjZZE461M4ta3ujSUXbQiC/ex17Uy2wIV+lTyZQHH3jwKdFbhFC9vWo5rR1JjHQSPBzk9etKwIAqURYFDDIzjr1qLm8Fyq5EOmac0QxmkXO41YCfLg9R6d6G7EX5ir5ZzipEQZ54XHFT4zjiiMAD5uvYUnIpx6jFVigAPGO9J5SSnAQfWpZBsGS2FFUpL7GVtxljxmiKctioRcrpEk0rQOFTLUiW9zfctlE7VZtLdgAzn5z681ftwduT164x2pSqcvw7midlpuV49NgijU43MKf8AZIztG1anByTkc0gPXHXpisXOT3ZOstzNvbVIvmXIYkYx6Vas9OiMayTDc555pLxN0kSH+LmtKNWABwMU51JKK1KbaSQ5IguAmAB04qYYI6HPvUaZJyRTyeR6VyMyJUXOMDDHmn42rhs8daapwMqcGo2buTx/Os7XYtwdzuytSwqv3m6GqclxGmNuWPoKFuJWXCrsB9eTW0aE5rRG8aEmrj9SddrRpyTxgU/w/Bsnckfw4p9pYGU5f5VPXPU1wXxE+IEPh55dN0CVJtSGVeb7ywe3oWH5Dv6V30KHtYvC0neT+4yxuLo4Sk3OWi/E2vid8QIfC1s2n6ayS6y649Rbg/xN7+g/E8dfnO5nluZ5J7iR5ZpGLu7nJYnqSaLiaW4mkmuJHlmkYs7ucliepJ71FX1WX5fTwULR1k933/4B+c4/HzxtTmlolsv66hRRRXecAUUUUAFL2NJS9jQAlFFFACjoaSlHQ0lABRRRQAUUUUAFFFFABXR+E/Fd74enCoTNZMfngY8fVfQ1zlFRUpxqR5Zq6NKVadGanTdmj6K0LWrHXbIT6fKGx99DwyH0I/r0rSMA5yMmvm7TdQutMu0ubGd4Zl6Mp6j0I7j2Nep+F/iDBelLfVWW0uenmZxG/wCP8P48e9fPYvKpw96lqvxPscuzqjXtCt7svwf+R3TQBlx+FZ1zZNGzSQHpzitTzJtqttBB5B9arzTsY8GPkg150I1IvQ+jcLq6KFvunZZCMAcYq6i47darQS+VFtEecU43Uo/5ZfkKdSnJvRaGag29C1sBHfFRkEKeOM/pUD3VyWGyE4+lNY3kg+5jPas1Skt2jWVNqOpMFUnj9ak+6oPBNUmjumJzlc9akSyuHU75CAfem4JbyRgoJO9y2DlCchcVWF1Eg3E5c9AKWPTSWCtMxHerMFhCjcrllOKm9NdbnRBwtrqUhBPfNg5WPt6VfgsIrYBcbnHerqqEUbQAMcYoIOz1JrKVZy0WiJ5m35DPLDFVFPm5AVeoqTG3GPSotm4/KKyvcaCM7sHHtzS7CxLEYAp6x4fHbGae/AwDxjFJy7C22KhUyX4KnhBirqZBPPHWq1opO9j3wKsI3U8Uqm9uw5rXQlVsn0HpT1TLA1C0scZ5YAVXl1FQv7oFj61EaU5/CgjSlLZF6SVYVPmHgetZzSvO+FDBegx3ogilvJNxJPcZ6CtvT7MRtkDcfU1rLkwyvLWR0JQoK71ZTtdLbGX+XPYdavSx2thbSXFy8cMEY3PLIwCqPUk1j+MPHOjeFY2S5l+0XxGVtITlv+BHoo+vPoDXgXjTxtq3iuc/bJPJslbMdpESEX0J/vN7n8MV0YLAYvMGpy92Hf8AyXU8DMs9hh7xveXZfqdj8QvilJdrLpvhlnhtT8sl50eQeif3R79fpXk1JRX2WGwtLCw5Ka/zfqfDYrF1cXPnqv8A4AUUUV0nMFFFFABRRRQAUvY0lL2NACUUUUAKOhpKUdDSUAFFFFABRRRQAUUUUAFFFFABS0lFAHTeGPGereH8Rwy/aLPvbzcrj27r+Fer+HfHOia4FikdbG7PHlTkAMf9luh/HBrwKlrgxOXUa+trPuj1sDnOJwnup80ez/TsfTdxatE4eNQVPJFWINki424PfPavn7w/4y1rQtqWl2ZLYf8ALvON8f4DqPwIr0HSfifpl3gapayWM2OZI/3kZ/qPyP1rxcRldeP95d1+q/yPqMHnuEru1R8j89vv/wA7HoTRc5ximGIio9H1ew1VM2N5BPjqI3BI+o61qmIDPHFeNUjKm+WSPdly1I3i7oyniyCMYpyRnZVt4vm9afFEQtKTtExUCosBxk9cYpChWVSOMitLysngdeKZLFtw2Pu8VkqmpcYWZSA5ye1SqnGT0q1Db7uSOBTXiYvtxwDQ5puxXLqQhM/j608Q7elWViKsOKm2KBluFA5NZub6EtMovFlAQcEcmqF9PHbLukbk8Ban1C/+9FagE4wWPQVmxadJcuJHyxP8Rrvw+Gduerojop01HWZVOqTP+7t4sj/a4qxF9pk+85HrtWuitNJt4FA27mxyTU9x9ls4WknkigiUcvIwUD8TRPGUU7U4XHLExXQwILCWTorMD/E9altpQGPNOSP4RXMa18TvDmkIUt5n1CcZ+W2Hy/i54x9M15r4j+KuvapujsGTS7Y9oDmQj3c8/wDfIFdVPCY7FfDHkj3en/BPGxmf4ehdc3M/LX/gHs/iDxFovhmEHUbuOJ8ZWBPmkb6KOfxOBXkniv4s6lqCyW2hodOtW4MmczMPr0X8OfevNZZHlkaSV2d2OSzHJJ9zTK9nCZHQoe9U9+Xnt93+Z8njc+xGJvGHury3+/8AyHyO8sjSSszuxLMzHJJPUk02kor2jwwooooAKKKKACiiigAooooAKXsaSl7GgBKKKKAFHQ0lKKOPQ0AJRS8eho49DQAlFLx6Gjj0NACUUvHoaOPQ0AJRS8eho49DQAlFLx6Gjj0NACUUvHoaOPQ0AJRS8eho49DQA6KV4ZFkidkkU5DKcEfjXUaV4/8AEem7VTUXnjH8FwBIPzPP61yvHoaOPQ1nUo06qtOKfqbUsRVou9OTXoz1XTfi/MmBqWkxScfM8EhQk/Q5FdPY/FXw5OqfaBeWrHqHi3Afip/pXgfHoaOPQ159XJ8LV6NejPUpZ/jaejkn6r/Kx9KR+P8Aw1KNsOqwEjpvDJ/6EBUg8T6dcgiHUtPb2+0pn+dfM+R6H86OPT9awWQ4eOzfzO+nxTWj8VNP7/8Agn1HBqy4ws0Dgd1kU/1qQ6pHHku8Y45y4H9a+WMj0P50cehpPI6T6/h/wTo/1t70V9//AAD6hn8TafEP3t7Zx/79wg/rWTf+MtG6TaxZhPSN93/oOa+dOPQ/nRx7/nWlPJaMHcxlxVU+xSS+bf8Ake8t4+8KWcgLXc1yfSCBsfm2KzNT+MlqrKNL0iRgp4M8gXI+gB/nXjOR7/nRx6GtllVBvmnd+r/yscVbiPG1dml6L/O532rfFfxLfblt5YLFCcjyI/mx6ZbNcZqOp32pS+ZqF3cXL+sshbH0z0qpx6Gjj0NddHC0aH8OCXyPJrYutX/iTb+YUlLx6Gjj0NbnOJRS8eho49DQAlFLx6Gjj0NACUUvHoaOPQ0AJRS8eho49DQAlFLx6Gjj0NACUUvHoaOPQ0AJS9jRx6GjIxQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25104=[""].join("\n");
var outline_f24_33_25104=null;
var title_f24_33_25105="Patient information: Alternative medicine (The Basics)";
var content_f24_33_25105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/51/21300\">",
"         Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/29/39378\">",
"         Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Alternative medicine (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/alternative-medicine-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H39184956\">",
"      <span class=\"h1\">",
"       What is alternative medicine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Alternative medicine is any treatment or technique that is supposed to help with health but is not part of mainstream medicine. People sometimes refer to alternative medicine as &ldquo;complementary medicine.&rdquo;",
"     </p>",
"     <p>",
"      Examples of alternative medicine include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Acupuncture",
"        </strong>",
"        &ndash; People having acupuncture have thin needles inserted into their skin in different places. The needles do not hurt, or they hurt very little.",
"       </li>",
"       <li>",
"        <strong>",
"         Herbal remedies",
"        </strong>",
"        &ndash; Herbal remedies are usually pills or liquids that contain substances found in plants. Even though herbal remedies are &ldquo;natural,&rdquo; they are not always safe. Plants sometimes have chemicals that can hurt the body.",
"       </li>",
"       <li>",
"        <strong>",
"         Homeopathy",
"        </strong>",
"        &ndash; People who use homeopathy take small amounts of substances that would make them sick if they took them in large amounts.",
"       </li>",
"       <li>",
"        <strong>",
"         Mind-body techniques",
"        </strong>",
"        &ndash; Examples of mind-body techniques include hypnosis and guided imagery. These techniques are supposed to calm you and help you change the way you think about your symptoms.",
"       </li>",
"       <li>",
"        <strong>",
"         Massage therapy",
"        </strong>",
"        &ndash; During massage therapy the person giving the massage rubs, kneads, and presses on the other person&rsquo;s body.",
"       </li>",
"       <li>",
"        <strong>",
"         Reiki and other &ldquo;energy therapies&rdquo;",
"        </strong>",
"        &ndash; People who believe in energy therapies such as Reiki think that energy flows throughout the body. During Reiki treatment, the person giving the treatment &ldquo;directs&rdquo; his or her energy toward the person having treatment.",
"       </li>",
"       <li>",
"        <strong>",
"         Special diets",
"        </strong>",
"        &ndash; People with cancer and other health problems sometimes hear that their condition could improve if they ate a special diet. These diets may contain no meat, or require people to take special supplements.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H39184963\">",
"      <span class=\"h1\">",
"       Is it safe to try alternative medicine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many forms of alternative medicine are safe. And some even work. But some forms &mdash; especially those that involve taking supplements or herbal drugs &mdash; may not be safe.",
"     </p>",
"     <p>",
"      If you use or are thinking about using alternative medicine, mention it to your doctor or nurse. He or she can tell you if there are any risks involved with the alternative medicine you have in mind.",
"     </p>",
"     <p>",
"      It is important to talk with your doctor or nurse, because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Some herbal medicines, such as the herbal antidepressant Saint John&rsquo;s Wort, can interact with prescription medicines and keep them from working.",
"       </li>",
"       <li>",
"        Some herbal medicines are toxic and dangerous. For example, kava kava (which people take for anxiety) can damage the liver and may not be safe.",
"       </li>",
"       <li>",
"        Some special diets cause people to lose weight very quickly. And that can cause health problems. Plus, special diets can be very expensive even though they do not help people get better.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H39184970\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=see_link\">",
"       Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/33/25105?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15335 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25105=[""].join("\n");
var outline_f24_33_25105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39184956\">",
"      What is alternative medicine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39184963\">",
"      Is it safe to try alternative medicine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39184970\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_33_25106="Chronic GVHD tongue";
var content_f24_33_25106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple white plaques are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25106=[""].join("\n");
var outline_f24_33_25106=null;
var title_f24_33_25107="Crohns vs UC";
var content_f24_33_25107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Algorithm to guide the diagnosis of Crohn disease versus ulcerative colitis in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 683px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm to assist clinicians in differentiating ulcerative colitis from Crohn disease.",
"    <div class=\"footnotes\">",
"     UGI/SBFT: upper GI series with small bowel follow-through; PE: physical examination.",
"     <br>",
"      * Computerized tomography (CT) or Magnetic resonance imaging (MRI) may also provide evidence of small bowel disease, supporting the diagnosis of Crohn disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America, Bousvaros, A, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653. Copyright &copy;2007 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25107=[""].join("\n");
var outline_f24_33_25107=null;
var title_f24_33_25108="Pseudocyst of pancreas";
var content_f24_33_25108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan showing a massive pancreatic pseudocyst compressing the stomach and obliterating the pancreas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25108=[""].join("\n");
var outline_f24_33_25108=null;
var title_f24_33_25109="Mepivacaine and levonordefrin: Drug information";
var content_f24_33_25109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mepivacaine and levonordefrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/1/34835?source=see_link\">",
"    see \"Mepivacaine and levonordefrin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg; 2% with Neo-Cobefrin&reg;;",
"     </li>",
"     <li>",
"      Scandonest&reg; 2% L",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg; 2% with Neo-Cobefrin&reg;;",
"     </li>",
"     <li>",
"      Scandonest 2%&reg;  with Levonordefrin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"     Usual dose: Mepivacaine 34 mg (1.7 mL) per site or mepivacaine 180 mg (9 mL) for entire oral cavity; maximum cumulative",
"     <b>",
"      mepivacaine",
"     </b>",
"     dose: 6.6 mg/kg or 400 mg (whichever is less) during any single dental sitting",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"     Calculate the weight-specific maximum",
"     <b>",
"      mepivacaine",
"     </b>",
"     dose; regardless of the patient&rsquo;s weight, the maximum pediatric",
"     <b>",
"      mepivacaine",
"     </b>",
"     dose is 6.6 mg/kg or 180 mg (whichever is less) during any single dental sitting",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Carbocaine&reg; 2% with Neo-Cobefrin&reg;: Mepivacaine hydrochloride 2% and levonordefrin 1:20,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Scandonest&reg; 2% L: Mepivacaine hydrochloride 2% and levonordefrin 1:20,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14723454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection solution for infiltration: Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of mepivacaine. The effects below are more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Disorientation, dizziness, drowsiness, excitation, nervousness, respiratory arrest, seizure, unconsciousness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports: Paresthesias of lips, oral tissues, and tongue (usually due to nerve blocks of the trigeminal nerve)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to local anesthetics of the amide-type or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Has been reported with local anesthetics including mepivacaine; clinically significant methemoglobinemia requires immediate treatment with oxygen and/or methylene blue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, hypertension, and ischemic heart disease; minimal amounts of vasoconstrictor should be used in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Use with caution and reduce dosage when administering to patients receiving other CNS depressants; effects with other sedative drugs may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium metabisulfite: Contains potassium metabisulfite which may cause severe hypersensitivity  reactions (anaphylaxis) in some individuals; use caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate dosing: To avoid serious adverse effects and high plasma levels, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may cause significant increases in blood levels with each repeated dose due to the possibility of accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with patient status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F193030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual infiltration doses of mepivacaine with levonordefrin given to nursing mothers has not been shown to affect the health of the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Polocaine 2% and Levonordefrin 1:20,000 (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Levonordefrin prolongs the duration of the anesthetic actions of mepivacaine by causing vasoconstriction (alpha-adrenergic receptor agonist) of the vasculature surrounding the nerve axons. This prevents the diffusion of mepivacaine away from the nerves resulting in a longer retention in the axon.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Upper jaw: 30-120 seconds; Lower jaw: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Upper jaw: 1-2.5 hours; Lower jaw: 2.5-5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infiltration: 50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inferior alveolar block: 75 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ayoub ST and Coleman AE, &ldquo;A Review of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1992, 40(4):285-7, 289-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/1397990/pubmed\" id=\"1397990\" target=\"_blank\">",
"        1397990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1993, 40(2):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/8185087/pubmed\" id=\"8185087\" target=\"_blank\">",
"        8185087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(1):16, 18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/7911769/pubmed\" id=\"7911769\" target=\"_blank\">",
"        7911769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Recent Research on Mechanisms of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1995, 43(4):316-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/8940589/pubmed\" id=\"8940589\" target=\"_blank\">",
"        8940589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Local Anesthetics,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1991, 38(4-5):128-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/33/25109/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10138 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25109=[""].join("\n");
var outline_f24_33_25109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193034\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193035\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193042\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193036\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193038\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193037\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193025\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193014\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14723454\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162767\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193040\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193028\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193018\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299670\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193022\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193023\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287254\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287255\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193030\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193031\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193017\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193027\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/1/34835?source=related_link\">",
"      Mepivacaine and levonordefrin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_33_25110="Contents: Critical care medicine";
var content_f24_33_25110=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Critical care medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Critical care medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute respiratory distress syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/16/10505\">",
"           Acute respiratory distress syndrome: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29945\">",
"           Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4871\">",
"           Acute respiratory distress syndrome: Prognosis and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37863\">",
"           Extracorporeal membrane oxygenation (ECMO) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5591\">",
"           High-frequency ventilation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/984\">",
"           Liquid ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/42/2730\">",
"           Mechanical ventilation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43784\">",
"           Modes of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/52/9033\">",
"           Novel therapies for the acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28407\">",
"           Oxygen toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39078\">",
"           Prone ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9065\">",
"           Supportive care and oxygenation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/39/28282\">",
"           Transfusion-related acute lung injury (TRALI)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Advanced cardiovascular life support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Critical care cardiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/49/35610\">",
"           Antiplatelet agents in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/20/39242\">",
"           Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28072\">",
"           Basic approach to arrhythmias due to digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/53/11098\">",
"           Beta blockers in the management of acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/48/37641\">",
"           Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16329\">",
"           Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/13/9431\">",
"           Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37863\">",
"           Extracorporeal membrane oxygenation (ECMO) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22421\">",
"           Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/43/1721\">",
"           Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44567\">",
"           Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/36/13896\">",
"           Intraaortic balloon pump counterpulsation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39225\">",
"           Mechanical complications of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1849\">",
"           Modes of cardiac pacing: Nomenclature and selection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35701\">",
"           Nesiritide in the treatment of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/41/13974\">",
"           Nonsustained VT in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/21/30041\">",
"           Outcome of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16233\">",
"           Pathophysiology and etiology of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24055\">",
"           Pericardial complications of myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/48/38666\">",
"           Periprocedural complications of percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38537\">",
"           Postoperative complications among patients undergoing cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/49/39702\">",
"           Prognosis of nonsustained VT in the presence of structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/57/922\">",
"           Right ventricular myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/24/8585\">",
"           Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/38/39530\">",
"           Troponins and creatine kinase as biomarkers of cardiac injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Critical care gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20761\">",
"           Abdominal compartment syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2330\">",
"           Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38538\">",
"           Acute liver failure in adults: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/2/24616\">",
"           Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28538\">",
"           Approach to acute upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30841\">",
"           Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14297\">",
"           Etiology of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7272\">",
"           Etiology of lower gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1928\">",
"           General principles of the management of variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28023\">",
"           Glycemic control and intensive insulin therapy in critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/35/34359\">",
"           Indications for the use of transjugular intrahepatic portosystemic shunts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/32/13831\">",
"           Nutrition support in critically ill patients: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/17/34073\">",
"           Nutrition support in critically ill patients: Enteral nutrition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/58/8102\">",
"           Nutrition support in critically ill patients: Parenteral nutrition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/39/43639\">",
"           Nutritional support in advanced lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24826\">",
"           Overview of the treatment of bleeding peptic ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44774\">",
"           Pathogenesis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32810\">",
"           Postoperative management of the critically ill obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44504\">",
"           Predicting the severity of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33688\">",
"           Role of surgery in the management of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18776\">",
"           Stress ulcer prophylaxis in the intensive care unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/5/40025\">",
"           Surgical management of complications of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/61/23514\">",
"           Treatment of active variceal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/56/41865\">",
"           Uncommon causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Embolic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/48/38664\">",
"           Air embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15016\">",
"           Amniotic fluid embolism syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/26/27050\">",
"           Catheter-induced upper extremity venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6042\">",
"           Diagnosis of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/12/33994\">",
"           Diagnosis of suspected deep vein thrombosis of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/21/25942\">",
"           Fat embolism syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5448\">",
"           Hyperbaric oxygen therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/28/16840\">",
"           Placement of inferior vena cava filters and their complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42503\">",
"           Treatment of acute pulmonary embolism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ethics and prognosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29945\">",
"           Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4871\">",
"           Acute respiratory distress syndrome: Prognosis and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/40/12938\">",
"           Communication in the ICU: Holding a family meeting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/60/26565\">",
"           Ethics in the intensive care unit: Informed consent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24934\">",
"           Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32887\">",
"           Ethics in the intensive care unit: Withholding and withdrawing life-support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/35/44598\">",
"           Intensive care for oncology patients: Short-term prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/56/27527\">",
"           Predictive scoring systems in the intensive care unit",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolyte disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6613\">",
"           Alcoholic and fasting ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31432\">",
"           Approach to the adult with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40646\">",
"           Bicarbonate therapy in lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/55/4986\">",
"           Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39479\">",
"           Clinical manifestations and evaluation of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/2/9258\">",
"           Clinical manifestations and treatment of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44069\">",
"           Clinical manifestations of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2167\">",
"           Diagnosis and treatment of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20934\">",
"           Diagnostic approach to hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34005\">",
"           Diagnostic approach to hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44295\">",
"           Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/63/11254\">",
"           Evaluation and treatment of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9366\">",
"           Evaluation of the patient with hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21832\">",
"           Evaluation of the patient with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/48/40710\">",
"           Loop diuretics: Maximum effective dose and major side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20215\">",
"           Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10074\">",
"           Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18072\">",
"           Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/10/42154\">",
"           Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44435\">",
"           Renal actions of dopamine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36533\">",
"           Serum anion gap in conditions other than metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21526\">",
"           The anion gap/HCO3 ratio in patients with a high anion gap metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/54/17258\">",
"           Treatment and prevention of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16041\">",
"           Treatment of hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/52/24393\">",
"           Treatment of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44632\">",
"           Treatment of hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17306\">",
"           Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14568\">",
"           Treatment of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemoptysis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26838\">",
"           Massive hemoptysis: Causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/47/30454\">",
"           Massive hemoptysis: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29558\">",
"           Overview of massive hemoptysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertensive emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28246\">",
"           Management of severe asymptomatic hypertension (hypertensive urgencies)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24040\">",
"           Clinical presentation and diagnosis of ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/30/8679\">",
"           Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/23/375\">",
"           Diagnosis of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37464\">",
"           Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/51/21306\">",
"           Evaluation and management of severe sepsis and septic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35576\">",
"           Fever in the intensive care unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/32/44552\">",
"           Infections of central nervous system shunts and other devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/16/29960\">",
"           Investigational and ineffective therapies for sepsis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5449\">",
"           Pathophysiology of sepsis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1800\">",
"           Postoperative mediastinitis after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/53/31578\">",
"           Prevention of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24744\">",
"           Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6695\">",
"           The ventilator circuit and ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/20/7498\">",
"           Treatment of intravascular catheter-related infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intoxications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6613\">",
"           Alcoholic and fasting ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31432\">",
"           Approach to the adult with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28072\">",
"           Basic approach to arrhythmias due to digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/19/33081\">",
"           Beta blocker poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31736\">",
"           Calcium channel blocker poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10345\">",
"           Carbon monoxide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/18/7466\">",
"           Cyanide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/13/20694\">",
"           Ethanol intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16297\">",
"           Gastrointestinal decontamination of poisoned adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1129\">",
"           General approach to drug poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5448\">",
"           Hyperbaric oxygen therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12744\">",
"           Internal concealment of drugs of abuse (body packing)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21560\">",
"           MDMA (ecstasy) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/43/4792\">",
"           Meprobamate poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/18/21799\">",
"           Metformin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/47\">",
"           Nonsteroidal antiinflammatory drug (NSAID) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/51/3897\">",
"           Opioid intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/5/28758\">",
"           Opioid withdrawal in the emergency setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/25/33176\">",
"           Organophosphate and carbamate poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/28/19913\">",
"           Salicylate (aspirin) poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/26/11690\">",
"           Selective serotonin reuptake inhibitor poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/63/16376\">",
"           Serotonin syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/29/41430\">",
"           Serum osmolal gap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36231\">",
"           Tricyclic antidepressant poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28264\">",
"           Valproic acid poisoning",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mechanical ventilation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21991\">",
"           Assessment of respiratory distress in the mechanically ventilated patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24040\">",
"           Clinical presentation and diagnosis of ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/6/33896\">",
"           Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15545\">",
"           Endotracheal tube management and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37863\">",
"           Extracorporeal membrane oxygenation (ECMO) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38183\">",
"           Extubation management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5591\">",
"           High-frequency ventilation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28519\">",
"           Inflammatory mechanisms of lung injury during mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/18/10535\">",
"           Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/984\">",
"           Liquid ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37673\">",
"           Management and prognosis of patients requiring prolonged mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24486\">",
"           Management of bronchopleural fistula in patients on mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/61/9176\">",
"           Management of the difficult-to-wean patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/42/2730\">",
"           Mechanical ventilation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/59/8120\">",
"           Mechanical ventilation in acute respiratory failure complicating COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/5/14423\">",
"           Methods of weaning from mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43784\">",
"           Modes of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1850\">",
"           Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/1/13336\">",
"           Overview of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/42/11945\">",
"           Overview of tracheostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31430\">",
"           Oxygen delivery and consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28407\">",
"           Oxygen toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27127\">",
"           Permissive hypercapnia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/32/26119\">",
"           Physiologic and pathophysiologic consequences of mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/60/30663\">",
"           Positive end-expiratory pressure (PEEP)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/10/39078\">",
"           Prone ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/10/32934\">",
"           Pulmonary barotrauma during mechanical ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/54/9065\">",
"           Supportive care and oxygenation in acute respiratory distress syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6695\">",
"           The ventilator circuit and ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43060\">",
"           Troubleshooting problems with noninvasive positive pressure ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27095\">",
"           Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16182\">",
"           Ventilator-associated lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21112\">",
"           Weaning from mechanical ventilation: Readiness testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21140\">",
"           Weaning from mechanical ventilation: The rapid shallow breathing index",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Monitoring",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/33/15894\">",
"           Arterial blood gases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/51/26424\">",
"           Arterial catheterization techniques for invasive monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/26/27050\">",
"           Catheter-induced upper extremity venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/1/29\">",
"           Complications of central venous catheters and their prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/23/375\">",
"           Diagnosis of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33402\">",
"           Evaluation and management of elevated intracranial pressure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25221\">",
"           Insertion of pulmonary artery catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33925\">",
"           Oxygenation and mechanisms of hypoxemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/53/31578\">",
"           Prevention of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27128\">",
"           Pulmonary artery catheterization: Indications and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/10/44199\">",
"           Pulmonary artery catheterization: Interpretation of tracings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9736\">",
"           Pulse oximetry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/20/7498\">",
"           Treatment of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/35/13877\">",
"           Venous blood gases and other alternatives to arterial blood gases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic critical care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36889\">",
"           Acute toxic-metabolic encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/17/275\">",
"           Beta blockers in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26952\">",
"           Cardiac complications of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/22/5481\">",
"           Clinical features and diagnosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33402\">",
"           Evaluation and management of elevated intracranial pressure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19337\">",
"           Hypoxic-ischemic brain injury: Evaluation and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/32/44552\">",
"           Infections of central nervous system shunts and other devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/43/25271\">",
"           Neurogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40038\">",
"           Pathogenesis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/36/41543\">",
"           Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/28/42439\">",
"           Respiratory complications of spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19642\">",
"           Status epilepticus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/265\">",
"           Treatment and prognosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/34/15913\">",
"           Accidental hypothermia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37032\">",
"           Acute respiratory failure during pregnancy and the peripartum period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/17/275\">",
"           Beta blockers in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4633\">",
"           Complications of scuba diving",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6646\">",
"           Complications of therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/55/34681\">",
"           Critical illness during pregnancy and the peripartum period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26809\">",
"           Drowning (submersion injuries)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5448\">",
"           Hyperbaric oxygen therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11769\">",
"           Immunologic blood transfusion reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/52/5961\">",
"           Indications for red cell transfusion in the adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/21/10582\">",
"           Intraoperative and postoperative blood salvage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10852\">",
"           Iodine in the treatment of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38294\">",
"           Massive blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26264\">",
"           Negative pressure wound therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/21/31066\">",
"           Overview of inpatient management in the adult trauma patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/61/40920\">",
"           Pain control in the critically ill adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/26/13737\">",
"           Patient assessment for air travel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/33/38420\">",
"           Prescription and technique of therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/31/25082\">",
"           Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15833\">",
"           Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16007\">",
"           Severe hyperthermia (heat stroke) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22790\">",
"           Smoke inhalation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44663\">",
"           Thyroid function in nonthyroidal illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33655\">",
"           Thyroid storm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/8/31878\">",
"           Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/39/28282\">",
"           Transfusion-related acute lung injury (TRALI)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/49/793\">",
"           Use of blood products in the critically ill",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/44/43720\">",
"           Use of neuromuscular blocking medications in critically ill patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/63/3064\">",
"           Use of oxygen in patients with hypercapnia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21081\">",
"           Use of red blood cells for transfusion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38516\">",
"           Continuous renal replacement therapies: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/40/28295\">",
"           Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/54/12138\">",
"           Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/14/38120\">",
"           Hemodialysis anticoagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/32/31240\">",
"           Hemodynamic instability during hemodialysis: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/1/34839\">",
"           Investigational biomarkers and the evaluation of acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20215\">",
"           Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/28/2501\">",
"           Nonoliguric versus oliguric acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4170\">",
"           Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18072\">",
"           Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10457\">",
"           Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35498\">",
"           Prevention of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44435\">",
"           Renal actions of dopamine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4553\">",
"           Renal and patient outcomes after acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/25/33174\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4696\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19481\">",
"           Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3402\">",
"           Tumor lysis syndrome: Prevention and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Shock",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40646\">",
"           Bicarbonate therapy in lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16329\">",
"           Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16281\">",
"           Corticosteroid therapy in septic shock",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44777\">",
"           Diagnosis of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/51/21306\">",
"           Evaluation and management of severe sepsis and septic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38294\">",
"           Massive blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/20/5449\">",
"           Pathophysiology of sepsis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24744\">",
"           Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/62/6120\">",
"           Shock in adults: Types, presentation, and diagnostic approach",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/47/42745\">",
"           Treatment of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/20/13639\">",
"           Treatment of severe hypovolemia or hypovolemic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40505\">",
"           Use of vasopressors and inotropes",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-D98BCFED45-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f24_33_25110=[""].join("\n");
var outline_f24_33_25110=null;
var title_f24_33_25111="Images of posthemorrhagic hydrocephalus";
var content_f24_33_25111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Ultrasound and MRI of posthemorrhagic hydrocephalus in a patient with grade IV IVH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up ultrasound and MRI performed six months after initial imaging demonstrated grade IV IVH in a preterm infant. Coronal (A) and sagittal&nbsp; (B) ultrasound images demonstrate marked hydrocephalus (arrow). In addition, IT2-weighted (C) and FLAIR (D) MRI demonstrates massively enlarged right lateral ventricle (short arrow) with near-complete absence of the right hemispheric white matter and relative sparing of right frontal lobe white matter (dashed arrow).",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging; IVH: intraventricular hemorrhage.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25111=[""].join("\n");
var outline_f24_33_25111=null;
var title_f24_33_25112="Pemphigus foliaceus scalp";
var content_f24_33_25112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60530%7EDERM%2F54341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60530%7EDERM%2F54341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDs421ZUBkliJ6cL1pZbq/jzl4N3ucVgT6nfXIIMvkxnoE4/Ws+SzMql2kYsDjk5ryOa2x7yj/NY6oajfNx/o4JOCPM71Ib7UUJ/coxHdXBFcmliSpOMBepJpTC5A2uxB46mhVLborlidQdX1BGw1o+T0O4YqCTXLonBhVW9GkArAFpI2AZXIHYsakS0RSC2Djge1HtH0Dlj2NBtZvJmCwxRlumPMHFElzqbMMwoCc/xVjXtpG2MKQR0K8VT23ySAw3MwGehOc1PtNdSlFW0N6RNVfnMS/8CrOuLfUiCftEa/QVNFqF8qBGSNiOuScmq91fXWcrbgPjs3FXeAe+jnNeaa0i8y5v5MDsDgV5jqN491csQ8pQnhSSa6zxLDqFxJLJewyEHiNE6fn/AFrAWOK3WOV1hEiZGB824+9dFDljqcuIcpe6zLhiLSqnIJ79Ka+VYr6ccVo4LXO4oPKj5Yr79eKpj95OXwBuywwK61K7ONxshFt8RTOTnYVX86t2kGV4A+X+Ed2xn8sVLDiSNo9mSX3tJ2GFxU95stLJEGM+Xkg8N8x4PsMVm5vYpRS1Mg7riNHkbgttQn+71P4VFlTIxUEKBkfSpGBYAngkcKOy+gp80ZSTyEKksQW29Qf7ua1vbQz33HJbM0cfIBkfBOevenxxb5ohyiyybQR1C5wKs3K7YpAikYAVW7DA549z/Ko9KXzb6FnYKqHLE9Cew/Os+a6ua21SL1lDBCtxDOCx2AKi88F+p/HtVph+7LkMTlcKowAByf1qae3Bvb6SHIc2+0qeTvXDcfgDUqsqxAYPlurBs+/Q1zyd0mb01qN1pPPmkUKg3FS+OhUjIrIgjb7NNJMGKIchW/mK3fLDw5LZ3x4JPYqCuP1qtCE/s/M5wC3lkfj2pKWlinDW5c0m2jmsx8p220pmHrtx0/Otm/gH9kDduMss0g3D0OCB9c0aLakabdyQgHzFSHAGD1y2aZcSPcCKNW/j+76ZGDj8KhtmyiZWnadJLPCwbBkuNhCjHA9/Tir16sdnbzLFGXvJflUDkqN2B+fP5VsaVFElpBKoCbZGYvjgcECqunHzJru6kX98JEVR1wcf0HNO+gctjm9QgLai2GBKBuR0wP8A9RrMkIQTeTM0ZSQiMjjIIzW5bIsl3dSPxHIWVSec5HP86xoEZ/NU4JZlfkdsEYq09DCSvsM/tHUrWxSX7R5gZsAsPTg/0qex8SXbOolRHySMjrUd5GZbaONRlijAAjHTBqrp0RWe3jO0Zk+91PQ/0quWElqgVSpCWkjrbXxHC5KOrKynB4q8mu25XcJYsY74rjTCBLHcx8ZHzqPu49RV+0sEvHkSRFVGIUZ/vAdvwrnlSj0OuFeo9zauNdhEiqpQE47frV7RLyO+QtsXBPpXOT6ebeW23Jv8oGJzjh0/hP5HFTxW09myrbzFWjGfmGAyHpn+VS6Sto9TWOIn9paHcRxRNkiNMjsVp/lQk7XiQk/7I4rkbDxGzsq3KSxSYzyMgj61v2mpQyhSXYis2nHRm8WpK6NaOzi25hEQb+6VH5jNV3iVlfNvC3YhVAIpEvYgc+YR7YBqOS4JY7GOSchiMUXJaZAsVqWeMxxgA45QfrVDUNOt5NpCJHID8kiKP19an1CRyqybV3H+JWwRWX9uZHIuEZoxyzD096d7DaTWos628pMd9bRiVRjzIlx9Dj0rPlsI1bMYjdTwRtGRVxruEyD/AFcg+6N3GM+tZ7zpK/CFMdgc4b0qlds5aiUdiLU47X7Eg8lFZIW5A55bqa5uziW4l2bFVN25mAyQPQV1Wt4ktvLKqfkAmPQrkcGsJ1tIIhHC3lZHAl4H5j+tdcXZHBPe5aNrEv7tIhscDD4z09PemW0Vvb3SskSGIHPzDgjuCe1VVlltyVnYtAe6jn68U64RjETOga3flHUn5j2PHT0NOzW7E5Euo6NFDLOEZcuokjAUEBexB70llZxzWJMsCuYvlJU5yp6MM+hq7pf2e4WPTyyxuoLwy8nDY+ZT756Csi/ik0+7LxErICQ6ZIznk47YNUm27Gckt0IlpHbXCieNDEQSv936eo+lUb2z2oZ7cfuwQrDHKN6GrSzZtnLOZY/MwUYZIUjOfqOlFnkLc26bmMsOEQnOSpyMHuDzWive5GmxlTBDtdRgOOV/ut3FNcgqCF2sowwH8XvUwYmNlWXah52t0+n1qB1eN9rDaw54rREM+kFiLtgrlc4Aq15GEDMA2Oi5qxBEJpFVmCDuB6CrXkKTwu3Jzj0FeUonqcxmpbO/Mo49B0FNuIkgXc3APA9a3CipHvk4QdeOlUGhF1cPKxZUH3FP8I/xolGwRkY+y4lTKDYg/M06GBwQShJ7c1ui2XjHOaVrX7sYUZ6knvWfKy+dGKtuznO0jnvUrWbDgDGa3Y7Ve4/ClS13NuIwvoKvk0J9oYkdmcqQoOO9WDYKw+7WsESPIIGO2BSHkbIxgk9auMEJybOWvtMBZlAzx6VyOueDLa6BkWPypcZDx8H/AOvXrBtS7ZK5/Cqd3YF85BFNwa1RSmpLllsfO+qaPqGjW88Ri86OUgeaq8gfT3rGjIIkZRtbaFUdO/8A+uvonUdHBQhRtDcZPevMfE/gtS7S6eBFOPmK/wAL/wCBrWFe2kzGeFur0/uOWkCrokCwR4d5CrZ6sCe1QSK91CpHmMN7OX25wowuM96k897ZGF7BiSBiEiIxucjr9AOcd6W9uGltSFmfdsO1BwpXrwB6E1skzmbXUpJtS6UyRlVQAJlfvN2J+lR2MJklPzEylxGPYk4z/OprOOS6hfLbSM4zzjjPH5dKjtXlkfehYpGd3TnH4fWtH1M/Mm1C4V7+RIyWiBC5HcL6fjV/TI4xPZ29woUFhNNkckngH6Af1rLRkhMwJ3TDmRx069Ae3ufwrV8MkT6xaC6JbzZVVnxwBjIH6VMlaI4vW5uatGbHWZXD7vLKlmIwCXOCB+GKoSFo7F1kP7xVOPbFWLyNrwaoJUYzSKzJzgEq24D8qa1m93uVGGSiHrwFPXJ7YINc8jpje5a07a+mws/zkKwP44qlf28ggtzI4VVkMh44UZ6Y+grY0+2SO2RY9xWLKt/v/wBKp6ynmPGij5UkBfHHUYrPqdPL7p0zAWNmqR5RCqndnlgRkn681lTkxXixMAJZX27gOg9D+GK0NTffpFlLHwqJg7Tkgjpn2NVLe2P2+2MhO9cdTwWxkn8zUy7GkY66mteOttpMCFQGLb2x6Z6VTtYXi0yEEESNmaT1y3QfypL3fc31pEWBiLFs9tqA4GPTJq3rWxdGjwWDyuFBHYBcmrRnJa2OLWQO80TNmIM0Y7Ywcn9cVFp+37W4cFRsAIz2wamt4R/ZrRLjLnP/AOqnCLZfs4ORgptI4+7xRdIlU3YjuHMekxOwWQ9FXOGTjnnt2pIrWKWKwubZvJKtsCyDg8eoo1GNVhVEY/6tMA9M4rYs4Y08P228jJmBUjnt0p3FyNlW2spf7JYeX5yIGCNCQ/BOe1XNHQGLASQ8CTDHBUjocfXj6VWhhGnQ3GyWSPcdpIUc/rXRaNIZLCIpdEzKoLu65+XrWbdzaMWinLNFO0INuisFCybxkK2ex9PaqOqahGkzW/lJvxsyFDbh2H0zW3Jp8k8M7Qtayu+HwJPLJFUW0hYGjkuI5DIoz5hIwCeoB7ipu73KdjGt7GTczLFBI8p4dE24x179KsOskO8TwpvH3VViuce/atPTbOezkwIIhn5mwx5X8eKv3lol3D5coijd2IZklBCDrkj1NPViSUTlRqYiJEaThhyfmDLj6kfzqzLrLQiMNkMxxhl24+uMinanoW1WCSrufqGz19ARx0ps2nzRpG8Vuzwjnpu59MihxT3Qe0kloxzawk8LyeUygfK23kK/YH0z2PSo5rxhHHG1urKyh8iTaxz+nHNZtiyM8shUIHOx8Enp2I9a1dVjWSKIyKRIFBEg6MBxz/jT5Y3M/aTa3Kk1uzLHMN4jwVI2j5sHp+VVmSGOXz1bB+6VPGPb61oKmLJIpcRqk2VLnhhgcj8aTUVRoITlS0zYdtwAAHf2qkjOWu5mXzT3LmRBlmUKSpByMdKzBY3LkgJgHoMg5rUayjKyDfhtoZSD2qDyfLO3zCijtnkmrjKxm4XGwoba4IkhWMsuGkxjPtirNrHDJFJbs6opcMGTrC397/dPRh+NVWJWEGMglX24k5BB7n0pmALgPC5JAG5k+UD6k/l70076kNW0J7a3nN7JHNFsv43zG6H/AFg7A44OexqXUZYtRhkSUBbyA784yJEH9R3qSzuxevNGJI7CeOP5GGckqeh7j1qDWXNtKs7pJGWYl/L+6jeoHoefzq9WyLaGFNGi+eFIVEKsWPO0k9R7c1CFlgHDgTQsGUq2cg88Vr7Y1mlLRJLDJgMrcjOePw5rMlgFtdGGTcgXmNmbgZ/pWsZJmUo2HW0dveXhS5ljthKjNFOwwFcc7W9iRjPuKzi5KbCBgHI9R+PpVy7iRwxiIHAIXPU+tUpVZH2uMSAYZfT2PvWkSWfVliT9nDFTufnp0FXLePcMnqO59KzoC+0LnaAOMHn3rUs1Kocc46Z5rz46noS0ILzbNMkG4iNPmY+vtUsMQOwNjc/JA/SqUbAtKe5bj1xWhan5nbOAkZI/Kkw2J4bf94gH8XSpp7YG5dSBkcYo0yTZcQkk4HTNWImJu7gk5+bH4e1UldGbbuRxwgMQ23I44pHjVRjIznHtVllHAOCytjniqV67RozhunAOO57U2kkEbtkT7CDlQCSc9/pTYrpLYqY7YSP/ALR6H/Cq6M75UsQD6dCPrViSMxWuD1b73vRC8matWWpFLfXsjbh5AP0/TNVTdzdTHs7Fgcj/AOvSqWLBOxPP0q8qLzuFU0+4X5ehjy3DXBCu3l54Axg/jnpWdfaTHO0v79zODnaW4Priulmt1cHABHuKoS2mdwRQZQCcg9RWEovqaQnbY8l8c+H1kiSRM+bGMq2PmHcj3FeayKyo6dGj5Q+3cfrXv3iK3HmZJyCmee9eO+KtP+zakXjUYcbh6Ajt+Na4epaXs2TiqSlBVFuUFj2RW8aHYuPOmZeCvHArSsfLfTWB/wBH1K4bylLABJgBzn0YZHPQ1g2ryeccEnzcIxPcsehre1OOGPUYEiiQTwMNqyP8rSZyRnP+eldTXc4E9DnJ4Xti8EqlHDYcN2x61v6BILadzCCBDavKpxyZOcH+dVLma3ubya3uoJkkEjATI25k57g8ke3UVqzWkunQPcFc2sqRqJ4z8vXbjHUHknBolLSzCMS9DkXPmEbIHbIUnOxj/TJpLV2F1eWsg5QmVj69Dj8Dio9NcverBNn5FIbHp34/AGpbCJ21NLgHO8mFy38XzY5PuMVzPQ66a5rGtYq6xTMGYea6yFQPveoNQ3EKy6nsckRTsqsQOg6ZrbgWOJoVhVhtcn5ugOD+lUdVXZCZAMybOmOVJPINZM7ktB1sPNivbSdcFZVO0dSE7flQcRSLKkgd1Ekig9FYcYPtSrOf7YE+4H90r9fvtnkn6inyWqxXExRy0DBdh9QTn/634U276IqMOo20t86hZtIDjYR+mT+FafioSSWtomyKP5pSNowMYAzTI8jVRKu4gLsH44H8hVjxUjLY2kYIKLb5ZgM8s2SPWq2TI5feTONs4Hi3LxhW256844qLaTf7cEFVLFex54Fba7VsJpI13MDgEDvwBzU9tYxF/PiJLJsDAjnPU/XrWZrZLQwbnzGVuEBjQZOORjt+tXFmaHSre1TayFjIoH3hlema1G08TJv2oA52emTnALe9OXTp7KaCSMbZIzkMOdpApOQuWLRjPK11ppiO3Gd7MR/WtnTYsaTHv+abCxAdj7fSqF3b7ovKjQLlwOOrnOTVnT7p4JSsnCqTjngE8fpQUqehZmgMt5ttyohjIUYAy7Duf6VcYKsCNcW7ednEZR9p9yexpll5clxu+6iOSSDyQO4q9qtxcT3KzG3jGxQEwOAo4ApWXUTg20itfQyXFl9mDpPCBuWP/VyqfbtiqDaNMYgtsS05HzKeGHqPer6OZ5Yt42Mi8K3H4+9Wr24VSBMEUrxgkBifrT33MpRa0RyhtMzFP3oyw/d9QP14plxAIpQYHlgfkjbLx/nit2UtLHloshTkDeO/cH19qxCjzvIG89Byw3Jnip2Icb7lINcMCzpDOG/iGD+dOk1D7oKxq6ZAXkEcdKtafEwIEBTzAeE2sDSSzW1wog1C0dZC3+tjB4x2YHr9apMzlG2xTa7t5g6OroCd2GIIzis65P2x081lQIMohA2n3Pr9KtSpYsGEQMsIOTsbY3ueeKqtb2zE/ZWnUZ/5ajkD3PStEzGTHpIi3CiLAfPzMw+92wB2qgjmOcrISGydxXnZUs8SoE2ybio796hmTYxSTAP94dD9apWC7Ww6OQvDJEoyWGc444/nT4kRopFt8eY3B3D5W/wqCEmNt5YAlD8y85z2qa3Y/OYwwUgEoo+6PTP607WIfmMtlDyqHi8qeM847n0z/jVgXTQ7/OLTWu7O49EHcNVdBG0TfaJMpH9zkBh7n29qe1yXAkVFYMv72B8jcOny/hVJ63M+hDcoNrvGQygsrqpKMv1HOe3NV2hW9gSKYAMAfLkPLA/3T6r+oNX5LZlsmFrLJJAAGhfo646ox/QfSs2OeKdgWlWNsfu5P9rsD6c1cW7aENdGZ8qqr4yAABzncAfUe1QsQ2Vk/wBaDw453D3/AMa0Jh5hDAFbonpwVf1wex/nVN4wWMYj245baM49eP6dq3izJn07A4KAHr/L2rWVhHaPIDkBTXPpIHkWNNpV8456VpGYiymjz823GRXnxdj0pRbIrM/uywHXua1LU4s5mPUjGKxrBy8QI+mDWmzYtlX++RmlGXcU10L9lkTRgAYyOTU0DkOWXrvJ4GR1pscRVY3PUEYJ6VLbghfm2q2e1aK9jJ6jVkaR2JPzbj0qrqGG2jA2kjGTkipAGXJBPLHOKz9RZwVODjOBUylZGkI3ehZ3/KiAc9STVpZFKYK5B9axrCQtOGlJPbBNa8bocHpWtLVCqKzFNsCNwAPHPrQsZODGpII5xVuMD++wGegNP8nOTFJtkI59D9auxnzWKflNgkqcYz0J4/Co4YleRWAB5x6GtmzuhCuJ0ZSeGwc7fetBZ0MK5w0IOVIALDnvQo3JlUaPLfEdsFhiwV3DKkt25z+VeReM7cpjePmRh8vqD7/1r2jVnWW2uoyPmL709sH+VeU+K2C2zfaceWMjcBzEfp6Vxv40z0Ya0pJnA6ZGsMrzl8IgynGTv6A49Rk1ceFrzzxIysXYR/RiR8w9iAadBYkW8kUIYs8qvwwwF5A57g+tS226B7dXi3ugZ/LbgOOmw+nqPeu5yuzzYwsiTyBq6u67kvrdA74HNxCMAZ9XX8yPpU0t3cK19Pbk/P5aCNhlWUN0I6fjTriBre4S5tJCqMivHMR86EEfK3v/ADFX9Ts9kFtPBtKTna4H3Q2e3sc/hWTqXszdUbJjEtw/iCKcABXOxwPvISOh/vA84PWrcFm63F1EeA0hZOeBnp+oFULTfDrqPEC4ilAk3c7lB9Pb1rporVXTchJkkfMT54fjIyOxHSok7m9GNi9p8aXVsPnAkI+bHY1UvoZg0oO4b2IB3cnjrWnaJGLgGBdmf3mcdSRn+dA8t72LzCAibgSc8Csn5nWtzE0qNmRJGG5ol8uQ4wcA8H+la9tGHVkjQOuTIN3G1T8wH09DRp9ukVx+9LeVJCxY9AeTx+NOW0kCW2xwDsyjE8MnJAx644xQnpcdtSvpwX7TAZAzHzCTnr3qXWZyNJjYEl7mRkG7sBg4+vNSR/v5VkUqky4DDsw96i1KHNpY20gUNbxBm9SzEliffpT6FKN5IzbeOWGFS5XYriVlI4A6YNb6iCUJJGqwtIxLLHzjj+VZiLgNEzbt/Uk9q01i8qEeVsLYwABnBrJSY5wuyszmYCMgEDAVQvoeprVtY/NaQsMDHyg9M1nIrqv7xlBUfeJ6eoFKb9UHLHd69sU0+4p0r6Ikmtk3u3DYPpWbcxwxLICuBxvOOpzTru4myfLZvmAI44Iqms8iSq8u1yQV2tyD70X1Lp0mtWy7bFXVYgAclcMRyCP6VpPG8T7Z5wN3RW5yPWsuBkhZWbIGchV+nQmrJle6AOxlB6lqb21HNWEurghVRSHdeCzDIUdse9Z4hbBMpYknksa1XswSSh4Ucev0qEwqoLv29+fxqHd6GV0QxQKu5oi5TvngD/8AVUF28SSCMTu8jdkXr+VZerarKbgWdox8xjkledo966Lw7p0Fvb5k3lm+bc47mqUWRJW1ILWGVEkkdUcDBCOMOfoR/KopoEvCzSQyBQMLsyPm7n6V0Qgi6xhIVJ6jrTDpVzCMxFJRztdhyPyNOxl7t9Tzu6slt5GkgbzcjaIgQAT7kmsqW+vIoxCirFAuT5fBAPtn+dej6vpwuI2WeJUmH8S8MPqO9cBeLCs728kGyZDkmOQgEevpVQavZnPVhbVFM+ZcAcI8mMgL1P4dKVIzKFLGRVJ5J4/OmyFlj3xzNs3becEjHfA/nUjTiVcxDcw5dVGD/vDPatWn0MlqJKkce4IY3duNxyMVUS5bytyMQRnv1PpntS3EzMcBGZuuWNJb2stzIqsoUAFyqDhfcmnFdyJ67FiyKXoWR18q6z829fkc9ueq/TpViC2lkupXDB/lx2ZR6gVFBalyVYGQeoOPwFa9vZrD5gQDci5bcRjH8uKbl2Fy6amNOj2sbyoxRhyEzjcQecf4Gq0uyd2ntSkNwMGRET5TjuV/wrVuVgikyzEsM4UkEVRuPs8koR9sbn7hxhs46gimmTJdzMuCGlU3FtGh6F4cqD+A61BMYpQQJSSv3WJBz+PB/OtVokkdI/MEeV5DrwCP5VmzQzQ7gUjYHIZ0cMpx6itou5lJWPdbKSKOdQMBwPXGa2IJg4K7shuM+tcJFfLnKMrY4x3FaNrqylArNtI49xXmxlY9Vq+p1GmsEZ4H4KtjNa6SbWRWwFB6+9cY1/ucSxuPNUfMufvj2960LbV0kQIzAMOQc96alYTg2egjDKCOT6k/0pjEA9tx/CsHT9XSVdrMFZeCKvrOrsGDAmuhTT2Of2bTH7mPGcAZz7+1UNRYqmcHjkCrJmU5Lfd6DFVLho5QrKei9Kzk9DSOhQS6H2gbfunByT0rSjmwwz06VhTKI2cqCTTmvHRSBgMoBJPf6VNKo1dM2nDmtY6yOfgbT19amUvtOJDz6DFcXFrOwcvzV2LWs/xjFbqojCVCS1OjlZzwGYH1zVV7oxnYztCcZxyyk+n/ANes86srjlh+dU7vUIHG1mXBPHNRKppdCVJ9UUtQ1CQfaYXhHJJLKCSq9a8x8Y3yxhmGS2NoyMhh3z6iur1TWEgN0zSHyw52SZxtA4yfauNvrtNThmkkkYSnCRN/A/IP3f5d6yprmkm+h0zfJBxW7KenW6S6a0cTf6OVGwMwPkMWzz6xn9KTypl3Iyt52QCG/h284z9a1tNQBrPzYo/mjdXYj5ZF5zg9voakhthdfv7dpFlg+WZG5GOzA9QOMZ9a2k7mMIctrkMce9H2gDzRteI9N3XaR6d81oOi7rHyo827fK0fUjDdcd6ktrdDbN9oYg+arJIBkYx2NLdoV+yyplX244PGfUH19qzvY64wTKEMKJqcksQKuGccnk5GPxHIrasrMRxrGBJDOMt5bf3jzx6ZHrRHDDcxZkRUuNwjz0Df4Hipo5JFuSsnzsTg568en4UXKUL7F5s/unw8eAUwvG4+v60y6KKm5d7KGADEcnjnI/CnwM3kyrIF/d87W+bC/X8an2oYhHtU5YYByeT39qTdy0rEEiK5hLd1/hOAecn+dT3VnK8SxIN5jbcp4yvsDTbhWSaOOGNZf3YVwgyoOTyT2qZWYWzqGQMxX7uefx7Urh0ViNYI0l89N+7gqqDof61DOouZW/cMsjH5zv447Vf0u3unvCJAJIWBcqP4fxrVNrDtLqASeuaFFsTmovzMC3toJF2q0qSc5DDK/gRVt4tuCw2Mo4PUOPqK0HiWGDiNcYyCM8fQ1lCZlVlkf92DzuOCpJ60+XlGm5alDUNkgUyEoh9Rg/nUF7a7bdWXBXHrzRqLjc8RwNhOcN39qpbpJQqJuwFwv071Nk2dUYOysBuQnmRjK5xjd/CfSq8m372MluBzw31NNikMp/efORxgcZFJHnJKnoByRnH+NUjTlSLFlHJNPsZSzH73fiujtYQkQ3qyhO4aqOhxEBCy7lfljnAArZcKHVXVtwU4X2/pUXTOGtO8rFLaI2JDFkzxtHT0zXNeItXFpiOOXfM4KqcZ/E1t69frbWLzsyjaOAO1cJo1vJrOpGacMV3enbsKSVyI9y94Y08m5F3KH2scjrk+ua76SaMR/umDOBgADn6fWqcEUaIIoVKhDnB447/jUiSL5jvJEVBJT1xj0rRuxEndjvPRRvhSSMkDJVgefx/pUSX16xYwsxXPzRFgN39R+FIWU3AMQXJP3exHr9a1xbRuitNbrnO1W/iH0xUWbFojMhnEYZZ7UGXGechgPx6iuO8Q2NreX4k+2LbOzcM0Z8tj6MRyv4jFejNpEixr5VzP5Z58pwDg+x7VxXjCBtMcSXiSAE4EiAAv7Mp61pG8XcxqWkmjir232XYRDFJHJwrLKMFh2HtUaRywtlMKwG7jHNba21vfQJ9knjdWwyxsQjA9MYI496zLixmt52hntJUJbb0Lq3Pt1rXmZzEUkTtLloyJOSEY/K309PpU8cRjh/jEpblSMD/9VSQKgV1lGx+cbuDn2HY1A4kGcTDA7Hr+RpN3C1iQ3BgV3ndY0ILLs55z3FSw3scqrIsShU43Ocs/tjsKz2i2grguzdSOcfhTgkbOCxZjjlsZ2j+hp6CaJpYTcSZaTC/xEDgE1XmCbTEu6QfeDjAKEf56VcEMTgxxXRXPOM5PSqq2KvcMBIDFtJd0+UfT6VUWZyXkRPsMrXDzKHTn95xk46k0MY5oSVKgAlzNGdo/Orklnaw6bI0wYOvClW+XPoR7+lQS2JeyiSLG3AO0j7568j+lWmmQ0c/Hf3rsWF1KG6DnvVqfVb2CUJHeGYAD5yM8+1UZgIB5TAGQcsR29qr9R6V0ezi90Z88l1Nq38S6nGwzMrD3X/CtZvFt3CqPNFFKp4EiNgn6iuU27IxnqeRTSSigsMhuoqJYenLoXGvUjszubXx0sZBKTRkfxAZrorD4jQYCvNgjuwIryNkwD3HGD6+lWrCPmWeRSUhwSPVj0FZywsFqtDZYuo/i1PbofG9rOAvnxgjqN1St4otzwLiP8DXlmhWa/wBoxyXIVt8Acgjvg81JrlkLfUWjwilXExAHY4HNc7pK9rnTGr7vM4nqA123lAAZS3rmr1prFsTiYxFR/eYV4/eaamy8WGNpmOGDbsDaRnPHvWvYWUR1G1BUbWtgyjHXOB+fFSqSWtzTnbdrHr8eraKybXjs8DpnBrNv73QB1lto+f4JNv8AWvIbvTt2ooVXPmMjH5cdWqee12X1wGtVbErYYdQAePw5NXuiFdSO6utZ0ULIYbiSYRgFhE5OM9+O1cvf+JLKUA2FtOdx2LJJIRg/Ss+INZrPcRKvHm8bOoXAII/MUk9lCq2YiI8skSqx/usQcf0qOVbmt53tcZqsUkqo1384+XagztUDqT61cW3RUtLYIsiSQys6j13Z4PqBV+/skmluFMyqWRdpb7uCSD/SjT4s/Zpw43QOYi2c8f071V7IOS89SGx32qQmT99bk8ntn1Hocdqtxn+ztTV05iLFFZOdy9WQj1HBx7VqPpsIRlTc5lz8h4XnPf1HUVnXFvLBexFVZll2NIF4yRxuHv8A/qpPTUtRRYESwzO0TuNwVyMZUg99ver6wwXlkXMYCxuCTH/zzPfB9DxRc2zCNCXQsjHBznKHkZq7E6RQSLDG0jqpDbj1XuAO/wBaLGijpoZgsHVZDbysxGTgr8px/wDWNSotwkL+YkWVxtcHcSfp6VamCusE8UrEBlU7vp39Kljtw6xGQmEB8BlP3j2xn0/KobNbWRFHNE673LDcnOExwRgjH9KvwmSW2WPyHWNcASABWP0zVWa2jtZ4pJlGyQYEw+Yrg9fY1oo0zlFCAy9CTznvn2B60r9CZa6olWFUg8tIgoH3QCOD3JNK0sMRwS2QOhPf1q1Zsk8BS5VVkJ6A8EVJ9ljY5eMkLwMjkCqtpoZcyTtIzYryYzlYlIHTBOMe9acchRscrIevHUf1qXaFjYTc8dCtULjaw2RqdqnO09vcH0oSa6hdTeiJZs7Nvzg+h4GKyNThLB3IxkY681qL/wAs0YqoJ+8Tgf8A16q6gSrMNqu4OMgjr7dqp9y4aPQ5e/RopUST7zICDjkcdQaq7kLqD94Y4I7fWt/WbdLsYCjEAxknHGAOfxrBkUxGNGQhgMnJ6D2NQ00zvpzUlqU7vZGRIpPzElR3qTTrdr2ZVwoCnJwTyKkh8vcPtIUqVZVJGcH/ABrR8PweXbvLEpVJD/EeQP8A9dJ6IKsuWJtwp5aI23bH1Iz0qzwEPAYDoTxj1HvTCXSNN0ZHHO0dRWJ4k1EWloyJuMrHC49Kn0PNaucr4uu/td81pFnIG9QRwxB6Y9MVo+HrV7RE37skZIJxn6Cm6dp/2hVuhEgtn+ZW+bKt0OMnv1rdaBEVdqMTjBzwcYoka3SVileXm04G8EnJI5+lU4rktIxyd+Q3B6ipb8xPCgUbdvO3pis4SLEsZBIkY8g9x6VC11JSR0mnRPJIJVYkMc567fY11Ol21xKTJ5itgkDHBxXPaE/l7FMbiRuhI6j+td7pcflQhYTGCB1dSRW0FdnPWlYhaOSI8s+SQW4BP4+lcN8T2tp/knZGHyje3IBPTOK67UkeS4XzpxIAc7VXaB/jXnfxBnLny5kk2tyjkAKD7gCqe9jKK6vscZII9/2e3jZXVcfNGcnn8fzNXbX7SECmZgF4IUkAj+lFtfPJIYxDMhVSCWBJPt/9ap4QXKNIuwkZCkY3H3GelU0Zq1yw09iV/f2/AG7c7Bz9R0NUp44ZWJWVGGQV+Qg0s3kGRgiBdo4HQE+maltSqqT5MYLYO1RnOfU1LNuVdCm0QXHPljGOMA/WmXURlCbLlFCckK3ze3atvT7GGeeae/PlwxAswPJlI6RqPU8fhzWfNDbxFQQVkd8kYyPwFUjKUUUpdNWTe0eGdV+7nr9aLaN7aBmdpEOMMI1zkfToKs3AluJHEI3q3VgoUDn+VT+UrsDd3DyNjCHByfQD1H1q0zJooC3E5KLG0o6+Y5wWJ7hfpxTr1JhIAjKUB2gHrnHNaEsywxypgGd24k7harW2RLuBWVzztf8Ax/pTIZwDZeQl+ATTo4yzcDGPWrEEPmlpDkxjsByx/uj/ABq/FClorNLgOewOcD0rqlOysc8YNmWIgVeSQkIvU92NVn69etWr2bzZAqIFQHhRUUcLMcKCSCBVq+7Jer0JLbDhI+gTLHJx+H51saFavdQxRIm4KzO/PfHX8hUGi2UgCXLJ8quowRjcpOMj2ro9LWKBLjqHbzGwPrwPwrnq1Fsjoo07vUvQWuy/0xSCpks2XJ4yQcg56HrWbfCS61m7mYnHEYGcYI4/nXRX0e06S6KFKnjccjGMYzVCO3H2S83Id/m7lH/AulczkehCndWNPw/ZGWWASKATAUxjjLLx/Iio7GJ7TV9EJ+9saEKoxjrtq1p0u4MYtyNHFvCgdME5/rSaoNk8U6KNkZRwT2B4NTc1jHa5j6iJI76OJkbiUE+4DdPrxU2qjbqN9cRgmMbbcFhjHQ5q/cRRJr8cwJmjGJeRgYB5zUWroYr66giBMefNBPQrtwPxzk0Xsrg17xUjiaUFFBKPEcMAM5Y8/wAqr2qu+kaeuxfPjDwc9cq2QD+f6V1OjmJdFghuQnlCZpF4y4JXgjHY1Vkt1ivIYiWMF1udQ3/LPJyuPyzR0NH8Rlq2+GOeeMBo5FLJjACn+QrR0W2Zr29hljUIXJYdmxnp74q62nyR+W21FyxDADIz3B/z3FR20jQ6zHJKd9u/yMCOU7Z/kaa0CS5tjZtlgKLFGWaMYTMhwfbP0OearXmnJcWMUcQzcQpvh3NjJUn5TUiym4mCTMVbmMleCrA9vY9avzRtJCG3skqthd4xuOM0yEtjJliDh3jKjABeLoc9x9KbaiW3aOFxncflPYCpJswzob0eWyDY3HBH1H3voauxLCWAiDXGzDhf8B3FQ1c6Iuy1BYA0bRmbgnI7Yx049alA34ExG3GNo6Zq0lvHJA6hQ8g5AQ7SnPf8TVuCzw6lQVG7OCDx9aLXJc0UrdlyouQ/lEckD8O3tVqOG1FzII5SA6D5SM8dBmnXNiQAZFHlnnAPSiHCxgPHtcn7vXCjtRZrRkN3V0yKOE24bCnzTk4Qj68Zq2JZPJjkGV3EEk9j3zUcKmR9x2kjByKvSISHUbSFHHf8qIkTZSknyd6qX5I3Dn8xVO8QQQgqQh68Y3Z7irZxsIVVwOw+U1DdRCaJRISF5BJ5BNBcdGZFzcvIqKSWQMeemPT8ajiuI3KKW+bjcOpI+lOubIOH2SIGPCqOmR3x2qna6dJHuckyc59ce2ahXuddocu5ZKCWbJO7qcMT64qtMiJv8wDyiSMk5OfTFMklKCSVV9C6EEnd/ep1vdrJO+wDcyhueefQ5rQTg1sSzWltPC7CMebwfN5GBjj86msQUZVBBxxjPX1/SnCWIoTEzOsqgbcfdOe3qKm8tIY12Egg56ZwPpUVFsc8ptqzFlmLxsMOpU49sCuFvGk1rXI4VBWBH+Y8fN6n2rqdbuYoLSRmJjjUc7cnP/66y/C2nGQNdmI72+YKhAC+mf51L1FG0U2dTaW1tbWqJGEfjIA5wB/KqVxIY2JjyDITgEZPT19KdczSRr5b+WCzAAAYI/8ArVUu7grA7vgsvG5T09/pUvVmVurOf1eUrsDHdyxDd81z2sTOk6YyF2g5rWvpFkABUYz8wB5/D8TWb4gSWeWGWbCzOnIAx9OKaVtzSEvePQ/BLm4t7WRiQuzknjGOCK9AS5SK2A2qA/8AG4Jx7Y6k+1eZfDhJ5wIC3lrGclv6CvRrqea0QW9q67267F+b3JPetqT925z4hXnYqRRyyySzyRyLDyec73x0HoteS+MLeTdL9pufsa43EyS5JyfQZJr0/XL8wac0UzSMOMAkn9PSvG/GlyJJGSCImWQ5MhGSoBPA9c/0qklzIzbahJlRpfLgt0DvMJR87udiMR0+XOTx7+9bQgiutNIYSJfEB0wRtaMcc+/pXN6dbNLp7mbJ2OGQAcgEfN+Fb1oTDcKG6tb5Q+h5yMflVyVmZwfUktolMsSOA5njy5PIJ/vfX/ColtDHcPDIyRJ2wOR9B3J7Vb2KYo5cg7l+VU5w3oajhhaXy3IxLuK56kY6Cs2rnTDUnYuit8xjhVQFT1YjGT/U1XZ28xBLLs6YXqx+npSXIDXJhVwSucyZyWP+eKMiWJAch06J070r6l+zUkNLsWbbvRR3c8mmKuJiUXL4yWYnKr9ahnnImkRCVxnLL6f561AxlKRozKVPPuR6mqucs6dixdziSdobVwIIzxJIhVpff6e1AlgjaNb5VmQncGC8HHoe1MtXfa6gApjnngD05q/DLaKjfa7WM5BKhcqOO/PSrTuc8kchbRtbtuVCXCnC7sKAfWq11cAQsVAd2PLsP6fpWjcIfssoGc4+YbcH6t71RSFrhmcr+7jj4JHHtxWsZK92S07WRUtLVnUtgbmwB/jWjY2WJA0y/KnzOO7DsPzrVtrF3jlKgfu4S2Mdc9fxrduLDNu0nloX2RnIGeM9al1rmkaCM7TC8hk80KQy7eOAGHT+Qp2hoLmNWJyXVsxgdCeT+tXNGKW2oNHcx7ozwVPQ+g/Gm2kP9naqssB8xGfKbuD9PqOmawlqdEFZo2riN59KRY0eaSHDZXGQBjoKhjthcwJKBtV3KPj8z+v862oId0qxxsolIO3b6dcfgTUdtYO1yI2Hls7hz/Dk+uKm2p0xlyj7LT2ju1VshZYwF45KnPP0zxzV1rVWto7WZBlQYicZwcHk/lWik8ctxDO8Tr96NsDjB6c/UCrf2QThnCjckgb5Tg+9aKJlKp3OLv7IrdRzp80JKpuU5BXI60+O2+0ajMMM4MSA7gAB/jWxrNoLZg0SlSzfLszuYdQPzzTrUxm6mEkK7iFwV6MT2P680rdCufS5h6ZZG1tSpQl4Zgpbn7pHyn/PpVvV7OZbnT5FIYhEwp6ZGSB7ZyRXUrYP5LCylIO5l8pwGBU84JprxvbwBZlgdR8m0gjBHKkDsf8AChwLVfUzbIKLWaNmALDcisCSVB4Ax/EOR+FQra2k9wwmZ/KYhklWM7cnp36eorVNi88sk8UbA43L5RBaI5/x54pIYLe7h8llCTRjOEOC3fIB6Uai5luihci1t2JnMi9nOwcY6MOfXmp1lgWGe5uZWLSANJtTg89dtXGs454NkrAshwjBSd2P5e4qaHSgLeQW0qujjDxnjv2z0Bosw5oWs2Y0M1heqFeR5FztJWE7V/X5afZ2bWqHKO8O7KqiDIH+fStSw05Y2jcoMH5Rx+hq4yvECyjAGMgHP6UKN9WU6iWkSrFBDdSqZNrhxtG5tpHHQjqK07a3ZQoL72AA+ckkYqGxWOYASIBvB3A9R7j3q6toYwiq3X9apIwnLoVLmIxhXwd38JHY+w9aY1u8wyjRKcAkMuSa0WhJwFbBU/K3BNMjtHVtqk7i24EjqKLX0Ep2RnxQmH5AADnJxyMU5uUkUZ3dOa0/Ii2uSuB7nmqM8CRk8A/jz+dJxsNTUjDk3rPxkxjklhgg+lT27ku2FJVgBwePpmnSQv5eN7bSSQT2qWFEwp5Ck7sHn61EUbuSsUri3G+RzGxIwM4HH41ltcpbzTFnG1Rl1H8BHvXQ3sBaFnzIigd+QTWBfW5dUhiXHnEgkkYY+n403obUWpaMwry6WeQyR5EmcjJ6/SoSsqu3mgbhjjbyc1pGwPnSLt2yKwCqxx0HQD+tMuIhKY2vHfZGdj5GMccA+9RZ9Tt54pW6FjToc3MTJs2YwNvbFad1CFZhCX3IMM6c4J9qq6Jbnynb5SzNncRjcO1aF05iVSQBH9xj6UnqedN+/och4pu5FaNV2l5nC98fWur0a0S1h2w/LG6hv94+tcy6/avE1tbhg2Msw64HY13RtZYbQYQIv3+TkYHeiKvqZ1pJWic54gZY38x3U56n+7j3rj7+/eRJFUEluM+grX8a6ssVrKrgYOBn1NeenVXaVcxDYOMbsk/U04wctUQ5qNkzr9K09pWEzKPLXoT2PrS6jDJcanHDsSQNhV3D+vaptA1I6hbiOCKRR0LFcKPx6VfbyrN2fybia5ZCqARkLk+pP41LTvYuLs7lrTbiPTLy38gSIiuMSIobJz1YeldDqGrGzkd7jLzHJ8sjI/MVlaTZXV4A8q/Z4gPljQYOff1qxqDxQwSRsGXghXz978e1OEnYznZy1OY1fVJr1zKEk3YwE28fr2rmZmW5u/LnhEc4581DnBJ5yOma66SaOFFCrtVlBXed2foTwax55hNMZlh8yaR9gcna4Hc8cD61UVqOdmrIgisY4jKhL7SuwOr54PUkGkliTNvNbyboMKyq42t12kc1oRbJUSGILgxsfNyfnxweaq4WcRxPBgM2FOdpAyCD+Fao55aEDsYr+HYCDCfKGRxnOeB/npV9HY2sQUtnczSqqgZOcZJ96p3cLR3YmEiYaT+JsYOOp/nirCBTIsDTfM+19wB5x/Sk9zWnLQpSFEj+0PxJu2lQOB7iq0rBZishKnhlZRk89qtXBYkxhP4tx5zVfUcQrbzKu4MpJUHjOe9QzeM9kPcqVczRgqRjcp59Tn/CqDSsHwgDpkMSRx9fyq2hMsR3pn5dxzxtP+e1V7wtAqxSLuLruVj0Ye1BMlcjSMNtaOKQJK2EwCQ7n+Eev07VHq03k3Qg3S/wrKZVHDj7ygDsDW2zwappVhCmqQWRs49jwShlG4sT5ikDv378Vna1cQ3uuRtDMt2VhSEzMuDK4GC5+v8AStUlucM97ETxNLLKh2v1aU+hx0/HrU9hZZtxkgM67Wz3z61ej08lFKgOzYdi3DA+h96uW1uDKyqQOS2WGCe4571m3odCgtxmn25XMbgmXHIB447/AJVtxW0tsrQuC6+XtJ3D7oPBHvSRW4niHyhJF7qfbg5rVjgW9twL3KTA484dOB3xSSGzn7qwAuEmhQszDJBJABB6Y9OhqMW4mmAchUkJGGHAbsPx7GtxrSRHB35RWwWJ4zirM9tHgkJtWQfNgZ+hBptXKjoUNPt5Ehj3R7wjAspHQjrg/l0rpLOzS7aKSGYhM7ljlXIz9evNZ8CSwnfFCrQtwdxJZW9fT8q6Gx2zRBQqt0YFF+77U4oibK6AIGglQEKSy4GBjOevr9atND5gdHkK55XIx19+9WQR5m27jRmJJWSNsBuOmD0NBUR7VgOYhk7WXsPbpWtjJu5mS2081rMrPIs6kMpxwDnp+NSpbRSyKSVI+7wccgZ+vc1agJeNlXzOMEoT0HrinfZl8yJj8rlux4JORU21HfoLaRPDK6qQyOwbY49R2I5q3eGKSTzJEwzLh+4bB7+/SpHt44WDjJJGSBn9asOiyxq6rG7EcHpxVkdblK0gQOzxKEZgVcA/yqte2kLAFo/NVRkZ6j3Bq7FGseElD7V6FDwc/wBKfh4rjAKmJ+eBySP50mtC07M52aFoXIjl8tnGQGyUb8RyDRp9zLuK38flz44Dcqwz2NdCYLc/J5bfMSdrL39KgtrTYJFlBXHAyMnHb8ajlaZsqqcdRRGXyq4wwGAV5Pepxb7vvOSegz3HpViKIKh2qU2gcjpU0icfw7ehOPu/hV2MOfUqwJtYhkAUdd1WFj3qTjvkD0+hqJwyANtQ567Tk/hSZDSA+Zhu6nrQJu+o6Y7OFXB7+9RQkGX5STzyw7fjTpH2ybmOQRwFHNKi5jY8k8fL60bjWxVvJPLjb5snPzGquSeP4cZ5PDCpLxJGX5SU/iOOM+1Z6naQpcHHXPcGoN4x00Gva8ZAIB5xnrU0CEhVypx29BUaOy4DDAA4L/zqxvMkQ27T02nODikipN7C3BxFtwuCOARnPNc3qapITuJRvQD5h/n+tdDKyF1WPbtx0I6Vj3bWqm7MquzLEyoc9yDyKclobUHZmRHb7khWCT/TGk2DD9B2z+NWtehUSR6aApCN50hbh3Y9Sf51bstN+yW9rfXOx97hzuOMDbnAHc1XEi3upyXR+433VIwFHQD8ql6RNJ1Lyutl+ZZtUREVUBJ6KB69ualvsJHl8LJt+6T2+v1q7ZKjE7fu5x9MdazNfdYLV2K/wnAPPftUWsjnveRheCo/tXiW/uZv9Uo2IxGM4ra8UawNNtHZDiFQQOelYvw/bbpN3dncfNlYoc9MfzriPiNrT394torcJgvjjJ7Zpwi5WijOrJKTk+hzuq6lNqV20sh+XJ2rnoP8aZboZXVEjUsTjJ5qvHFK7AKpZjwABkmvSfAPgS7vHF3qKmCE8gEcn/AV0TtFcsTCndvnmbHguyvJUVZQXVQMBRgCu3uNIMP2e8vHP7p+c5wq7T27itbTrS2063CJGFUDGMd/f1qC4Zp228Fenzc9R0rO2lmVKfNK6MWCfZAhRIx5nzBzkiq+pWz3cTjepP8AejGAPqOuKsNG/wA8cPkAwgY2kg89/wDPpVG6lmHyxiRV/iZgM/gai1tB7ao5bUrCWCXDhSwJP3QyFff2rGuLaQttjUqjqM7WwSP89q6PUJLhZxazoXjGNyu2TjqOarXNrJNCjWzytg8qcKW/H60rGl7mbayTQCNXikkQYTGdvHpnFLqCpAwaHc0yrnnkL7Ke+PWr6aazQjzGjjiU5/1mc49eeKpqvmuQp3fLlnVc4QcgZNWtjKSu9DNMSokkty8pEpBTaQp3exNRJcx7iYbdg2WQGSQtjGOwq1qFs1xpwYSeSFk3RZ4yCP8AGoYw1tOsm1VGNxB5zlccU2KLsJdPPNbbQyIAoULGu0N3JPuPeqN45jtLUHbu+ZQM9fmqd7gfZ4VQndIGmPsucf0qG6SG4kRzGdqjAI4Oc8n0qWi4SY2AsAQ2SjHBz2Ipkl0IoGiuE3ZBC552n2q1FPZgSMwuVdkyMFWXPvUYksYJIZj5lw6ctDNEPLJ9CQc9Km1tTdzurI2rOTUj4csBo91ZWqGMiVHkjDl8nLNu65GK53UkuxrUTajLHLcFAWeJlYEAccrxWg+raYSNujae6twwMLAk/wDfVQFreS6klis0t0aMARxfKoI6lRzjNXc5nF7tHY6faRCTc7OruM8HBA7H6VpiyiVA4MW0feDSDI9eBWJDKLUhfNYZHDqwwfpV+0kRnyYxMv8AeUksD/jU8xrKLepeto7FpQDAkfBAcvnn6CrqacOGgmRmxktGMEj8OtQLtcHylkiwfnR24J9elbmmxDysqNrY+YAA1S7GctDIkt5oZmnRFnt5V2MBxyB157/4Vb0+Lc6iONnOMFM8j/61ajQqwIkUGJ+N65OPqO1S20SpuAISNcjaBj8j6U7CUyhd2xtwXhPlxyfK6suTns2OntUWnx/ZroGTzdknPyt8ufX/AOtW7FEpjMbDzIm4DHk4+tZaYtJ2gk/eRZ+Ug8qe1N2TBSurF25ifLDzDyMxuDnnsPas+TUJUZXkUYfIIA+63Qj27VqPygEeI2PHHIz2+mazLyJ5mcBSHzlg3r3H40Sv0HTSekh93co0eEILqMY3Yb161FHeM0YGC44ZT3H1qrbwNFF5cuwXGdyswJ8z2/Cr9hD5c4UxlYn4Oex9PpUK7epu4xSNmCR59ojIYFemeSKVY2jkJKYXuQ2dpqCJUt3RN+GyCFz3/wAKviRDFkLkA9SD+Nao5GiKWLeRHEQm49O4PrU8cW5WSXO8DHT8jSR484xkZBHHPI/GlErGU5c5zwcYzTuLXYUjcnlTtvDDocZH4066gzZOYmeKQJnrkZHTijZ8xcZIJxh+M1HJCjZDfIc8jdwM0mBG87bkDMFLjOAMZP8AhUkZRoWyyZyec96IgBEIXaJ+NrKeTkVAxCybHjCpjr1x7mi9h7gw37lD/Ocjcgxz61WlmFtAoLKNp5Yjpn/GpnVVVvLftnrXNamtwZ85I52ncM49DWcpW1N6UFN2uaiSNMwfeXcdh3q9bMyMwc5ZuPf86yNKDJA2WfO45LdT/wDWq7PcKvylznjIHOKE+rKnHXlLcj7lAOCCcANknNVWtsR7iM8nDAc5qKKbDOjM27BwcZGfSnWMhkbbGrlEPIPQ0+ZMlJxK7xblJJBAJzvPUZqTpt+Y5AOAR2Pap54gWlMIbfj068VXjTdEGbkj5T9KOpV7jHjkkSXg+Yv3RjNZt9bu06C2BcsQzDP3iccfStkySlWUHC7gce+KqXVuklxE0isVGSQDjIxnNNounNp6mbr+oCeOCEjcYiVyRwvoB7gVBpkO0g+jZORnio51E97g8KjBcdye5rY09QqnjOSeKzlqzR+7GyNCzVREvBAIAK9ADXJ+N5Ui06SMEBwuNxbaDn/CuubdFDgfcfkk9a85+I8zLpsrY29huGaclpYxhvdlKxuxpHhJi0yzZQtuQ5DGvLzI80rSOcuzbm+tdH4gvtug2NpH/EilvoP/AK9c/YJuuEBPBIzWtNWi5HNVfNNRPVPhf4UF0ovrhVI6gGvXZGjtoAsfyY4GBxiuN8MataabpcCu6KduBzW3ZXpvi0gwsY7Hv71mmltuVNSlLXZFqSRjkbi2eakZBJH0Kk84ouZYmi2oo3E8EetZsF/5UnlT/I33c9ec9j70X1JtdaFi4RWiLQKq5ThT1J9D9RVHzjLGWeOIYGcsOTmrNxPCUBZGcjjhRgn8+Kr3FvHPskXfuOFZtoXfTbfRh6nPXJFyzIkgiY8AFQVJ+vas17OS3XMzZkDbEVXI3DvkVt3EMj+b5Mtukatgrn5x9fSsl5YY7hAjLLKfmLMSdoHU4/xqV5m6ktkVpI0hUpKYSWBkYZwAB7D8KftEc0pWKJVWICUjoSegx7e9TpbLcK7lUCzSAky9WI6D6AelQ3U0b4gAURhiT3LsOAf/AK1UjOXYx9WVmh+VXESoHDAZ3DPGR9ao6wWnTyYt3nbSAF/vd8Cte7kEn9nxWu5Tu+eVxjcwz0HoM1nasIXWRZGCoExkcfX8aRDRzV1M9lNbiQKXVFUpuHOPXFPtZNrXEuQySHjPrSXOhsGjlbzJIV+Vdi47dWY4AFO8hhEFiYvBHncQpzk98enpVNJomEmmLLIqymJBiVlBZj0QelTLB5dum9cNIMHPp6kVFDYzyyuxibZnLZ+XIx71pTQK1vDLc3Ki5A5SP5iAPu/T0qJKyOinK5m2llLcZjhheSR/lTYhO5h2FaF0tvHsiWC5gmQhZhMw69+MDHPSuotbu3axMls1wJ4rc2qoIjsiZ2y0u4cZIP1qhrqW9xcq0RaTyo0tzJKMNIVGCxB6fjSSsEnrsXrOznikIuE2Qj7rY6fUH1rTiiijXaisZM/dUgA59DVkW14ZQbvbcDsoOOB2rSjw0eZ4WjXpt29qSHKQWVltiAS8aOUH/VyjP/161YTIqHcsR2L1A5Y/hVXKqke4l4ieCeTH+Pp/Kte2VXhwRlccErn+VaIwk+5XguiQA4IDd+n+TSYjLhXMmwj74Gdv1Hp71d8pDGdyrIvUnHB96jS2VsshKdtucH/69GpKaEtQqrtikzk4yvINWrm1WWPzEOPlw4Y8/h7fyqKO3Nsh5ZUPXC8j61Yt22/cOQBuHp9fpVLzE3rdEFrZ7IOFBeP/AMeHv/nrUzWyyAPuB453dcUomRH+QlG+mRUhlUbm5APb1p3Q02ULi1WWHY8atJywdSRz2IqpbsYWCzndGpx5i88/7Q7GtuAhlbZnYRnio5oFceZFMI2/ix0/Gk1cuNSysyk9u3mq4blSNw68e1TDesqgr5bueCGyrf59KlggSEINyqpJ2gnv3FPnhX7qvyDlHHbvRYTlcYGUMzsGwn3iTyv5dqvIqt1Yk44Pr7ioLMM5csVye2OnrUsi/uf3ThQOgPY0zOTHbXdgrElVGCQeppjK5kYfIMYyRzTIJM8LuQHnGO/pmkV1dyV4YcFPU0DI8oJNwJEn3WG3g+lRxsru0kYA2/K4Y4NWXwA3ZgM57VWcqZN0WVmUYPo3fBpMaGyMJ3f72Mdx1qCW3+QbwrcHBxzj2qQyBJA7EhiOB/jUk0q/LsY8DAPX8qleZom0ZMzrbqhVS+WADdvxpn+tJZIyMHBK+nbNW7mAOu9XXqM5GTn2xTZQpEm7APUkfKDSZspJleOImZpPM4zyD1Pv9asWcbKX3iU5HTgH6nFRIwBxgMxP3jx/+upYZj5u7IYdMnv60lZBJtkhRVCgN8rIBj1NV5GGzOAMcMN2asSSmTgklRnAAwfWqj88rtIHbGMVbIiSx73SUBS2CDj0461Ru7pLc28jAjJJDe57Vf0+YM8iEfNjB456dKparAPIPQ7eV9j60PbQ0ha9mZcawyXm6EOyMSW3DB3d62tLUsQeo4rH08gEtjJxzx0PetvSckugIGD61HmVVNC7XZCxA5PTP8q838fWrXGmTBQQ7DntyPWvVLhPMtxt4YHgeorj9cgWd/mHA544xTqdzKlLU868M6Vb3+hnzkR8qUZT3rhtQsptKvfJfnB+V+mRXovh+YWXiWeyfmG5y6n0Yen4UvxC0RbywZolCzrkxt6n0/GnCVtyalN38+hleCdVtWu44HjV5m4GTXpEd/u+WAFsDgD0rwvwS1sNXRLyJmD5QP1Mbeu3+vavojSbNNsTsEEpUBvL9h3qpU7OyIhV543ZRa+YEJIjqG4xtrI1aYLCXRjz6d8V1es2o8gspAGON3evOtWZkna0Y9WBFYVI2Nqb5tTrbG7WaFGl+bdztBGTWvIbKO3yUumUDlWK4PtXJaE2wsGyRuA9OK6fUpl2gz+Xhe3TI9KcZaESjrYpC8jlhBFslw7ZG2Q7Wix2VuOtUpoINs0VotvHMw+ZsEk+gyOSfeiXU2nZvsdvFBaqPnkc4IX0GOQap3Bt/wDUWPnedL85/eYkcDrk9gPwrRNNA4NEMlmkcQMkoTahOxju2k9D64qtHNaRsqRSCS9fByify7AUs9vDdXYSF5bZJOEEfVl6KPXnrz2xSppkenRK2Gk8skMS+GY+gIqrdiXZfEzNvbhWEc0kOyNQVjlXkOc849vesbUwn9lsszAyL87tn7uenH04rUvLmNwHSVnEOEWNCAsXpkn0/WsUECyvHeJpIiQ28/ebnv7GoYuVshivbgWzJZ3EkZh5MTAlWXvj1qg2pHbI5vbuFA20rGx25J4APWlaQyCdsFV24RQMHPHOfWoLy5kljiiHD8ggpnB7c+pFVGxEkPF3c6gGiaaKWcH92epYd1ye/TFXLe3muVIaRDxgZbaBjisJHl+2gh23oyspHQEHnj1rsYLiF9OFzHD94EMoHAY9T9KdSI6MtTf06f7RoxtrW7t4yLQxNbyTBP32/O456gjv7VmeIilxqAeOYXDLFHHLKvSRwMFv/r962rW3ni0zTns9Jtbp2TMkhtw7bsn5T6EcVb8QWkMlldE2UEDwiIK0C4/eMPniyPvY6+1Q1oaX1NyxtnR2nky3y/KC3C1awZZccqnqMcj+lOh2OjZTB9M8Ee9SPGREMg46gY4AqbBzakkVsjN+7LZ/iJPX/PpT7YzW1x8gAjPy7MkfiD/Sm2pYttG0AHoWz+tXndfLCyLhj054J/rVK1iXfYfCjCTcGOO4xwfrVkBXTJGTnnHBX/61QI48rnJ3dADUwPyDHyHtg1Rkw3FXVQuVb+Lpj602T92hxHuK8gD3prTqxUADBHcUrsTnLNlejUNjS01GKylSSgTJ+bPJ9qldWOQ3LKOV7j8aUIrRq7EAsNpUDr/9epSgjYkKWAHTPSmkO5DFJ+8ICfu8cbTyB3q9FEo2s5IccZHGR71XiUEBtucHG5R2qeRhGQyfOuPmC9jTsTJ30QPEoDL1A65HCn1ppTZ8oCN0JXPU0il2bORtYZ4PUUx8B8kY7Aj9KBJNDgnlyM3IDYbbg9Qe1AU7pCN3lucggZINQxzmUuxkxjnAOfwp5mby4yDuVex/hPpRe5VmMmLRNkEbM84HQ+tQJcBmbeQJEOCBz+R9KWSVtg2pgnk9+M1XmliQ7SN4GOAnrUFxRYecbFPUt1Hcj2qGCNEkMkTsrZyVbnBqLzFkm2Y4UEfN+lStJEjBeSemUP8AOpZTViGSFpgodtyZwBjrVhFCxEHdleAAKCWVWQkgnpxTUOWxuAYYOAP61XUTbZWkDhsqqLt5wvJx6026lSQGMbyy/MQSBwen1pmoebFIhUv+8PIB6f8A1qzi0gty9xIpAO0rjGQe3vWbdnY3jG9mWRMEZFwWz3I6Uk0xDM4BAz2Awfaq5ZsBo0bHPrhT60iyp5a+VGquhO4k5JIx1FNGjjbU0I38yAAcEd+hqJ5AZT8zK4+93GPWmDCyqoYlT2YZ6980zUAVQ4UtyOvf/wCtVGdtbBp8mbxw/wB5hjPTjNX7oMbCVH+YsuMnk9f/AK1c3qE8umXNm8kRUSnPHLAHjpW5JcD7LGy5zgHk8YNCa2ZcoPSS6mPpoAlK5OS2Qc8ehrZ01m+2beAXH4cVzVrco95LGRjDcV09kf3sCsoznO71/GpWxdZNHRJte3Y8lgOAOtc5q0ey3lJAHHHvXTQqnln5gG6jtXO69gwuQDjsD0rSWxx0/iseV7yvi/TZEGD5hHPcV0vinKRlU+ZnbCr71yHiKU2mp212v/LOXFdg0RbSl1C5OJPKJjX0z3P1rKL0aOmo0pJs8isLcQeKfLB5WYHJOAcnr7V9J6a/2eGNWkRnIG9VH3TjgZr55mi83xSEhUGQugIJ6nvXvenPJbWJCkmTA3Mw5OO2K3T975HPyWh82Lrk+2zkaRvYIRnHvXniFbvWfNcfLGMk5yOeg+tb/i68ITblnZjkr/eJNZVvZtbLHnBaQhmA6Ek1hUldmsI8sTQ8P7xqLRtgNncOODxWxqxQjBJVgNu4dqq6PAhvpJOBgAD2z2qTWEILcdOuDWb0QLWSMdtRSOaJChaJOBH5e4ufUnt/StNtaijthHZaWZbiYkOqJtKjvk9Md/esa4eSELJEgZ8ff9Pw71RWRli8uSdyu/dw2Mn/ABq4VHFHROhGorm/qd3czRXMVpAjXCgHew2ICexNczfwvdLGbnUYHO3Bijb5Ux/DxVlZQsCqWUo4JdCxIjJ45/2qyWhTJHkfL12rIfmAP6Vo6l9zFUOViXklta7Vhja9JOVUfKgbuT/9eqzTSSlEjVUUgqxIx1HNWZ7eW5ihRI/IhP8ACOT6VRuIhHJzJI0kODtxgH3z61F77DdPuUTAQJM/vJnHCkeh5wP89Ka1q0tjORzcRSLLkdfQj39asTnYftUZzKTnnpHT4FFvLavn93NJucEfdTBA59acXqZ1I2VzNkhRZoLrYBuPzEfxc81JpN0YL1Lcsoic4G7tz/jS3CGNZo5MHYu38O1Z+ocsZoC24HJ5zjp/9erTvozmfus9h0+0tk01JDBPJJ9nafckxQPg8qMewrL1PyI7mNbWN44pI1lSPcWwGHU56Gm+HdTt4tM08XF5fGWRDOhhZfLiJ+VlGe/HNRaiEmvXuIpJZEkOC0xBYkD24x6VM30NKd3qegokSxhlVeRncelPgcTNmINtUduM/wCNQICicOB2wRxj29aWOWJxtIwynAI4FK+wNFzKwgho8j2HOajhPmSZYsT1G/sfWplT5NzZxkfpUM65A8pRgDqO4PahsSsTmTDqI1IGOGP8qsxEsQGQZHeqqpmNY1UqVG4E9RxU1tMCiiRT8uVORyp700+4miY4kBDdgRg1PGNg3E5zjIxnNRRqCC4Ytxjnj8alVWYIQRgHGQefoatbEkqoc4Cgc85oUSJngDf1z0IqtO/kRswVjnGc+tPS6E1srvzITwSe460J62E4vcnAKgBGxzuIB/lTVZ3LkgYAy2euO1JkNLh1AB6jPTPSowG+0MAMbVAOTwaYANu4nlQT0IwOnNMkkAtwT/Ceg70+QseQCvQkelK8asQuC0Z46iluUVrdYiwKLkNzx1pZsCZ9hIyBkYxmljQpKVGTHuyo9D6UskgCl22njAJOOnahOy1HfUzTc/6QVydqYGB0FSgLLu8hySBnd6VmardpxHv4k5+Ucn6VNZSCG3Cj5mbI3HrUc2p0uFlzFq3jij3F8knBG7v70/7oKxoFXHUcE0sbtyjIplPy4JqvIr5XdwXHPOenHNJsy3epZhfL4ftxg9hipcqoVyDtbAwOar7yqDLAkjK4H4GhH8shfnAbPDGjmFYdMg2s2/AH3vaqc0ce5t4YYO7GM9O4qzPOuMqAOcnNVVnZXU5U85A7Y7fjSuuppC6KXmS28W4yOAWPJ44+lMiUqZWcKgbBJHc96kuRG9yHkDFs+hxUc8wEe0gKvOT/AHaDfpYnhdmdAOQchQD1AoumZoWLfMEHemRt5IRSVbGGJxjt1zTZRl32HKFcZP0pkcupzmsXEEV1HK7uwY5weSg+vet69uI5dOiKs23GFJ4bHY4rJ1WxSSymkiUtc7RjnIwT6Vmx3Mq2HktkAoo5OcEH17VN2rnZGCqJNdCqlxJ/baMnzM42kZ6mu70u4WWCIDIw3IPY+leayB5rxBCCX3ALjj5vUV2XhN55dVk+0NkOm45GDu6E4pU2Xi6do38jtLbVFVpFdfkUcEd/asvWp1e0Z0OAR+VXrixjkDOMg+3FYusoYbby2wdq4wD3rSV7O55kVFyTR5V4kL3eo29sv3DKNzHpXWajcfZ9KntmYlIgEAB6fSuYXZFrYllw0gfIXsoHc1ba5fU7mW3QKRI3mPxnCjoPrURasXVV3qM8D6YH1t72ddyOSYyRgk+4r1GZ/LiPJBzgEcZFYOkWccQDqMoqnAx8xPpxWhf3RjsSznadvy+5q02kZP3mrGG27UtcdkG9LRdwU9GY8Vqzwh7qJowCoO4gdAAKqeHbWQabPKqEy3EhJHsPStK2/eRzMFAOMbfTvWN76GktHp0GaaPJmn3c8KadqsnsBu9aWy+9OcleQMGopj5wOQOnX05pdAXxXMqVQwKgfLs4welY8jKSp69+nStyWICXDAbSD+Nc7qDNiWMnCg/w9c0I7KOugj3AiRyn3WP3arxTqs6FRwBtLdOD/nNU0Z+jZJAPT1qcKpDbkBPQ9sUdTWcEjTtnEc22QjaOA/YUahp7Xsc8kKBZkXcOwIznpVW0XL7i+0jK7SM8Y4+tbdvKTAjLGdo+UqG7dwPbvWi2OSorO6OSMEsFszSIwU8MoIIz7+gqJ4VmRppGIO0nHXkcYH0OK6i8WJIyyOF+XaUC7uv8LDuKw71IIozFFGxinOViLZdfXJ/X6U0jKck0Yzg/Y0b+OQLnJ5+Ukc/WqV4sds9nE7Eq4DMen3v8K1r6FLa0VnkikLORlBjIx0xWdJJEmotK0H2hYJFcxyZw3bb64rSPmcVTyOy0aa6h0rT4rDU9OtVEZ8yJ3UMXyfnOQeSMcdqt3rzyThbmeG4mKKXljIK/QEADNYVtqumS2tv5WhWKzEHzAS+Mhuxz3BrXuXRJwYrdLaJkGI48/nzSZpSO/Z0bDMjcYFXbVGAyAJA2eM/lWfH5iHzUVfKcfOu7jNWoZGLbo4yCPU4/Gs79zRxexeCj5unI/hPOKiO6NQzMckcZ7Hrj8qYsxwfNJDEcD+lPeVVkhLqu1uCCc8+1VchLoOkIljD4IlHzR9t3qDUcRNyzNGcDcA3HpSlwqiM8ITtVgaW32KJSWO7qOxNJ6jtZXNFZNkACngnZk8UliwaPDY8wSbCM/rUdsjkLuOTwR3yaro4ju5wM7sgscdD0q+a1jO26NK4RZIyrKpycZBplsRG/3SVAwOOlVi+LnawGzhdx4596tRYaA8AL1yOoHpTvdiasiCCUlpCcjBCsT6dQamSB453ZgDE/o3PPeojiKV1bJJXIP49KSV/OZI0JB9+nHY0h2LUgDK25ycIARnrVdYyvCk8kkc9ePWmFncsdyMMjd9AKSK83zKBjCNgZHtTv3Cz6FhlkRV3YYl+5wQKoahlrYsij0Geuc9at3MuQ+5MoCOnWqz7GynzBc5OO1S3cqGmrMT7I0kpYkEjghuuPb0q7AyRlw8RX5hweak+zmNc888lien1psY+eTzWBA+bOPvCptbQ6JzTRZZx8pYsvPPb/ACKhnJOCsg5/ECo8kkojnAOM46U+cuvyoucjICf1ouZpWZHaECExysCxPX0p0rOrjYQwHPPOaEdNh3/Lkgk46H3p8WV3BVQxMMBiaXQbZFkCKQkE8Y2gZxSBcJtcqApBXHenMSM5RiuSAQMc1G7kMzbGDY69cUbDQsgbyI2Zgy56pjn3NZd+AjvxmIdMf3jWujlodnlgxkfL261SlLQyHzduPQDOPSh2excHYqpl/Ldw20jgN146jinIWMkke05xlQBj/wDXToxsdA/Hl9MH1pJlZbgnII25GDg5osWQLNHayFpIVkUMDsY9cfTtnH1rkL2ZvNnKoY1MrnZnoCc4rsb6EsVZjsG4ZIGSBntXN6rEPIlYk53AABeo7An1oltY6cPJcxzjyMrhxkYOQQMGu58FzvNf+a7BmZMknq1cPKCsvKhnByMnPPoa6rwGyxajErHDlGBX0/8ArVEXZo7MZG9Js9OjXZGd+Dk8Z54rm/ESl435GPbuK6TaTGMHGemK5/W1GJOeT+QroltY8Cm/ePH9cJhupXRwHAx9a2vBsaLpsg6yynLeuTwP8ax9dEdzeYTDYOWbPTB54961dFcJHIgI4+UbeMVgnbU6pq56JYoYbOPIDOwyQOlZmpRtOY0GMs2Bjuc9PoK1IiJIVEWCFXaD2z1zUMaRvPGccR5AJ7n1qpPSxhHR3L8NsltZRxL1VSCfes+JFNvJngg9vXFa7qACFbcduRnis8KEiJC4Jc81LJTKNuCC+0/LgAH3qvIreTsDAAA8+tXjEsaLkfNu5JPeqbjiRePXH1qTVEDqpjzIcovI9RWNqEKhmGT835Vt42wkycHpxzWZeHI5JZMHOPU0zelKzKMMKTRruGJM7SfXFU75QJWjRATncuBjHrk1PFcHy1ZQARwdw9Kz9RHmEMpZdwxt+vOKdzdp31G2bb2YFjkDIx6V0OnoYrcNEVL5JLOeMDkGuasIyJWC4YEg47jtiujkikMX2TccMP3ir/EMZFK9tTKr2KV7c73A08BQMoZ2HJz3Ufpms+6tyYNjSsh2sTt65HYmr/2eQQf6PEuNp5JxVaS0LReZcs74IKxg4BP+FNNnNKK6GcluLu6s1f8A5ZtvcdcKP/1VnK8XmM8kXnrK/wC8iDbBt5OMjnv1rXmW523G3aQ0ZJPTvj+vSsqO0fzkRRmNhtPPBNaXstDCULs6Hw/pEF08dxa+HmFuCxV3vyAR0yAe2e9aeqwGN1Q232Z0UBk87zMZ6c1UsbqHZaGSG5jjMD6a7BMq2ejJ6nJ5FTalcqZ1jCyhYI1gczLtdmUY3Eds1behMLpnoCW4SNWiiLL0G4/dqyiuoG1FJHLNnAxTPPRZTGqEA/Lhv50STbIgfuHPAAzxnpWV1uaaskUsHAk+7jIJ9T60wrEW2OQNv3QRwR3NSx7ZYZMbwq/NuI5NSPawzD53+YYI6An2prUG7ELsqKyOu5UIII6099sjBgNkqY3E9dtIDHAh3EbX68ZxjiprdoSkjyDBYfeHWh6uxN+pNBIRvVGXEXz4z69hVc4ed0wVDnJO3BGKtwpHnlwu4/NkexqsjFsyfe5x6YFUKNtSw7RsJQhG5MMo9RmpbicmMFlPQZx0x6moQY5rsIo2u3Cj170k6FZCu4LG2VPcA0XJYvy+e27nfhfQVCA0EOYiGVXxtI6D1zTYi7yyKzcMC49yOwqwu8MzEKN3K5/wpXTKtYqt5iOZEwIyQG9gKhjuWkZvl2784J6A+tW7rDxvkbiQCOO+aqAus8saqcbiwOP88VLuWmrak0snlqrrt3MMBRwOtMSWN1YOrbyeSBTJo/NyZBseM4wDgH6VZRwsG7IJYcj0oW4bIp3rvEcI+4Y6dcg06Ah0UgEEA9R1rN1UXG4x25CMSDkjJI9qtacZGQLI55U8kdM0r6mko2jcsRIArNu43bj6EUx3iK8sQ65+71pyg+WmzjI2n3/Cql4HicMyYUcEr97PsKG7IUY3LAdVfKOdzDpj07VII42YyNhtnOOoyaqyu23JHBwF4+Y/WrUDKzMNwQBMdaaBqyGSuV+VMPGudzD69hUJQgx7AwUYzx1HvUlwUEAGD5YHUHg81JJh1AyFXaGOGwaGgRGGDEsVIUcegqF0LxEHbgfLgnk0+4mXy1QMSzZCqO4HfFRSqwyMnft6np+VJMpIgVQJOSR9e59Kdh4yvmSbyeASOOaZbkzHbncy84bjj2/KpJcNAFDksScd+c9Ka11KbexFdjbEx+9gZOD0rMaBne4UAupUOAw5Hr+NagcjcHxkAHA7D0pluB5zNkbGGD+FPccJOOpw+p2TW2ZgB5O4c4xjPSl0m8ex1C1l2sNrbtuOq963td06WeB44kDRh9wBP6/lWVJp1xblJJslQmBk5wtZS02PVpVYzhaTPUrS6WW2R42DIwBHNZOtAmNwucEelZXhW4uEQ2+x5EBymB09R+Vat9NviYoRz3Jre/NE8WdN05tI8z1aySCTavflj9Kk8NW5kumhC53KpPH481p6nbGckKCzMDkk8D2rS8MWBgtZpmA3SMFz6KBWNtbG8pWjc27b93bLyPof5VZiUfaDswMLn8OtSzRRR2wVMFVJzj2qKOJg7NnAK7eDjPeqsct76lksGhV+COmc1VkJWXy2BwCPfPFNMn+hKrdv8adE+58k5P3vpRe4JEF2UlOMDg1QlZVRgxPHSrN3kbtrAKpPzYrIt7gzzFF+de5P4YqZOzNIrQUyMQ4BKqDxn1qpqMWIW4ON3ze/ertwGRZExnjdnOfrVFwzRsznhvmKn6UkraGkHrczFCiHeBgD7xz1HrVCMgkt97dyFz0BPWtNrYmGQoc7QOPr2FUEjlFxOnlgOh5GOop7HVzpodp0RGoAKp2kj/Gt6MeZdRO4ZegbJ+opNNtCGhweNwxn1x0rQMGduGUyDGTjvnpT5Wcs6ibsZ5Ri4VGGVIU+34VQuCRIzFH2Fecc962UthGGySf4iT1rKlZy5JG3HT3zTa7kLXYzNQkjaB4onUrIQOTyBnNZ0gnkSNYxGixnAIOf8mtCYRtJkgcckkCmfNask1u2yUHKMvHPrRe4mi6Yra902xSS++ym3jMW2SNipGSd6Fe/r9KZqN1HeXTOjO6JAkYlkUh3KjBcj3rRs7n7LYWPn6ze25lj3JBHEGCLkjPWoNVtNs08xv5Lt0WMyGWPaSjj5GUjqO1a9DnvZnZ2kMgvGnkmzGB90DHNXpMTLkBuDuYMe/tRbwh4mQFY2HOMgn601lU2uPm4OQ+R82e1YRVjdu7Ly4ESMDgbcgAfjVe5JjQMuS27dux0GKYS0cJj3byBlR2B9KtRsk5VJG24GGI6Va1RGxXkjZl3PIGUKcAjg06CVYrlopMgEBQTzUm5YwsUS5V/mUnvTGwzsJGAfPBbsTSs+gbqzLEszy7gu1twyxHO0nvUtufJtWtyuWLZBPrVBYjGSY3xKijjHbNWQ4k4iRz/AMtOT0NNdyWlsRFFad5JCylDlVBz/wDqqS0KyHynbC7sng5A9aZcSAgKgAbGT/Wo5Y2Kq6NhgwYsD29KVrMp6rU0N4gl+VVZR0z3FRSSkRFpMLzjgZyDVR7hzcbyGyUPBGAv0pksz8IxZhwc9jTcugcruToGhiQ4KkjaMDrnufWoWmwuxpDgHDbf8aZJcGbZDuKqDjHr+NVxtRiWIyf4XPP51Ny1DuTNcxmTdu3Rkjr2qQTb3AR8Do3PHPaqD4gkLorhW4YDsPbNWLCWNiXg3KgbGD/Old3sU42V0WCQhUucyFsfMKUggsI8Ao/JI7d6ryThsYBXecirIJdAY+/LZ9KdyWmMkkG9sF3wdwYCqs80Z3K8hLY3AD+E1YCgeWUztXkt6e1VtRtVSJ2CqWAyS3QqaGmxxSI7q4Ii3oCX4JA7/WrTKgKSxBWQjdgCqjYWVXRj5TnDM/Xp2qW3Yy2inIJQkZxg96T3LktNCxI2WVSuVPPAwM0rFlG4qoZlzwf5Um4Hpk7fm2jiopJQs6LImflOwjtVXtqyErlu0ijndiR88eefX6e1VJH3EiMNjkksMn6UltK5mLR8gsA2eg4pbktJIU2lUz27kUJqwbMq2u4yMDh8bQvpz1/KpJFUFnUsw9RwM0kNt5SOGO4AjGeADmh41aMxuGcglsZx74oWhd03cRpN4Td1Pb1/GowFDJISDux07fSoyCkatErBOc5GcfhSKxmtywwSpBGB29qdwsXJoEkQHnlux61FPp0cj7QCUHUHoavnBO3BHOakmwONvB96pruSqjT0KWnpMrokI2lem3g1otpMUvUkMeRg4FMidUYtGcMeM1egkDKwG4gNyB61UUkROTvczptEjjiAPAK5bAyfpn1qQWKQ2ipGgwhyQvHNaU0oKHAJJb1zjioFcCM4XIHv7UWSZlzSMwZFsFcDY65Bz0I7UyFz5gWRgMIGBJxVtiv2fYqjBfnPb8PxqIwCXzioBcIRtPoDzWTRpfuVLnebcLj5V6HHJFP8ljCo2jITrnGasOgVjGjdVHXk88iorgkxhWcKd232NPl6juU2G0vu5C8sfWs6NY45H8gKsgBZh7ZBqxOzCT5TwcDr2JqvaRsJZpZM8sQR24FT12NLEMzCQLjKjBU471WaQ4jXhiR17gdMGpz95WA4DBTz6n/CqkrKrQToAoaby/m/uj2pguwqHcjBwNqZOQMc5ptvA32uVZsB5MHd1zn1pttKd8o2hkU5bPuauxN+9SbG07UYD6GmhOTQ62jZJFBPUhge/T/61WEUedIjFi2OCOCD1NVrQ7bqbewK5zj/AGeatXx+ZJw+52QFsd8L1p6WJ1uNU7pIkk6eXtJXqMZrPuETYjyKMYw+KvWVzk73QYKnBI7npUWotHsDKqneFLCkl1HezscsEzcyRN0BOKi2CNlMmdzA4z0zmr00a7y3XOdvtVe6DHyAPuqv5HipB6mpZFFsbYau2nGPn7N58bs4XJz93+HPTNZ2tXN2k19bXBgZ5jHL5kQ4eMD5Ap7IB2qRrqyltYotRtJ5HgGxZIJQmVySFYEds9RVDX2kfUYZJI0gRrdPIjRtwSPHygn19a1T0MGrM9Qt4JJFUFSHU9c1JbosUeJgCQxAC54xVhWkEoMiknpuqQyRhiY+dw4AGeaySNXNsVtsj+YjY3gE8dCKjWN/voRliew7+lK84iZWWRcYwVI6nvUkr5i81F5U8ZHQ09GTqQoxES+Z95Xwo6bR61K8aeY6OvyoSV568VA6kuC425U4xz360TtIDJ5JQKnTP8XvRcpLUsCaQpE/HzDac9QOlJbyFEmMbIoRsHaMYFVYZEmVjjcR8pHGM96V1QLN5ZJDjupwPXNHMJq2jJHK5MiuSSOFY4GfTNKJsSohY7D68gU1Iyg8oE7WAK7+hGKiTc9gpVfmR8lh1NS9x2JXcI5WRlGWwO4JpJgY4hF5nJAA29PWoVUkOm5Sx+ZQx6U7zjJArK5DIcMccAUXuO1mOBCRKpQ7lOQR6GqzWZnunLbV2lSWIz09KtRR5cNw0bAjg/rU8cRWIGSQFSOnfFFr6BzcuxWvYt5SJgDuU5fPcVDawqlqCGzIhwR061aePzFXK4bPykenvTItsMr+cDufsBnJHAp2V7lKWliK6tzIrHKqUbcCvb2+tSK2J1bPzqu1gDwQehIq7EU3uAgDspI4yDjrUEzopZmGQw5Hrj3oatqTzX0JlVUZoywOfnGRURjE0ipJu6FfmPWo0XzNm1tp4zjt61OEAKFCXDNjJ6+9XHUWxkXFtJEh5ZQAxUZzkj2qTTnJii3IfLbKE++atXPmRIuYxKFYr16Amktci1kQ44kYqemAT0xUte8ac14gQUcFFOQSTnvS3H3kMZG71Ydu9RvcKNyE5ZGKEn0xUyxsbIrIcbV6g8/SlvsQ13KsbFZWG0Rgr8pHc9/xomY70cvyOCOx47+9TsVyquCSExk9qr3KEEeTwu4MQR1B4x9KLWLWo5XaWJt+GCyYUk/jTmaORxuz83pxioEU/Oowrbsr37VZQO8gw6kZDnjkc8jn2NWtrEuxXlQQwDe4wH+6DyFqsCsAlAGFGNgU5yKl1BB95flHIxnmkWNX5ZeSuTk81DetkWttS2Jw4jOcAgd+tWUfKLnls9BXP3pMcYG3CRNtZwOB6U3T9QO4oxK7cjk5z/8AXp31K9jdXR0mxATnAHPPuals5BAZVX7ykDJ/pVKxkZ5pCQShAIGOtW7TDXcqOgGVyPcitF0MJJq6ZZRhJdbiSUI3cetUtojLFWZfmycdKmB8uWZ8gJgAYGOef8ajlTy5Nu478L1GOtJmfXQiKArI2Q2JSHJ7DAp6uqzKpOHZnXA4496UBXMjAYLSY6delUwJkv5IpV4Xa2VPBo2GlcuSFDLEuAGV1Q++0f8A16Y0CyW6goOVZmb8flFCfMiPEMOoMhLcjpyKht5WxiUEbo1U5Pbdn+tPQWttDE1dhBKidVcBfoe1MZvKmm35PmYbC9uMVPq0atOzK37ojOe5wPT8KqsWMWVY/MAzccg4zis3ozZapEM4XzQgw2T0Ht3rJucrPhBlwSRz0NXo3Lz56qeSR15NV5v9e7KQXD5BHOeKFsWvdJlK+fKMLlnAPGO1SysAhaME8cAduKqOCYxIzfOZR2wcYqxEFXy41yqFWJJ+mKaJequPgKrI7FsgxkP2BGM1aj6RI4cJ5YOWOeKqxASMCVCxsoU88DjFW/LXz4VZsRthSQe2aTROg8lY5GPBRiOcdB7VRu1AgC5yw5JH6VoXBUR/KowCV6ds1n3hVFyANjAMCOm7gYptFRMmTCZ7kYwPc1FGkMkyPcb1hB+fZjdj2zUrN86rj5up9qijiMkyxRsu6RsAu2Bk+pNSmOWw64Oh+Y4LamGHcBKydbure9vo3tvNEMcMcSiQjcdoxzjitbUdCvBKyNJZhhwyNcoCPrzXOXlvJp98YH8oyAhv3biRSPYitVc5na+57iGKuW3KwGOSOc0ydVQLsOSSO+PypjDOUVj8xycY4pGQqyMSpbqDjOMVizSw+ZEwhI2KVI5HXNQwMC00LZKAb1PoaeHVhskKsD8oHv2NQ3ybomIU+YuABn0PPSkNLoy0khZY3dMhVKHHU4poIbdA6srAgrnnnHSo7OcMGTneCSWbpyfSrLoSd0W0bFDEjqM+1VdvUHo7DVjh3yLGAu7nOO9VreQxXBt2OXbdtGcA+lGZMt8uUQDnrn1qR5UkCr5AaRSCHH8OKm+o9SK48x5RtUr5akjPIPrinrETA7Fii8FgO/pUklzvaJCu3BPUf5zTdnmRZEgVQ3GRzk0w6WI2tUim81GBI7E9anREZd8WCjDcFPOaidI/K8x3BdTtwP60lvMsaeUCd4Od2O1LRMbu0PSJ2iBD7QWOxV4x65otkkyNu4yKcEe1TxowViJBgncrbec0yeUptlDgneM4FVZE3vsOxGIt5O18bc56VA8jlGkI3jAPAx9aczK9wFkUYORv7U6aPG5U3NHu+9n8qVw2Jl2boZIm2oWJ47eoqNzwxTDfMfmPcelELkIFwfKYbgD0z6UoC7GEabQCCVqt0AI5QW5VQ7nAP+FSxkSoC+MK5Drt9uKhaRhGgypCsCccZHNSLIwmkRSQcHI/lTQmNkc7pEyMhsMB1+lVLeNjPJGD1Jfn2NTSoPtDk4DYVuO46UKM3Ec0P3ySQO2Mc1NrlJ2VhkkEW0q3Vj8zHgk+tPSVGlKqHwjrkMOvHepIATvZj5gLfKT296WMIs7pgE7QRz0OafYV+5E6+ZK4kICg446Y6VXuoSmAmSykYJPbNXJIlW73kDDMQ2TgH/8AVVS4Y+XsDquMe+OabHFlFLhm84Im4qcdemKvxbT5uwkDoQeOoyMVn+UsTzyojHc+SvflalVwpaN9qAgDnJwcdamLfU1kk9i0qZuEwSwGQfyqIoodSQVXn6nmnxssbBCD14Y+h70ZaOZzsJ+cAsT2pmeqZTvYBMkqOSpOCrN0z2JFZGl8ajkgEA46fdz1rfmBkikWRVII4CnHIqpHZrHPLndGGwUIHTHem9bHRTqWi0aNsxUBVAwMgkH8qtuwWRmXA3R544FU7QuMFmUsWBzjGR71PGoF6vmMrIYmAz3waq6OaW45syIsqsOV7nPeomcuJC3z4BABPII9atQNBDC7sQFwVx261nTKZHkjRvkIDjB/hJpeZF9fI0YyosxIcOu8n6ncOKZdoSY2HA5KgfmKbhlsYo0wFTduHrzmnXbFni2YEbNkDocYPFUthdSN3aCYoCAVUrnt93vUDBQW5bGG/kKhE6yKsjY+8wIzjtwarzTYO8MGThs/QdKVyuXUr3mZZNxc7FXb+OO36VDMrBWQ8CQDoec9BiieVGgIQ7g7sAFGeMf/AK6dPzAjMABGozg+gzU6F7WMmaMRKJJXAyo2k9xk44qiZS5QK3JPboea0datRIvyg7RHk59ccVlaevl3MZckd+OR0oe9jVWcL9TVU+fbxwFedxBPvz/9anW54cGMkxRk4HfHWobbchypZjk5IHUHvVobWmZQflO0nb3GKZiPg/1TEgYxkcdKldwsqPGMY4AP9agIK+ZsOVJHX0pHfO5WxwTnHpUpgTyZKS9SdoZeevNV5iAhQHbsJBJHFTlwWRVJAIHNVnG8bMcsc5J7UhrQoSovmM2AwbIVv61V8hriUJFGzs2QE67j7CtK9iJRRkAZ3ADtWYzSDKqGWTcNmw87vb3oSKvpcp6np+r3MoklsbuSUAIW8k8gDA+v1rFljls9RVbqB4nBD+WylTgjvXTavY65eTmZ0EU7BQ0YugpYgdSpbgn0rlb9LmKeRbkTLcxttcScke3NaJWOWTue8NBAksJ3EBx8xA4WoHYIZSHIReGbHBHpRNDtUgK+7AJOePrURdT5UeCVAIYk9ayOiKuOeWGcxFWAIAwvqPWnTCOOQ5QKoPU84rLhidJiQhMe7AGfWtMSLNEyKGIYEEjnBpJjkraoSBtjtuQsi4AYelTy7fMwjhAw+6Tgke9UkRkDIjZOzeQfbtSCfHl5/eBCCxxjg0X7i5epety2WaP7jcMmaYkrNM6xxBWDA4U4NTRyrcWbPHHsBbAbPpVS4HnOzDgEDleMH1p7K5K1buTTXBaMhFXkEEA859aZbgIB0Hygkjsf60xt0UXljYdp4Y/eIqSNG+6gBUngtz+FSm2yrJILZFG7ccfKQeMmoUlVmiaM4ZgQ2RTZz5E8LncA33sCnxqxlYGIqC+QwGPlpLsVa2pPp3m7Jlkf7np0HPpRG2XkzgZ5PotRFCkrMrYJGSOecGplUrL5oOUcZKnr71ad9BO3QDg26AKWJbDkdgKa067QFyw3AMCOoqUjAZV2/ON2c4GKZdwq0LcbRIuc+hFD8iVYW3fZZlfmGxydp/PNSzRgzgrKzK2Occ1mi8jhW5Sc/eQEEnrxxV6OYSW9vs/iXDY9qSd1YHFp3I5EkYDH3uh7VPFGHlAcnhjGXH0pEjWRC29mIjOSPY9akDSNPtkwyttwRx+FXZCu2IimOBM8nZgMfTNMts+ZGijH+sXA7jrSYHljazAgrwR79KjglJvflbyxIWX5h04pjSLEcqsVR2CuFLHA44NRmEeert8yMgzg4xk8UyNdzBiuI0BVgfTNTRMvkgyY2odgI9M5BotcnbYa2yMDnKjdnJ6mqTBT/qiOgPXrVsYwAEGd5wO+Kgmjzgk4VW6Yxjjn+XSh6lx0GQoghdssG3HOaiuJo0lbcMnb1zzn/Cp2AcN5f3gyk89j0FONus0ykoBxsbB9R2oV9ik9dRlpsuH4Dbgg+jGpZMgeYeQcHaenvU9mirIu77pXC8cdqS9XdbGMKqsmVDdeQf8ACqtpczbu7ETIGkUgbY+cKeO9DQbpEVTwF5/POKnjiJRMMrE4Ug/TrUjELuzhXXP19hQoicrbFdId9tLuGCh6H8xVdYjJNJciTPlkEKeqk4zVolneZAWXeoOT2OM1V0ufyXvIX6qQQGHrU9VcabaZM6TCORSQ25iV9CCD/hWZA4e/iiDYTyMED1GCa03m2MyTKhEZ6DnsayIo2TUYSGBfY2BjHYcUm9ghs7mxAxLPk5BY89uQCBT3kHmI0qrgS7PXAxn+tQRMFilKthDKpx1OKj1KVgzZbhXdm+g6cfpVrYi12Z1wpWGaMKAnqecHPQGmTOFtQCfuopYeh/zmppmj2zMyhUEhBTPoM/zNQkbYnMqr5gO04PHrUGt+4kCIsMaKmAGOCe+cnFV7hisp3dHAyPc4qVVUx+aSdolLDjPYVUE5EzNIcOjYLY6c5/lTYkFwSZJyx+UK3ynnPb+Zqk0Kt5aqMttCnI6kVNOxjlffuZNpdgDz1zSWoZniDYCgFiTz2yRSS6DvZCwbWLH7ox83HQe1OhPlFJCCZPUnjA6VBCWkypXGVAH0qyVGzAZNynbgn/PvTJYFgqzlQVyh+XPPUUkhDruPUquMU1Tvcj2FS/uxEUPLAdfTml5lIikYq5C9B2HHfpStLtAVQJOO3bBz/Omycsc/fb/DrUMzBCHUsVHXPrmlZsZHOWI6kDHBI9qqW92LG6gu9m/ymBZScE+pz2q3K6zRgFtpXJP0zVSyngh1K3mux+5D5JxnAHQ47880+oS2My/sdIWVpJb+8i3ZYJJaZfH1zg/WsvWbxbu6R0jnjiSFI4/O++yqMBm9zW3dX5e5l07Xrn7bayNkXCNvMLY4dD6eq1h+NJo11BVgnjnWOzhjEkZyDhccVrFX2OObs9T21md+Tkqo5Ge/p9Kgmg3SkoERGJV0U4J460StIkLhow24ZOSASKS0JSLf5gAK4+Y5OawvfQ6ldK4+32W7OkkobaoGPXPvUcC2ySTlZJGOMLt4BIo3wyR7g+U3HkdSR7U23mt7iUxSfIwBIbGAf/r1LHra7LjuJIIjHtBC8s3HNVMRsi4ClDwcHrimTyoqvHuAZecZ61n28dzmeMyNhlOADjIpt9yow0vc1oJXtZZVMTbGGSCOAPWrJuo5EdYmVgp2kHjFVFkc7C4dyoGSWqK9jkhbMQDbhuyFzmldpCSTZYZULDbk/LgjHT3FEcv7uJSxDA7QSMZqPzUnhjVSSVI2545PU1aaJOBuyp4PH3T70LugdloxJV2A5AZSQM9SPrUSzo0PDBdjc884p84ViQHPByDjFI0AUyI2W5DA9MijcFbqTMVd1cOT8oVgw6Gi0ckmCV0IXJLdSe2KhAT96IlbAbgNzj/GoDLHbzJ8nzCXDds56VTfKK10aCREKFXBUKQMehqCZSqozNh14IK9RVng2pKAEZ27epANNlDEbiFwEBKkehxTaJT1M1rOO4ntzMx8thtb0+lXYolt4JIMDMUnBHVge1ReSTF8xIJYEKfSmRMweWSVi7xllIPPQ8UopJ7blX5iSItlTtYK6suR65qe2dZQo53xvjPY4pjNtK4jLIjevqM5FKo2eb8pGCDz2q1sJ7EjsYwAwDBXY/N7c0LLFJEJFDbvMBAHORTZ8zFVbaCxYrt4HQ0W6M9urIoVyu1gvTIH/wBanreyF0JlaPEpKZ+7n8880xYgBsBwHJ3c96sqm4uAmG8tTh+5qCciES5Rt2QRjrjvVMlNN2RWUtLKdjYzgkjtyeKfK/DfKd27t7ChY2iEeASSobPp+P0p3yEweYcB2yCalaIoz7cvFM8ARnI2nd3PXrVy0dHjk6MPryPx/OnMAssvlrwUGdw6kGkgjYx7ggyG5A6fe5/nQtCm09R8MgiaIGQKSuBx29KVtrNtBJXdn9Oc02CJS6sy7VHQHp171KiEu4c4dJDnng/SmiGxbdRCEBOEZMEkelMmjZpTLuVsEE59+KfEfNKHawXyzuPHTNJcFGUmE8AA59TmqauiepEJ2SErLgsoBye+OKhtJEF7eGUElgAB79xUl3gXLK6gebDlSe4NZzyJJ5o770B9R6iobsWlc0L1Wjj3rHmRXK84GQTjGaz7ZFkS0EnzSE8gnoMmtRGWSeEum1RKwYnnoOtZYVCJJFZx8qkAjBHfj8TStrcSdlYWV3SCGMkBmRiMHoQadLN5kKJhd5hYnj3xVedstJvzhRgnHB5pY2DzyLjaBG7HjoN2R+NDdmNrQg1NSXIZvkYFiAO+QPyqqqF7YrhmIYKB2JweasTY2AEfMyk5Hckg4qGS4VYp+GUb8kjtxj/Gl5lLVWHz5+xDcQpMuAF9MDmqi7Yra4MgYM0jDPXk9aluwfLt0PRnIP8An8hTZFQWxfbypZgD/eJwKPMLWRFEwlFyzx4LEAHPbH+OKhSQQ3DR5OPLbBPGeMcfnTlPl+aAwYlVPI6jv+tRyLmUsWyhwp+nGaeugbjiTB5TISGBOSeewFPZBGZRJliz5X+f41WVi8kZYlox8vPHXuKeJFdI3G4MMt79RzSESKP9I3qv8BwB24608v8AuXYsAgG3JGSec1EJSFEp+8SVx36UyZyo2k4zwy9aEWiVnwFGFyQDg/SoJZQxYbmPOMHpUL/fQdctggdRSy7JHJXIJxt4/wA9qVx2I5ZAkcpftHnp1rPk3S7VjUmRvlVQMkntU1yzBGyOSdv4U7T5hBfRvKwRV48zHCEggN+BOaFqyZ6K5l3OmortHNqNslxjBQhiqn0LgYH8q5TWEktBcQzIYpVJDL6H/A16DKkkOq20zvKskUawmzSBmLgLgqpA2lW5OSe/NcB44ZReRRIyt5MEcLspyCyjkA98dM+1dNGN5HDWk7HvPmMYpI2O5F6A1HFEi3DSKMENjA6dKKK457o7o7Ms31nElkXQEFlJOD35qsqCKziKE5xtyeciiik/iCDui0URrON2RCzEg5HpVeVdjLIjMrAdQfeiiqnohxK+nzSPdSQs7FFTI9fWrszNJbhSzDDcEHBooqY7feOS95E1sf8AQ3UgHGeSOagjJaJsk5zjPtRRSl0JJbd2aKQH+EZBp6SuySZOcACiirWxLGTsVO4fxAZHaopwGAyOkqsPrRRQ9yi7Idl1PGAMBFbPfPFEuTIVLHGCv1GaKKshbkN0uLeV8nO0Hr74pkA2T3mO6A80UUuqL+yPcmNiVY4wTg9OgFEzsElIPLOAfyooqkEdyvZSvJP8x+7NtH0I5rRtXIVgP4I8j9aKKpCqFyOVmJZsE+Up/SooMSyShwDx1796KKoxQy54iIUlcLxj/dqEqAbU98D+VFFJlrYdLxLIe7x5P5kf0qLzmDKmBtKOcY7iiigEPWVgkRwMlSpP0wf60+6O1nI4yMkflRRS6ErcuWwAmCYBTBXB9DnNUYWxPdquAFXAA/3qKKpdBdypdKJmheT5mEJxn61WjctayXDBTLzzj3NFFZPqa9AM7vHbZIwC5wOnPFVEuZBFDyOZEHTtnFFFNjS1HO7GGYk/ek/pmpFJ23cn8YiTn6k5oopBLYznkaQLuJO2NSPY5FMiG/DN1k3bvfBoooZSI7sZhtdxJ39c0AkwgFjt3dPz/wAKKKXUJbIahxNCvBDBFJ9s1XunYuATnDf40UVTJW4nlqYVyP7rfjUUDFpJcnorD6jNFFSgQ+M5Kk+uf1pJjllZgCfMxk+mKKKGWgnQG+lXoFY9PpUG4hmx2AFFFHcOhBe/NJg9Fxiqtwx2tRRSJZn3d1crZPEtxOsRBGxZCFx9K43xAMGADpiiiumh8SOLEfCf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scalp and periauricular lesions resemble those of seborrheic dermatitis in this patient with pemphigus foliaceus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pemphigus foliaceus lesions exhibit erythema, scaling, and crusting. The face and scalp are often the initial sites of involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25112=[""].join("\n");
var outline_f24_33_25112=null;
var title_f24_33_25113="Medical care of women who have sex with women";
var content_f24_33_25113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical care of women who have sex with women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Nina M Carroll, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25113/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/33/25113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of routine primary health care to lesbian, gay, bisexual, and transgender women (LGBT) can be complicated by the patient&rsquo;s inability to disclose their sexual identity and the health care provider&rsquo;s lack of cultural competence when approaching these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/1\">",
"     1",
"    </a>",
"    ]. LGBT women often underutilize clinical care services and present later for healthcare than heterosexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/2\">",
"     2",
"    </a>",
"    ]. The reluctance to obtain healthcare is facilitated by providers who lack awareness of their health issues, discriminate against them, and create negative experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, these women are often of lower socioeconomic status than men who have sex with men (MSM) and they often do not have spousal or family benefits, such as health insurance. Because they are less likely to use services that focus on contraception and reproduction than young heterosexual women, they are less exposed to women&rsquo;s traditional points of entry into the healthcare system.",
"   </p>",
"   <p>",
"    Understanding a patient's sexual orientation, behavior, and identity has a bearing on the ability to provide quality care. Issues related to sexual desire, sexual behavior, and sexual identity are important because they may increase a woman&rsquo;s risk of some health problems, such as sexually transmitted diseases (STDs) and certain cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3413618\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some terms women may use to describe themselves include lesbian, gay, queer, partnered with a woman, homosexual, and others. The term lesbian is generally used to describe sexual orientation, while women who have sex with women (WSW) describes a behavior. Some women who are just beginning to &ldquo;come out,&rdquo; or differentiate from heterosexual",
"    <span class=\"nowrap\">",
"     identity/behavior,",
"    </span>",
"    may experience a desire to be intimate with other women, but may not yet have been sexually active with women or even identify as being lesbian.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14847519\">",
"    <span class=\"h2\">",
"     Sexual orientation and behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual orientation relates to erotic attraction and defines whether an individual is attracted is individuals of the same or the opposite biological sex. While there are three main categories of sexual orientation (heterosexual, homosexual [lesbian or gay], and bisexual), sexual behavior may not be so clearly categorized.",
"   </p>",
"   <p>",
"    Women who have sex with women (WSW) embraces a complex spectrum of attraction, or experiences of romantic or sexual feelings towards other women, behavior or patterns of romantic or sexual activity, and identity, which is a personal self-concept that establishes oneself within a social or collective group. Studies surveying self-identified lesbians show a wide range of sexual behaviors (eg, celibacy, heterosexuality, bisexuality, homosexuality). Many dichotomies exist regarding sexual behaviors: past versus present, volitional versus nonvolitional, and admitted versus practiced. Furthermore, behavior is not always concordant with self-identification and can be fluid over time. For example, a self-identified lesbian may also be attracted to, and engage in, sex with individuals who identify as transgender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8142474\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In surveys performed in the United States, 1 to 4 percent of women identify themselves as gay, lesbian, or bisexual [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. In 2002, the National Survey of Family Growth (NSFG), conducted by the Centers for Disease Control and Prevention&rsquo;s (CDC) National Center for Health Statistics, reported that 1.3 percent of respondents identified themselves as lesbian, 2.8 percent identified as bisexual, and 3.8 percent identified as something else, with 1.8 percent not reporting their orientation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/4\">",
"     4",
"    </a>",
"    ]. However, 13.4 percent of women acknowledged same sex attraction.",
"   </p>",
"   <p>",
"    In the US, the year 2000 census figures showed that \"same sex\" households occurred in over 99 percent of counties, with the highest prevalence in urban areas, where they ranged from 5 to 7 percent of households [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/9\">",
"     9",
"    </a>",
"    ]. There were 297,061 lesbian families counted in this census.",
"   </p>",
"   <p>",
"    Rates of same sex behavior are higher than rates of self-identification as lesbian or bisexual [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/10\">",
"     10",
"    </a>",
"    ]. An analysis of six US surveys found that there are 8 million adults (3.5 percent of the adult population) who identify as gay, lesbian, or bisexual [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3413250\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines for care of lesbian, gay, bisexual, and transgender women (LGBT) women are available from medical institutions, medical associations, and the US government, but are not widely disseminated. Effective guidelines should be evidence-based and provide clinical recommendations for clinical practice, including antidiscrimination language that specifically refers to LGBT patients. A systematic review of these guidelines concluded that they provided a degree of evidence-based clinical systems support to guide communication, documentation, training, and provision of health care, but higher quality studies were needed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3413530\">",
"    <span class=\"h1\">",
"     APPROACH TO THE LGBT PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no stereotypical profile that easily identifies lesbian, gay, bisexual, and transgender women (LGBT) patients. They are found in every ethnic group and socioeconomic class; they may be single, celibate, partnered, or divorced; they may be mothers, teenagers, career women, or senior citizens. Professionalism and confidentiality are key components for enabling these women to identify themselves, as well as for better interactions between them and their health care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Some women choose not to identify themselves as LGBT because of awareness of cultural biases, societal constraints, and familial rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/16\">",
"     16",
"    </a>",
"    ]. Others are unwilling to disclose their sexual identity due to negative encounters with physicians that led to suboptimal care.",
"   </p>",
"   <p>",
"    There are many ways that health care providers can demonstrate",
"    <span class=\"nowrap\">",
"     openness/willingness",
"    </span>",
"    to discuss LGBT issues. For example, new patient intake history forms should have inclusive language that demonstrates sensitivity regarding sexual orientation and questions about marital status, insurance subscriber or emergency contact, and health care proxies. When obtaining a social and sexual health history, it is important that the clinician demonstrates that",
"    <span class=\"nowrap\">",
"     she/he",
"    </span>",
"    is willing to invite disclosure of sexual orientation. Conversely, respecting the patient&rsquo;s right not to disclose is important in order to build rapport. Being avoidant is as unhelpful as being probing.",
"   </p>",
"   <p>",
"    Information on sexual identity can often be obtained by using leading statements, gender-neutral questions and terms, and nonjudgmental acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients should be informed that questions related to sexual identity and behavior are asked of everyone. The discussion should start with general questions, then an attempt to gauge the patient&rsquo;s comfort level with disclosure. If the clinician explains that sexual orientation can impact specific health risks and had relevance to healthcare and preventive medicine decisions, patients may be more willing to disclose. Once the information is disclosed, clinicians should ask about and respect the patient&rsquo;s choice of how she wants that information handled; some patients may prefer not to have the information documented in the medical record or revealed in referral letters.",
"   </p>",
"   <p>",
"    The appropriate level of detail in obtaining the sexual history depends on the provider&rsquo;s comfort level with the subject of sexuality and their perception of the patient&rsquo;s comfort level around disclosure, in addition to what is necessary to provide appropriate medical evaluation and therapy. The Centers for Disease Control and Prevention (CDC) provides guidance for taking a nonjudgmental sexual history, including frank questions about partners, sexual practice, prevention and history of sexually transmitted diseases (STDs), and prevention of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/18\">",
"     18",
"    </a>",
"    ]. Several other resources are available in print [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and online [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/21-25\">",
"     21-25",
"    </a>",
"    ] to help clinicians interview and care for LGBT patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link&amp;anchor=H13#H13\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\", section on 'Sexual history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some examples of questions to ask in obtaining this history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are you single, married, partnered, widowed, or divorced? How would you like to be addressed?",
"     </li>",
"     <li>",
"      People identify themselves in different ways: male, female; straight, gay, lesbian, transgender, etc. How do you identify yourself?",
"     </li>",
"     <li>",
"      Are you having sex?",
"     </li>",
"     <li>",
"      With whom are you having sex? Anyone else?",
"     </li>",
"     <li>",
"      Do you have a primary relationship? How many partners have you had in the past month? Six months, 12 months, over your lifetime?",
"     </li>",
"     <li>",
"      Do you know whether your current partner(s) has had sexual contact with anyone other than you?",
"     </li>",
"     <li>",
"      How do you protect yourself against STDs? When did you last have sex without a condom or other barrier? If using condoms, when were they used, throughout the sexual act or just at the end?",
"     </li>",
"     <li>",
"      Have you or any of your partner(s) ever been treated for any STDs? When and what was the treatment?",
"     </li>",
"     <li>",
"      Have you or any of your partner(s) been tested for human immunodeficiency virus (HIV)? When and where?",
"     </li>",
"     <li>",
"      Have you or any of your partner(s) ever used needles to inject drugs? Have you or any of your partner(s) ever exchanged sex for",
"      <span class=\"nowrap\">",
"       money/drugs?",
"      </span>",
"     </li>",
"     <li>",
"      What kinds of sex do you have? Hand-on-genital? Mouth-on-genital? Mouth-on-anus? Penis-in-vagina? Penis-in-anus?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians seeing adolescent girls have a unique opportunity to interact in a way to inspire trust and confidence. This opportunity is important since LGBT youth are at an especially high risk of suicide related to isolation and low self esteem from societal, familial, and peer rejection at a fragile time in their psychosexual development. They are also at increased risk of physical harm from peers, substance abuse and other risk-taking behaviors, depression, and homelessness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=see_link\">",
"     \"Adolescent sexuality\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H21#H21\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Sexual orientation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like heterosexual adolescents, young self-identified lesbians may engage in unprotected sexual behaviors with male and female partners, putting them at high risk for STDs including HIV, and unwanted pregnancy from heterosexual sex. The Minnesota Adolescent Health Survey found that lesbian or bisexual respondents were as likely to have had penile-vaginal intercourse, and were more likely to use either an ineffective method or no method of contraception and to experience pregnancy, as heterosexual or unsure adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/26\">",
"     26",
"    </a>",
"    ]. Adolescents self-identified as lesbians also reported higher rates of a history of sexual abuse and prostitution.",
"   </p>",
"   <p>",
"    The Committee on Adolescence of the American Academy of Pediatrics has developed guidelines, summarized below, about how health care providers can address the issue of homosexuality with their patients in a supportive and nonjudgmental way [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be aware that some youth are homosexual or have concerns about sexual orientation.",
"     </li>",
"     <li>",
"      Provide factual, current, nonjudgmental information about homosexuality, STDs, and substance abuse.",
"     </li>",
"     <li>",
"      Probe psychosocial needs and issues related to school, family, and community. Provide counseling and offer referral, as needed.",
"     </li>",
"     <li>",
"      Perform a thorough history and physical examination. Screen for STDs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link&amp;anchor=H20#H20\">",
"       \"Screening for sexually transmitted infections\", section on 'Women who have sex with women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTIVE HEALTH CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of health insurance or insensitive encounters with health care providers may alienate lesbian, gay, bisexual, and transgender women (LGBT) women from seeking preventive health care services [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/28\">",
"     28",
"    </a>",
"    ]. These women are not biologically at higher risk for any particular health problem simply because they have this sexual orientation; differential risks for disease may arise because of behaviors that may be more common among this population. For example, the rate of current smokers is 12.2 percent in the general population, but 28.7 percent in lesbians and 26.9 percent in bisexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/29\">",
"     29",
"    </a>",
"    ]. Rates of alcohol consumption, and particularly rates of &ldquo;heavy drinking&rdquo; defined as 60 or more drinks in a month, are 4.5 percent for lesbians compared with 2.3 percent for heterosexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/5,30\">",
"     5,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few population based studies of health issues in women who have sex with women (WSW) on which to base recommendations. Based on clinical experience and epidemiology, we feel that there are a number of areas in which clinicians providing primary care to these women should provide additional emphasis beyond what they might focus on in heterosexual women. We agree with a monograph published as a companion document to the US Surgeon General's report Healthy People 2020 by the Gay and Lesbian Medical Association that important issues to consider targeting include: cancer; human immunodeficiency virus",
"    <span class=\"nowrap\">",
"     (HIV)/acquired",
"    </span>",
"    immune deficiency syndrome (AIDS); immunizations and infectious diseases including sexually transmitted diseases (STDs), substance and tobacco abuse, behavioral health and mental disorders, and domestic violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8142592\">",
"    <span class=\"h2\">",
"     Healthy weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overweight and obesity predispose to increased cardiovascular risk. When body mass index (BMI) was analyzed by sexual orientation in population-based studies, the National Survey of Family Growth (NSFG), the Nurses&rsquo; Health Study II, and the Women&rsquo;s Health Initiative noted that obesity was more prevalent among lesbians than among heterosexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/5,31,32\">",
"     5,31,32",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There is some evidence that weight gain and having a higher BMI may be more culturally acceptable to lesbians as they may not share the mainstream aesthetic goal of very thin women. Therefore, in addressing weight with WSW, it is important to emphasize the significant health risks of obesity, including diabetes, cardiovascular disease, and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8142681\">",
"    <span class=\"h2\">",
"     Prevention of unplanned pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority (75 to 90 percent) of lesbians have been sexually active with men at some point in their lives. In surveys, 3 to 23 percent of WSW age 30 to 50 years report having sex with men during the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/33\">",
"     33",
"    </a>",
"    ]. Sex with men may take place at any age, but during adolescence is common since sexual identity is being explored. &nbsp;",
"   </p>",
"   <p>",
"    Sexual activity frequently occurs without contraception or prophylaxis against STDs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Data from the Women&rsquo;s Health Initiative showed that 35 percent of lesbians and 81 percent of bisexual women have been pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, it is always appropriate to say: &ldquo;Do you have a need for contraception? If not now, remember to use condoms. Emergency contraception is available without a prescription until you can start a more reliable form of contraception.&rdquo; (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14846654\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most epidemiologic studies of women have not included sexual orientation or identity among the demographic factors investigated, making WSW an invisible component of the analysis. Actual risk cannot be calculated, but can be inferred by extrapolating from well-described risk factors for various cancers. According to large-scale national surveys, WSW are more likely to smoke and drink alcohol, have a high BMI, be nulliparous or of low parity, and have fewer preventive health screenings than heterosexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/5,16,37,38\">",
"     5,16,37,38",
"    </a>",
"    ]; in addition, they are less likely to have used oral contraceptives or to have breastfed. These characteristics constitute high risk factors predisposing to colon, lung, endometrial, ovarian, and breast cancer, as well as cardiovascular disease and diabetes.",
"   </p>",
"   <p>",
"    Screening for cervical cancer, breast cancer, and ovarian cancer is discussed below. Screening and counseling of general medical issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33186332\">",
"    <span class=\"h3\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;WSW have lower rates of screening for cervical cancer than heterosexual women, even in urban settings. This may be linked to the perception, shared both by health care providers and WSW, that they are at lower or no risk of acquiring human papillomavirus (HPV). Among WSW with cervical cancer, half had never had cervical cancer screening and 10 percent had not been screened in over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/39\">",
"     39",
"    </a>",
"    ]. The Women&rsquo;s Health Initiative Study noted higher rates of cervical cancer among bisexual women (2.1 percent) and lifetime lesbians (2.2 percent) than in heterosexual women (1.3 percent); the higher rate correlated with their having fewer cervical cancer screening tests [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like all women, WSW need to undergo routine screening for cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/40\">",
"     40",
"    </a>",
"    ]. The risk of cervical neoplasia is highest in WSW who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have a history of incest or early age at first coitus with men",
"     </li>",
"     <li>",
"      Have had sex with more than one male sexual partner",
"     </li>",
"     <li>",
"      Have been infected with high oncologic risk HPV types",
"     </li>",
"     <li>",
"      Smoke cigarettes",
"     </li>",
"     <li>",
"      Have been treated for abnormal cervical cytology in the past",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High oncogenic risk HPV infection, which has the potential to develop into cervical cancer, and, less commonly, vulvar, vaginal, anal or oral cancer, can be transmitted from woman to woman by skin-to-skin or skin-to-mucosa contact. In a pilot study of 149 WSW in Seattle, Washington, the prevalence of HPV was 30 percent, and was 19 percent among women reporting no prior sex with men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical cancer screening guidelines have been formulated based upon age and risk factors for cervical cancer. Increasing the screening interval or not screening WSW can lead to lost opportunities for health maintenance and prevention, or to delayed diagnosis and treatment of high-grade squamous intraepithelial neoplasia and cervical cancer, as well as other anogenital and oral cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical lifetime risk of breast cancer in WSW is estimated to be as high as one in three WSW compared to one in eight women overall [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/41\">",
"     41",
"    </a>",
"    ]. This alarming figure was inferred by analyzing demographic profiles and health histories of WSW in several national surveys. In the Women&rsquo;s Health Initiative Study, bisexuals had the highest rates of breast cancer (8.4 percent), although women in the other non-heterosexual groups also had higher rates than heterosexual women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/31\">",
"     31",
"    </a>",
"    ]. Patient information brochures, such as &ldquo;Cancer Facts for Lesbians and Bisexual Women,&rdquo; available at",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    , can be useful for educating these women.",
"   </p>",
"   <p>",
"    Since parity and age less than 30 years at first full term pregnancy both lower breast cancer risk and WSW may never become pregnant or may have children at an older age than heterosexual women, WSW constitute a group at higher risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .) In addition, WSW may obtain mammograms and undergo clinical breast examinations less often than heterosexual women, thereby reducing the chance of detection at an early stage of disease.",
"   </p>",
"   <p>",
"    Current recommendations are for WSW to undergo breast cancer screening according to guidelines published for the general female population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;WSW have higher theoretical risks of developing ovarian cancer because of risk factors such as a lower likelihood than heterosexual women of having been pregnant or using hormonal contraception for a prolonged period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/42\">",
"     42",
"    </a>",
"    ]. WSW with a personal history of breast cancer (particularly at a young age) or a family history of either breast or ovarian cancer may consider the potential benefits of using hormonal contraception to reduce the risk of ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H24#H24\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for screening for ovarian cancer are controversial and based upon risk factors, not sexual orientation. They are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for STDs should be performed in women with symptoms, or periodically according to national guidelines in those with risk factors (eg, more than one partner or a partner with other partners, previous pelvic inflammatory disease [PID], anal sex). WSW with STDs should be encouraged to inform their sexual partner(s) regarding the need for screening, diagnosis, and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious agents can be transmitted between women through sexual behaviors resulting in the exchange of vaginal secretions on hands or objects, such as finger-to-vagina contact, genital-to-genital contact or sharing objects (sex toys) without condom use or cleaning between partners. Sex toys and fingers can also transmit bacteria from the anal region to the vagina. STDs can be acquired from female sexual partners, even with a remote or absent history of male sexual partners [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/40,43-49\">",
"     40,43-49",
"    </a>",
"    ]. The risk of infection with STDs (eg, gonorrhea, chlamydia, hepatitis B virus, HIV, syphilis, HPV, herpes simplex virus, trichomoniasis) varies widely, depending upon sexual orientation, number of partners, and specific sexual practices.",
"   </p>",
"   <p>",
"    A meta-analysis including 12 studies found a consistent association between bacterial vaginosis (BV) and a history of female sexual partners (RR 2.0. 95% CI 1.7-2.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/50\">",
"     50",
"    </a>",
"    ]; in the studies that quantified partners, there was a trend towards increasing risk of BV with a higher number of female sexual partners. WSW in monogamous relationships are usually concordant for the presence or absence of BV; this has led some investigators to believe that BV, which is not considered a STD in heterosexual women, is probably transmitted between female sexual partners through exchange of vaginal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/45,51\">",
"     45,51",
"    </a>",
"    ]. For reasons that remain unclear, oral-genital sex, oral-anal sex, and sex toys may be more important risk factors for infection than penile intromission. Although it is not necessary to treat male sexual partners of women with BV, female partners should be advised to undergo screening and, if results show infection, they should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=see_link\">",
"     \"Bacterial vaginosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rapidly increasing rate of HIV acquisition in heterosexual women has challenged original concepts about risk groups. Women of color, their partners, and WSW who are or were intravenous drug users or sex workers may be at highest risk of HIV infection. Woman-to-woman transmission of HIV has been documented, although we know little about the incidence of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients being evaluated for STDs should be offered counseling and referral for HIV testing. The frequency of screening in other settings is arbitrary, but annual or more frequent testing has been recommended for individuals at high risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link&amp;anchor=H15#H15\">",
"     \"Serologic screening for HIV infection\", section on 'Frequency of testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3874972\">",
"    <span class=\"h2\">",
"     Prevention of sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures, often referred to as suggestions for &ldquo;safer sex,&rdquo; include avoiding mucous membrane contact with a partner's blood or vaginal secretions by using a dental dam during oral sex, using a latex barrier or plastic wrap as a barrier, and washing sex toys with hot soapy water between uses (or covering the toy with a fresh condom).",
"   </p>",
"   <p>",
"    Pharmacoprophylaxis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Offering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      prophylaxis to the affected partner in herpes simplex virus (HSV)-discordant couples (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link&amp;anchor=H10#H10\">",
"       \"Prevention of genital herpes virus infections\", section on 'Chronic suppressive therapy in discordant couples'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HPV vaccination (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14846531\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL ISSUES RELATED TO SEXUAL ORIENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have sex with women (WSW) may experience social stress generated by stigmatization and nonacceptance by family members, peers, and friends. A systematic review that extracted data about 214,344 heterosexual and 11,971 non-heterosexual individuals found that lesbian, gay, and bisexual individuals were at significantly higher risk of mental health issues (depression, anxiety), suicidal ideation, substance misuse, and deliberate self-harm than heterosexual individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/54\">",
"     54",
"    </a>",
"    ]. Results were similar in both sexes, but meta-analyses revealed that lesbian and bisexual women were particularly at risk of substance dependence (alcohol, 12 months: RR 4.00, 95% CI 2.85-5.61; drug dependence: RR 3.50, 95% CI 1.87-6.53; any substance use disorder: RR 3.42, 95% CI 1.97-5.92). Higher rates of suicidality and depression are most common in WSW who have not disclosed their sexual orientation, suggesting that fear of stigmatization regarding sexual orientation was a significant risk factor for mental health morbidity in this cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The environment in which many of these individuals live, the violence they may face many times in their lives, and their anxiety and fear during the process of coming out can leave emotional scars that often need to be addressed. In one survey, 86 percent of lesbian, gay, bisexual, and transgender women (LGBT) women experienced verbal harassment, 44.1 percent experienced physical harassment, and 22.1 experienced physical assault [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/56\">",
"     56",
"    </a>",
"    ]. Discussion of these and related issues is important, and referral for counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychopharmacological intervention is often warranted. Referral to mental health professionals with expertise in working with the homosexual patient is advantageous.",
"   </p>",
"   <p>",
"    Same sex couples, like other couples, are at risk for intimate partner violence. When same sex couples are in legally recognized relationships, they report having more meaning in their lives, fewer symptoms of depression, and less overall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/57\">",
"     57",
"    </a>",
"    ]. Conversely, same sex couples living in states where same sex marriage is not legal experience increased stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4887496\">",
"    <span class=\"h1\">",
"     PARENTING OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have sex with women (WSW) encounter special obstacles in fulfilling their desires to become parents, including homophobic stigmatization of WSW as inappropriate mothers, potential rejection by family, limited access to and availability of resources such as sperm banks and insurance coverage. These obstacles exist despite evidence from studies that have examined the psychosocial development of children raised by WSW and found no differences in sexual or gender identity, personality traits, or intelligence compared to children of heterosexual parents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WSW have several possible paths to parenthood, including raising children from prior heterosexual relationships; conception through donor insemination; use of a surrogate; foster parenting; and adoption. WSW who choose to have children have some needs similar to those of heterosexual couples, and other needs unique to their circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues the clinician needs to address with patients include the logistics, safety, effectiveness, and",
"    <span class=\"nowrap\">",
"     family/legal",
"    </span>",
"    ramifications of various parenting options, as well as referral to appropriate providers of fertility and parenthood services. The goal is to optimize fertility and minimize pregnancy complications. As a group, WSW are at higher risk of pregnancy complications than heterosexual women because they tend to be at an older age at conception, experience more stress, have a higher body mass index (BMI), and have a higher prevalence of smoking, drug use, and alcohol consumption. &nbsp;",
"   </p>",
"   <p>",
"    Resources:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alternative Families: www.alternativefamilies.org",
"     </li>",
"     <li>",
"      The Organization of Parents though Surrogacy: www.opts.com",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3875234\">",
"    <span class=\"h2\">",
"     Adoption",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=see_link\">",
"     \"Adoption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3875254\">",
"    <span class=\"h2\">",
"     Foster parenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/51/27448?source=see_link\">",
"     \"Epidemiology of foster care placement and overview of the foster care system in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3875188\">",
"    <span class=\"h2\">",
"     Assisted reproductive technology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report by the Ethics Committee of the American Society for Reproductive Medicine affirmed the right of single, gay, and lesbian persons to have access to fertility services [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/62\">",
"     62",
"    </a>",
"    ]. Once they have decided to attempt pregnancy, these patients need information about fertility, basal body temperature charts, ovulation prediction kits, donor selection from sperm banks (including a release form for sperm banks signed by a physician), laboratory testing, insemination methods, preconception counseling, and prenatal care. If the patient's female partner is present, she should be included in all discussions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Donor insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor insemination is an expensive, time-tested method of achieving pregnancy with a reasonable success rate in fertile recipients. Insemination is timed to take place just prior to ovulation, typically using kits for home urine luteinizing hormone (LH) measurement. Basal body temperature, although helpful for analyzing ovulatory patterns, is not helpful for determining timing of insemination because ovulation has typically already occurred once an increase in temperature is apparent; therefore, the window has been missed.",
"   </p>",
"   <p>",
"    Donor insemination can be performed by the woman herself, her partner, or a health care provider. A prospective randomized crossover study of intracervical (ICI) versus intrauterine insemination (IUI) of single fertile women choosing to inseminate with frozen donor semen found that IUI was slightly more effective than ICI in this population (monthly fecundity 14 versus 5 percent with one insemination, 14 versus 9 percent with more than one insemination) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/63\">",
"     63",
"    </a>",
"    ]. Donor insemination is discussed in detail separately.",
"   </p>",
"   <p>",
"    Most health insurers do not cover the costs of semen and office insemination for WSW or single women who are presumed fertile and want to become pregnant until there have been 12 cycles of insemination without conception (suggesting infertility, which is a covered benefit in most insurance packages).",
"   </p>",
"   <p>",
"    Some WSW request insemination from a known male donor who is an acquaintance but who has sex with men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/61\">",
"     61",
"    </a>",
"    ]. This can be problematic since sperm banks typically do not accept sperm from such men and donor insemination programs require directed donors to undergo the same screening and safety procedures required of anonymous donors (eg, quarantine the sperm specimen for six months and then retest the donor for human immunodeficiency virus (HIV) and other sexually transmitted infections before releasing sperm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=see_link\">",
"     \"Donor insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues concerning legal relationships with the sperm donor and the nonbiologic same sex parent should be addressed before insemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Co-maternity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some couples choose co-maternity. The egg of one partner is aspirated, fertilized as in an in vitro fertilization (IVF) procedure, and then transferred to the uterus of the other partner, who is the gestational carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/64\">",
"     64",
"    </a>",
"    ]. Although this allows both partners to biologically participate in the pregnancy, it is more costly and risky than simple insemination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prenatal care, childbirth, and hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal care of WSW is the same as for other women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    .) The presence of her partner should be encouraged at antenatal visits, childbirth preparation classes, during labor, and postpartum. In the United States, hospitals that accept Medicaid and Medicare funding must grant same sex partners visitation rights. When obtaining the social history, health care providers should remain cognizant that lesbians are not immune from domestic violence and should be screened for abusive relationships.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Marriage, parenting, and legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesbians may have been pregnant in the past, may live with or without children from a previous heterosexual relationship, or may live with their partner's children, depending upon custody issues. Others become parents through adoption or foster care. Issues that lesbians must consider include contracts regarding parenting, durable power of attorney, health proxies, second parent (or co-parent) adoption, and custody issues in the event of death or separation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a number of US states have legalized marriage between same sex partners, these marriages are not always recognized in other states. This discrepancy within the US legal system can create considerable conflict and stress when relationships dissolve and if one or both sexual partners move to a state where marriage is not recognized as legal. Advising patients to seek consultation with an attorney knowledgeable in this area is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8143115\">",
"    <span class=\"h1\">",
"     ISSUES FOR ELDER WOMEN WHO HAVE SEX WITH WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stigmatization, victimization, and discrimination are significant lifelong issues for elder lesbian and bisexual women. There are few large scale studies of health issues in older lesbian, gay, bisexual, and transgender women (LGBT) populations. One such study, &ldquo;Still Out, Still Aging: The MetLife Study of Lesbian, Gay, and Bisexual and Transgender Baby Boomers,&rdquo; was conducted among 1201 individuals aged 45 to 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25113/abstract/67\">",
"     67",
"    </a>",
"    ]. There were significant differences in being out and perceived acceptance by family members. Three fourths of lesbians, compared to only 16 percent of bisexual women were described as completely out or mostly out. The majority of lesbians reported some level of acceptance from their families, in contrast to the 31 percent of bisexuals whose family members were not generally accepting of their sexual orientation. Thirty percent of lesbians and only 12 percent of bisexuals admitted to being open about sexual orientation. &nbsp;",
"   </p>",
"   <p>",
"    One needs assessment survey in 2003 by Services and Advocacy for Gay, Lesbian, Bisexual, and Transgender Elders (SAGE) found that LGBT were four times less likely to have children and grandchildren. This situation, along with lack of access to a partner, can lead to social isolation and lack of quality elder care.",
"   </p>",
"   <p>",
"    Federal, state, and local services are most often heterocentric and gender-normative, and therefore not designed to meet the needs of lesbian and bisexual women. Research is also lacking among older LGBT populations with regard to issues of race, socioeconomic status, ethnicity, and geography. The long-term care issues of older LGBT women have also not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who have sex with women (WSW) show a wide range of sexual identities (celibacy, heterosexuality, bisexuality, and homosexuality), which can change over time; thus, it is advisable to discuss sexual behavior and partner history at each visit. (See",
"      <a class=\"local\" href=\"#H3413618\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is particularly important to address the issue of homosexuality with adolescent patients and provide factual information in a supportive and nonjudgmental way. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WSW are more likely to have characteristics that constitute high-risk factors predisposing to colon, lung, endometrial, ovarian, and breast cancer, as well as cardiovascular disease and diabetes. In general, they should be screened for cancer according to standard guidelines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14846654\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexually transmitted infections can be transmitted between women through sexual behaviors resulting in the exchange of vaginal secretions on hands or objects. Patients should be counseled about preventive measures. Screening for sexually transmitted infections should be performed in women with symptoms or periodically according to national guidelines in those with risk factors (eg, more than one partner or a partner with other partners, previous pelvic inflammatory disease [PID], anal sex) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sexually transmitted diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lesbians contemplating having children need information about fertility, donor selection from sperm banks, insemination methods, preconception counseling, alternative pathways to parenthood, and legal issues. (See",
"      <a class=\"local\" href=\"#H4887496\">",
"       'Parenting options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual minorities, such as lesbians, and particularly elderly lesbians, may experience higher levels of chronic stress as a result of their lifelong stigmatization from their sexual identity and this can have an impact on their mental health and health outcomes. (See",
"      <a class=\"local\" href=\"#H14846531\">",
"       'Psychosocial issues related to sexual orientation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8143115\">",
"       'Issues for elder women who have sex with women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/1\">",
"      Mravcak SA. Primary care for lesbians and bisexual women. Am Fam Physician 2006; 74:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/2\">",
"      Denenberg R. Report on lesbian health. Womens Health Issues 1995; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/3\">",
"      O'Hanlan, KA. Lesbian health and homophobia: Perspectives for the treating obstetrician/ gynecologist. Curr Probl Obstet Gynecol Fertil 1995; 18:99.",
"     </a>",
"    </li>",
"    <li>",
"     National Survey of Family Growth. www.cdc.gov (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/5\">",
"      Case P, Austin SB, Hunter DJ, et al. Sexual orientation, health risk factors, and physical functioning in the Nurses' Health Study II. J Womens Health (Larchmt) 2004; 13:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/6\">",
"      Diamant AL, Wold C. Sexual orientation and variation in physical and mental health status among women. J Womens Health (Larchmt) 2003; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/7\">",
"      Aaron DJ, Chang YF, Markovic N, LaPorte RE. Estimating the lesbian population: a capture-recapture approach. J Epidemiol Community Health 2003; 57:207.",
"     </a>",
"    </li>",
"    <li>",
"     Gates, GJ. Same-sex Couples and the Gay, Lesbian, Bisexual Population: New Estimates from the American Community Survey. The Williams Institute on Sexual Orientation Law and Public Policy, UCLA School of Law October, 2006.",
"    </li>",
"    <li>",
"     Smith DM, Gates G. Gay and Lesbian Families in the United States: Same-Sex Unmarried Partner Households. Washington, DC, Human Rights Campaign, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/10\">",
"      Chandra A, Mosher WD, Copen C, Sionean C. Sexual behavior, sexual attraction, and sexual identity in the United States: data from the 2006-2008 National Survey of Family Growth. Natl Health Stat Report 2011; :1.",
"     </a>",
"    </li>",
"    <li>",
"     Gates GJ. How many people are lesbian, gay, bisexual, and transgender? The Williams Institute, UCLA School of Law, Los Angeles, CA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/12\">",
"      McNair RP, Hegarty K. Guidelines for the primary care of lesbian, gay, and bisexual people: a systematic review. Ann Fam Med 2010; 8:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/13\">",
"      Roberts SJ, Sorensen L. Lesbian health care: a review and recommendations for health promotion in primary care settings. Nurse Pract 1995; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/14\">",
"      Harrison AE. Primary care of lesbian and gay patients: educating ourselves and our students. Fam Med 1996; 28:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/15\">",
"      Kreiss JL, Patterson DL. Psychosocial issues in primary care of lesbian, gay, bisexual, and transgender youth. J Pediatr Health Care 1997; 11:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/16\">",
"      Bradford J, Ryan C, Rothblum ED. National Lesbian Health Care Survey: implications for mental health care. J Consult Clin Psychol 1994; 62:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/17\">",
"      White JC, Levinson W. Lesbian health care. What a primary care physician needs to know. West J Med 1995; 162:463.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, Centers for Disease Control and Prevention. Sexually transmitted diseases: Treatment Guidelines 2006. file://www.cdc.gov/std/treatment/2006/clinical.htm. (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     Dibble S, Robertson P. Lesbian Health 101: A Clinician's Guide, UCSF Nursing Press, 2010.",
"    </li>",
"    <li>",
"     The Fenway Guide to LGBT Heatlh, American College of Physicians, 2007.",
"    </li>",
"    <li>",
"     GLBT Health Access Project. Community Standards of Practice For Provision of Quality",
"Health Care Services For Gay, Lesbian, Bisexual And Transgendered. www.glbthealth.org www.glbthealth.org/documents/SOP.pdf (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     The Lesbian Health Research Center at UCSF. www.lesbianhealthinfo.org.",
"    </li>",
"    <li>",
"     The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. 2011. www.iom.edu/lgbthealth (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     Healthy People 2020. www.lgbthealth.net.",
"    </li>",
"    <li>",
"     Gay and Lesbian Medical Association. Guidelines for Care of Lesbian, Gay, Bisexual and Transgender Patients. file://ce54.citysoft.com/_data/n_0001/resources/live/GLMA%20guidelines%202006%20FINAL.pdf (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/26\">",
"      Saewyc EM, Bearinger LH, Blum RW, Resnick MD. Sexual intercourse, abuse and pregnancy among adolescent women: does sexual orientation make a difference? Fam Plann Perspect 1999; 31:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/27\">",
"      American Academy of Pediatrics Committee on Adolescence: Homosexuality and adolescence. Pediatrics 1993; 92:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/28\">",
"      Kerker BD, Mostashari F, Thorpe L. Health care access and utilization among women who have sex with women: sexual behavior and identity. J Urban Health 2006; 83:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/29\">",
"      Gruskin EP, Greenwood GL, Matevia M, et al. Disparities in smoking between the lesbian, gay, and bisexual population and the general population in California. Am J Public Health 2007; 97:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/30\">",
"      Cherpitel CJ. A brief screening instrument for problem drinking in the emergency room: the RAPS4. Rapid Alcohol Problems Screen. J Stud Alcohol 2000; 61:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/31\">",
"      Valanis BG, Bowen DJ, Bassford T, et al. Sexual orientation and health: comparisons in the women's health initiative sample. Arch Fam Med 2000; 9:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/32\">",
"      Boehmer U, Bowen DJ, Bauer GR. Overweight and obesity in sexual-minority women: evidence from population-based data. Am J Public Health 2007; 97:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/33\">",
"      Koh AS, G&oacute;mez CA, Shade S, Rowley E. Sexual risk factors among self-identified lesbians, bisexual women, and heterosexual women accessing primary care settings. Sex Transm Dis 2005; 32:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/34\">",
"      Lemp GF, Jones M, Kellogg TA, et al. HIV seroprevalence and risk behaviors among lesbians and bisexual women in San Francisco and Berkeley, California. Am J Public Health 1995; 85:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/35\">",
"      Marrazzo JM, Stine K. Reproductive health history of lesbians: implications for care. Am J Obstet Gynecol 2004; 190:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/36\">",
"      Diamant AL, Schuster MA, McGuigan K, Lever J. Lesbians' sexual history with men: implications for taking a sexual history. Arch Intern Med 1999; 159:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/37\">",
"      Ryan H, Wortley PM, Easton A, et al. Smoking among lesbians, gays, and bisexuals: a review of the literature. Am J Prev Med 2001; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/38\">",
"      Saunders JM. Health problems of lesbian women. Nurs Clin North Am 1999; 34:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/39\">",
"      Marrazzo JM, Koutsky LA, Kiviat NB, et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001; 91:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/40\">",
"      Marrazzo JM. Genital human papillomavirus infection in women who have sex with women: a concern for patients and providers. AIDS Patient Care STDS 2000; 14:447.",
"     </a>",
"    </li>",
"    <li>",
"     Haynes, S. Risk of breast cancer among lesbians. Presented at Cancer and Cancer Risk Among Lesbians, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1994 Dec 2-4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/42\">",
"      Dibble SL, Roberts SA, Robertson PA, Paul SM. Risk factors for ovarian cancer: lesbian and heterosexual women. Oncol Nurs Forum 2002; 29:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/43\">",
"      Carroll, N, Goldstein, RS, Lo, W, Mayer, KH. Gynecological infections and sexual practices of Massachusetts lesbian and bisexual women. J Gay Lesbian Med Assoc 1997; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/44\">",
"      Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000; 76:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/45\">",
"      Berger BJ, Kolton S, Zenilman JM, et al. Bacterial vaginosis in lesbians: a sexually transmitted disease. Clin Infect Dis 1995; 21:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/46\">",
"      Kellock D, O'Mahony CP. Sexually acquired metronidazole-resistant trichomoniasis in a lesbian couple. Genitourin Med 1996; 72:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/47\">",
"      Rich JD, Buck A, Tuomala RE, Kazanjian PH. Transmission of human immunodeficiency virus infection presumed to have occurred via female homosexual contact. Clin Infect Dis 1993; 17:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/48\">",
"      Troncoso AR, Romani A, Carranza CM, et al. [Probable HIV transmission by female homosexual contact]. Medicina (B Aires) 1995; 55:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/49\">",
"      O'Hanlan KA, Crum CP. Human papillomavirus-associated cervical intraepithelial neoplasia following lesbian sex. Obstet Gynecol 1996; 88:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/50\">",
"      Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis 2008; 47:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/51\">",
"      Marrazzo JM, Koutsky LA, Eschenbach DA, et al. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis 2002; 185:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/52\">",
"      White JC. HIV risk assessment and prevention in lesbians and women who have sex with women: practical information for clinicians. Health Care Women Int 1997; 18:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/53\">",
"      Kennedy MB, Scarlett MI, Duerr AC, Chu SY. Assessing HIV risk among women who have sex with women: scientific and communication issues. J Am Med Womens Assoc 1995; 50:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/54\">",
"      King M, Semlyen J, Tai SS, et al. A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry 2008; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/55\">",
"      Koh AS, Ross LK. Mental health issues: a comparison of lesbian, bisexual and heterosexual women. J Homosex 2006; 51:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/56\">",
"      Kosciw JG, Greytak EA, Diaz EM. Who, what, where, when, and why: demographic and ecological factors contributing to hostile school climate for lesbian, gay, bisexual, and transgender youth. J Youth Adolesc 2009; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/57\">",
"      Riggle ED, Rostosky SS, Reedy CS. Online surveys for BGLT research: issues and techniques. J Homosex 2005; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/58\">",
"      Gold MA, Perrin EC, Futterman D, Friedman SB. Children of gay or lesbian parents. Pediatr Rev 1994; 15:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/59\">",
"      Brewaeys A, van Hall EV. Lesbian motherhood: the impact on child development and family functioning. J Psychosom Obstet Gynaecol 1997; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/60\">",
"      Hunfeld JA, Fauser BC, de Beaufort ID, Passchier JP. Child development and quality of parenting in lesbian families: no psychosocial indications for a-priori withholding of infertility treatment. A systematic review. Hum Reprod Update 2002; 8:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/61\">",
"      Ross LE, Steele LS, Epstein R. Lesbian and bisexual women's recommendations for improving the provision of assisted reproductive technology services. Fertil Steril 2006; 86:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/62\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons. Fertil Steril 2009; 92:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/63\">",
"      Carroll N, Palmer JR. A comparison of intrauterine versus intracervical insemination in fertile single women. Fertil Steril 2001; 75:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/64\">",
"      Marina S, Marina D, Marina F, et al. Sharing motherhood: biological lesbian co-mothers, a new IVF indication. Hum Reprod 2010; 25:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/65\">",
"      Parks CA. Lesbian parenthood: a review of the literature. Am J Orthopsychiatry 1998; 68:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25113/abstract/66\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 428: Legal status: health impact for lesbian couples. Obstet Gynecol 2009; 113:469.",
"     </a>",
"    </li>",
"    <li>",
"     Still Out, Still Aging: The MetLife Study of Lesbian, Gay, and Bisexual and Transgender Baby Boomers. MetLife, New York 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5426 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25113=[""].join("\n");
var outline_f24_33_25113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3413618\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14847519\">",
"      Sexual orientation and behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8142474\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3413250\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3413530\">",
"      APPROACH TO THE LGBT PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTIVE HEALTH CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8142592\">",
"      Healthy weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8142681\">",
"      Prevention of unplanned pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14846654\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33186332\">",
"      - Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3874972\">",
"      Prevention of sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14846531\">",
"      PSYCHOSOCIAL ISSUES RELATED TO SEXUAL ORIENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4887496\">",
"      PARENTING OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3875234\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3875254\">",
"      Foster parenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3875188\">",
"      Assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Co-maternity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prenatal care, childbirth, and hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Marriage, parenting, and legal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8143115\">",
"      ISSUES FOR ELDER WOMEN WHO HAVE SEX WITH WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=related_link\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11433?source=related_link\">",
"      Donor insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/51/27448?source=related_link\">",
"      Epidemiology of foster care placement and overview of the foster care system in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_33_25114="Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy";
var content_f24_33_25114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Christopher D Anderson, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/33/25114/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/33/25114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas are rare malignancies arising from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Surgical and other local treatments for cholangiocarcinoma will be reviewed here. Epidemiology, pathology, classification, staging, clinical presentation, and diagnosis, as well as treatment for locally advanced disease and systemic therapy for metastatic disease, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT FOR CURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, cholangiocarcinomas have an extremely poor prognosis, with an average five-year survival rate of 5 to 10 percent. Surgery provides the only possibility for a cure. Distal cholangiocarcinomas (",
"    <a class=\"graphic graphic_figure graphicRef52489 \" href=\"UTD.htm?19/12/19651\">",
"     figure 1",
"    </a>",
"    ) have the highest resectability rates while proximal (both intrahepatic and perihilar) tumors have the lowest. In one large series, the resectability rates for distal, intrahepatic, and perihilar lesions were 91, 60, and 56 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in patients who undergo potentially curative resection, tumor-free margins can be obtained in only 20 to 40 percent of proximal and 50 percent of distal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2\">",
"     2",
"    </a>",
"    ]. These numbers are even lower if a proximal tumor-free margin of at least 5 mm is considered to constitute a curative procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the current applicability of these data is uncertain. Most of the case series in the surgical literature (even those reported in the last few years) span 10 to 30 years, a time period over which much has changed in cancer therapy. Resectability rates for cholangiocarcinomas have increased over time, due in part to more aggressive operative strategies and broadened criteria for resectability. As a result, caution should be exercised in the interpretation of outcomes derived from past literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Criteria for resectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional guidelines for resectability of cholangiocarcinoma in the United States include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of retropancreatic and paraceliac nodal metastases or distant liver metastases",
"     </li>",
"     <li>",
"      Absence of invasion of the portal vein or main hepatic artery (although some centers support en bloc resection with vascular reconstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/6,7\">",
"       6,7",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Absence of extrahepatic adjacent organ invasion",
"     </li>",
"     <li>",
"      Absence of disseminated disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional criteria are specific to tumor location. For instance, radiographic criteria that suggest local unresectability of perihilar tumors include bilateral hepatic duct involvement up to secondary radicles bilaterally, encasement or occlusion of the main portal vein proximal to its bifurcation, atrophy of one liver lobe with encasement of the contralateral portal vein branch, atrophy of one liver lobe with contralateral secondary biliary radicle involvement, or involvement of bilateral hepatic arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as a general rule, true resectability is ultimately determined at surgery, particularly with perihilar tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/9\">",
"     9",
"    </a>",
"    ]. Due to their location within the upper hepatoduodenal ligament, these tumors often extend into the liver and major vascular structures, and preoperative evaluation of resectability is often difficult. Thus, surgical exploration is the appropriate treatment for proximal bile duct carcinomas whenever feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Preoperative biliary decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether preoperative biliary decompression using an endoscopically or percutaneously placed stent should be carried out in patients who present with obstructive jaundice is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The following issues inform the debate.",
"   </p>",
"   <p>",
"    In general, it is preferable to avoid stents, if possible. The ability to carry out the precise imaging that is required to assess unresectability is limited once a stent is in place. Furthermore, many surgeons find the presence of any biliary stent a hindrance to determining the proximal tumor extent intraoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, cholestasis, liver dysfunction, and biliary cirrhosis develop rapidly with unrelieved obstruction. The extent of liver dysfunction is one of the main factors that increase postoperative morbidity and mortality following surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although experimental studies in jaundiced animals suggest that preoperative biliary drainage improves surgical outcomes, clinical studies report variable benefit from preoperative biliary decompression in terms of morbidity and mortality. Much of the data are derived from jaundiced patients who have pancreatic cancer. Several such series report deleterious effects of drainage prior to pancreaticoduodenectomy, including an increased risk of cholangitis and longer postoperative hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. However, while compelling, these data cannot be extrapolated to the setting of hilar cholangiocarcinoma (eg, a Klatskin tumor), in which major liver resection is frequently required.",
"   </p>",
"   <p>",
"    Only one study has examined the impact of major liver resection in jaundiced patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/17\">",
"     17",
"    </a>",
"    ]. Twenty consecutive patients with obstructive jaundice (14 cholangiocarcinomas, five gallbladder cancers, one hepatocellular cancer) who were to undergo major liver resection without preoperative biliary drainage were matched (for age, tumor size, type of liver resection, and vascular occlusion) with 27 nonjaundiced patients with normal underlying liver selected from a computer bank of 261 patients undergoing liver resection for a variety of reasons. Although there were no significant differences in mortality (5 vs 0 percent) or the incidence of postoperative liver failure (5 versus vs 0 percent), postoperative morbidity rates (mainly resulting from subphrenic collections and bile leaks) were significantly higher in the jaundiced patients (50 versus 15 percent). These data support a",
"    <strong>",
"     potential",
"    </strong>",
"    benefit for preoperative drainage.",
"   </p>",
"   <p>",
"    However, a meta-analysis of eleven studies addressing the benefit of preoperative biliary drainage in jaundiced patients with hilar cholangiocarcinoma (10 retrospective, only one prospective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/18\">",
"     18",
"    </a>",
"    ]) came to the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in death rate or length of postoperative stay with and without preoperative biliary decompression.",
"     </li>",
"     <li>",
"      Overall postoperative complications rates and infectious complication rates were significantly adversely affected by preoperative biliary drainage as compared to surgery without preoperative biliary drainage.",
"     </li>",
"     <li>",
"      In the absence of evidence for a clinical benefit, preoperative biliary decompression in jaundiced patients with hilar cholangiocarcinoma planned for surgery should not be routinely performed. Randomized trials with large sample size and optimal biliary drainage techniques are needed. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best method (endoscopic versus percutaneous transhepatic) by which to perform preoperative biliary drainage is also debated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link&amp;anchor=H718231662#H718231662\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\", section on 'Percutaneous versus endoscopic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These unresolved issues as to the benefit of preoperative biliary drainage and the best means of achieving biliary decompression has led to differing approaches. Many surgeons proceed directly to laparotomy without preoperative biliary drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. On the other hand, there is often uncertainty as to resectability as well as the timetable of surgical evaluation and operative management in patients presenting with jaundice (frequently to gastroenterologists, who perform endoscopic stenting). As a practical issue, endoscopic stents are often placed to alleviate jaundice while these issues are being settled. If an endoscopic stent cannot be placed for whatever reason, a percutaneous approach is generally tried. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach is to selectively perform nonoperative biliary drainage selectively in patients with a serum bilirubin level over 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    deferring definitive operative intervention until bilirubin levels are under 3",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    However, if stent placement is planned, high quality imaging necessary to assess unresectability (CT, MRI, ERCP, MRCP) should be performed beforehand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\", section on 'Radiographic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients who are thought to be potentially resectable, laparoscopic staging can be accomplished shortly after the drainage procedure, while the bilirubin is decreasing to a safe level that will permit definitive resection. If extrahepatic disease or nonresectable tumor is found, curative resection is not possible, and alternative management strategies can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Preoperative portal vein embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the achievement of histologically negative resection margins is so critical to outcome, preoperative portal vein embolization (PVE) has been used in an attempt to increase the limits of safe resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. The intent of PVE is to induce lobar hypertrophy in patients who have a predicted postoperative liver remnant volume of &lt;25 percent. By allowing a larger resection volume to be carried out safely, PVE may permit a margin-negative resection in patients who otherwise would be considered unresectable because of concerns about insufficient postoperative residual liver volume. This technique is used more commonly prior to resection of hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=see_link&amp;anchor=H1061867819#H1061867819\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\", section on 'Portal vein embolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21978?source=see_link\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo potentially curative resection for cholangiocarcinoma, long-term outcomes vary according to location and stage of the primary lesion, extent of surgery, associated comorbidities, and treatment-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/1,2,4,28-40\">",
"     1,2,4,28-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main prognostic factors are histologic margin status and lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/29,41-43\">",
"     29,41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 137 cases of resected extrahepatic cholangiocarcinoma, five-year survival rates for those with node-negative versus node-positive disease were 38 versus less than 10 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Five-year survival rates are substantially better with clear as opposed to histologically involved margins (19 to 47 percent versus 0 to 12 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/9,37,38,44-48\">",
"       9,37,38,44-48",
"      </a>",
"      ]. The most encouraging results (particularly with perihilar cholangiocarcinomas) come from reports that utilize expanded resection criteria and more extensive surgical procedures which increase the likelihood of negative resection margins. However, outcomes for patients who develop perihilar or intrahepatic cholangiocarcinoma in the setting of primary sclerosing cholangitis (PSC) are dismal [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Perihilar cholangiocarcinoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For resected intrahepatic cholangiocarcinomas, hepatic venous invasion is also a negative prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical treatment and outcomes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Distal cholangiocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal lesions are usually treated with pancreaticoduodenectomy (Whipple procedure). A pylorus-preserving operation is preferable and is feasible in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/1\">",
"     1",
"    </a>",
"    ]. Five-year survival rates range from 23 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/1,29,51-56\">",
"     1,29,51-56",
"    </a>",
"    ] but are as high as 62 percent in selected patients who undergo complete resection of a node-negative tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, cure rates may not actually be as high as these reports suggest since not all series distinguished distal cholangiocarcinoma from carcinoma of the ampulla of Vater, a disease that has a significantly higher cure rate. Both diseases (as well as some cases of pancreatic cancer) are often analyzed together as \"periampullary\" tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymph node involvement and depth of tumor invasion are important prognostic indicators [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. There are no data stratifying outcomes according to the new 2010 staging criteria of the AJCC (",
"    <a class=\"graphic graphic_table graphicRef82369 \" href=\"UTD.htm?43/39/44668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Intrahepatic cholangiocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrahepatic cholangiocarcinoma is usually treated by hepatic resection to achieve negative resection margins. There are few data regarding the benefits of lymphadenectomy for intrahepatic cholangiocarcinoma. However, it is clear that lymph node involvement is an important prognostic factor. The benefit of performing routine portal lymph node dissection should be weighed against risks such as common bile duct devascularization. We recommend the selective performance of portal lymphadenectomy. For a peripheral localized tumor, we do not perform a routine portal lymph node dissection. For more centrally located tumors in which an extrahepatic bile duct resection is required to maximize the width of the resection margin, we recommend portal lymphadenectomy at the same time.",
"   </p>",
"   <p>",
"    Outcomes depend upon disease stage (particularly the status of the lymph nodes and the presence of vascular invasion rather than size) and the ability to achieve negative margins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/30-32,60,61\">",
"     30-32,60,61",
"    </a>",
"    ]. Among patients undergoing complete resection, five-year overall survival rates are between 15 and 40 percent; five-year survival rates for patients who undergo complete (R0) resection are between 30 and 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/53,62-69\">",
"     53,62-69",
"    </a>",
"    ]. At least some data suggest that outcomes have improved over time, but these apparent improvements may reflect better nonoperative therapy for unresectable disease, [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/63,70\">",
"     63,70",
"    </a>",
"    ], or better patient selection through improved imaging techniques.",
"   </p>",
"   <p>",
"    There are some data that stratify outcomes based on the revised 2010 TNM staging criteria (",
"    <a class=\"graphic graphic_table graphicRef80976 \" href=\"UTD.htm?42/62/44012\">",
"     table 2",
"    </a>",
"    ). Three-year survival rates from a single institution database of 60 patients with a mass-forming intrahepatic cholangiocarcinoma are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (T1) &mdash; 74 percent",
"     </li>",
"     <li>",
"      Stage II (T2a) &mdash; 48 percent",
"     </li>",
"     <li>",
"      Stage II (T2b) &mdash; 18 percent",
"     </li>",
"     <li>",
"      Node-positive &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survival curves for intrahepatic cholangiocarcinoma derived from SEER registry data and stratified by T stage are depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72346 \" href=\"UTD.htm?29/8/29824\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to further refine prognostic stratification, a nomogram has been developed to predict survival following resection of an intrahepatic cholangiocarcinoma that incorporates tumor (T) and nodal (N) categories as well as preoperative serum tumor marker levels, tumor size, and the number of tumor nodules (",
"    <a class=\"graphic graphic_figure graphicRef88821 \" href=\"UTD.htm?42/9/43166\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Perihilar cholangiocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hilar cholangiocarcinomas, bile duct resection alone leads to high local recurrence rates due to early involvement of the confluence of the hepatic ducts (",
"    <a class=\"graphic graphic_figure graphicRef52489 \" href=\"UTD.htm?19/12/19651\">",
"     figure 1",
"    </a>",
"    ) and the caudate lobe branches [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The addition of a modified hepatic resection has improved resectability rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/39,75\">",
"     39,75",
"    </a>",
"    ]. However, curative resections are still possible in fewer than one-half of patients, and the majority do not achieve long-term disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/33,76-80\">",
"     33,76-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, surgical treatment depends upon the Bismuth-Corlette classification (",
"    <a class=\"graphic graphic_figure graphicRef75886 \" href=\"UTD.htm?0/36/582\">",
"     figure 4",
"    </a>",
"    ). For type I and II lesions, the procedure is en bloc resection of the extrahepatic bile ducts and gallbladder with 5 to 10 mm bile duct margins and a regional lymphadenectomy with Roux-en-Y hepaticojejunostomy. In addition to the above operations, type III tumors may require hepatic lobectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/4,34,35,74,79\">",
"     4,34,35,74,79",
"    </a>",
"    ]. Since type II and III lesions often involve the ducts of the caudate lobe, many surgeons recommend routine caudate lobectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/4,34,35\">",
"     4,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type III and type IV tumors are amenable to potentially curative resection in centers with expertise in these procedures. Aggressive techniques such as multiple hepatic segment resection with portal vein resection (hilar en bloc resection) to achieve negative margins are now routine in specialized centers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, neither the Bismuth-Corlette classification nor the AJCC TNM stage (",
"    <a class=\"graphic graphic_table graphicRef51131 \" href=\"UTD.htm?4/11/4285\">",
"     table 3",
"    </a>",
"    ) accurately assesses resectability, and as noted above, true resectability may be ultimately determined only at surgery. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Criteria for resectability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A preoperative clinical staging system that accurately assesses resectability would be of value clinically. Such a classification, the Blumgart staging system, has been proposed that is based upon biliary tumor extent, the presence or absence of portal vein involvement, and the presence or absence of hepatic lobar hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,47\">",
"     2,47",
"    </a>",
"    ]. In a series of 376 patients diagnosed with a hilar cholangiocarcinoma whose disease could be adequately staged, this clinical T staging system accurately predicted resectability, metastatic disease, and the likelihood of a microscopically complete (R0) resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/83\">",
"     83",
"    </a>",
"    ]. Independent confirmation of these results is needed.",
"   </p>",
"   <p>",
"    Substantial progress has been made in curative resection for perihilar cholangiocarcinomas. In selected series, five-year survival rates are between 20 and 50 percent, with the best results reported from Japan (",
"    <a class=\"graphic graphic_table graphicRef63655 \" href=\"UTD.htm?16/48/17164\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,4,8,34,35,42,44,46,84,85\">",
"     2,4,8,34,35,42,44,46,84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least some of this progress has been attributed to the routine use of partial hepatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,40,41,46,74,83\">",
"     2,40,41,46,74,83",
"    </a>",
"    ]. The rate of margin-negative resections is consistently over 75 percent when partial hepatectomy (including resection of the caudate lobe) is added to the bile duct resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,4,42,46\">",
"     2,4,42,46",
"    </a>",
"    ]. This aggressive approach has resulted in five-year survival rates that are 50 percent or better in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,39,46,86\">",
"     2,39,46,86",
"    </a>",
"    ]. However, these improvements have been accompanied by higher surgical mortality rates (7 to 10 versus 2 to 4 percent) in most [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/2,39,87,88\">",
"     2,39,87,88",
"    </a>",
"    ] but not all series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/46,86\">",
"     46,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all series support a positive impact of routine hepatic lobectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/45,89\">",
"     45,89",
"    </a>",
"    ]. In one American series of 109 patients with proximal cholangiocarcinomas, the one, three, and five year survival rates among resected patients were 68, 30, and 11 percent, respectively, and the addition of hepatic lobectomy did not alter the survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/45\">",
"     45",
"    </a>",
"    ]. However, histologically negative margins were only achieved in 26 percent of patients, despite the use of extended hepatectomy.",
"   </p>",
"   <p>",
"    In addition, many clinicians suggest that the increasing use of postoperative chemoradiotherapy therapy has contributed to the improved outcomes that have been seen in the last decade with hilar cholangiocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adjuvant therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The major prognostic factors are margin status, vascular invasion, and lymph node metastases, as reflected by the TNM staging criteria (",
"    <a class=\"graphic graphic_table graphicRef51131 \" href=\"UTD.htm?4/11/4285\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/90\">",
"     90",
"    </a>",
"    ]. There are no data stratifying outcomes according to the revised stage groupings of the 2010 criteria.",
"   </p>",
"   <p>",
"    Other factors that are not captured by the staging criteria also influence outcome after resection. In one report of 65 patients undergoing resection for perihilar cholangiocarcinoma, variables that significantly affected survival included transmural extension to the gallbladder, histologic type (papillary better than adenosquamous) and gender (females better than males) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/39\">",
"     39",
"    </a>",
"    ]. Others suggest an adverse prognostic impact of preoperative serum albumin level of less than 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and total bilirubin above 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following complete surgical resection, the most common relapse pattern is local [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/86,91\">",
"     86,91",
"    </a>",
"    ]. Distant metastases (typically hepatic or peritoneal recurrence) are less common than with gallbladder cancer, but not rare. In one series, the initial recurrence involved a distant site in 41 percent of patients with a hilar cholangiocarcinoma (as compared to 85 percent of patients with gallbladder cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/91\">",
"     91",
"    </a>",
"    ]. Others report that 60 percent of patients developed distant metastases following a complete (R0) resection for hilar cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/86\">",
"     86",
"    </a>",
"    ]. These data provide the rationale for exploring adjuvant systemic chemotherapy as well as RT-based regimens for extrahepatic cholangiocarcinomas.",
"   </p>",
"   <p>",
"    Although it is widely used and recommended in guidelines from some expert groups, particularly in patients with node-positive or margin-positive disease, the survival benefit of any adjuvant strategy for resected cholangiocarcinoma has never been proven in randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No prospective randomized trials are available that establish the benefit of adjuvant RT in patients with completely resected disease. While some retrospective series suggest benefit from adjuvant RT alone [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/89,92,93\">",
"       89,92,93",
"      </a>",
"      ], others do not [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/1,94-96\">",
"       1,94-96",
"      </a>",
"      ]. Most of these studies have examined mixed populations of intrahepatic and extrahepatic cholangiocarcinomas.",
"     </li>",
"     <li>",
"      Fluoropyrimidine-based chemoradiotherapy is often offered to patients following a macroscopically incomplete resection of a cholangiocarcinoma; in this setting, its main benefit is in enhanced local control. Chemoradiotherapy for locally advanced cholangiocarcinoma is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link\">",
"       \"Treatment options for locally advanced cholangiocarcinoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Multiple retrospective series and small phase II studies (most of which consist of a heterogeneous mix of patients with completely and incompletely resected intrahepatic and extrahepatic cholangiocarcinoma) suggest superior outcomes for patients who received postoperative chemoradiotherapy compared to historical series of patients who did not undergo chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/38,46,92,93,97-100\">",
"       38,46,92,93,97-100",
"      </a>",
"      ]. One small randomized trial conducted in a mixed population of 207 patients with pancreatic or periampullary malignancies (75 to 80 percent margin-negative) failed to demonstrate a survival benefit for postoperative fluoropyrimidine chemoradiotherapy compared to surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/101\">",
"       101",
"      </a>",
"      ]. However, there were fewer than 100 patients with periampullary cancers in this trial, only some of which were biliary cancers. Furthermore, 20 percent of the patients in the treatment arm received no adjuvant treatment because of postoperative complications or refusal.",
"     </li>",
"     <li>",
"      Similarly, although benefit has been suggested in retrospective reports [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/102-105\">",
"       102-105",
"      </a>",
"      ], there is no high quality evidence that adjuvant chemotherapy alone improves survival in patients with completely or incompletely resected cholangiocarcinoma:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A single multi-institutional randomized trial from Japan compared postoperative chemotherapy (two courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C plus infusional 5-FU, followed by prolonged oral administration of 5-FU until tumor progression) with surgery alone in 508 patients with resected pancreaticobiliary malignancies (139 with bile duct cancer) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/106\">",
"       106",
"      </a>",
"      ]. The patients in this series had advanced disease; lymph node metastases were present in 84 and 88 percent of the patients randomly assigned to chemotherapy and surgery alone, respectively.",
"      <br/>",
"      <br/>",
"      In the subset of patients with bile duct cancer, five-year overall survival was not significantly better with chemotherapy (27 versus 24 percent). When the results were stratified according to surgical margins, chemotherapy did not significantly improve outcome in patients undergoing noncurative resection (five-year survival 8 versus 16 percent), while there was a non-statistically significant trend toward better five year survival among patients who received chemotherapy after a potentially curative resection (41 versus 28 percent).",
"     </li>",
"     <li>",
"      The benefit of adjuvant chemotherapy was directly studied in the international ESPAC-3 trial, in which 428 patients with periampullary malignancies (297 ampullary, 96 bile duct, 35 other) were randomly assigned to one of three arms: observation, six months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated FU or six months of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/107\">",
"       107",
"      </a>",
"      ]. The use of adjuvant chemotherapy was associated with a potentially meaningful overall survival advantage but it was not statistically significant (median 43 versus 35 months, HR 0.86, 95% CI 0.66 to 1.11). In a preplanned subset analysis of the 96 patients with bile duct cancer, the median survivals were 27, 18, and 20 months with observation,",
"      <span class=\"nowrap\">",
"       FU/leucovorin",
"      </span>",
"      and gemcitabine, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=see_link&amp;anchor=H21#H21\">",
"       \"Ampullary carcinoma: Treatment and prognosis\", section on 'Chemotherapy alone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of adjuvant therapy following curative-intent surgery for biliary tract cancers (extrahepatic and intrahepatic bile ducts as well as gallbladder) were addressed in a meta-analysis that included the single randomized trial of chemotherapy alone described above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/106\">",
"     106",
"    </a>",
"    ], two SEER registry analyses, and 17 retrospective institutional series, altogether totaling 6712 patients, of whom 1797 received some form of adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/108\">",
"     108",
"    </a>",
"    ]. To be eligible, studies had to include patients who had curative-intent surgery alone (defined as negative [R0] or microscopically positive [R1] margins) as a control group. There were eight studies of RT plus chemotherapy, three of chemotherapy alone, and nine of RT alone. Only one study included intrahepatic cholangiocarcinoma.",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with surgery alone, the improvement in five-year survival with any adjuvant therapy was not statistically significant (pooled odds ratio [OR] 0.74, 95% CI 0.55-1.01). The results were similar when gallbladder and bile duct cancers were analyzed independently. However, the survival benefit from adjuvant therapy was statistically significant when data from the two large registry series (n = 1233 patients) were excluded (OR 0.53, 95% CI 0.39-0.72).",
"     </li>",
"     <li>",
"      The benefits of adjuvant therapy were modality-dependent; in a combined analysis of gallbladder and bile duct cancers, there was a significant survival benefit for chemotherapy (OR 0.39, 95% CI 0.23-0.66) and chemoradiotherapy (OR 0.61, 95% CI 0.38-0.99) but not RT alone (OR 0.98, 95% CI 0.67-1.43).",
"     </li>",
"     <li>",
"      Pooled data from nine studies in which at least 50 percent of the patients had nodal or margin positivity confirmed a statistically significant overall survival advantage for any adjuvant therapy in node-positive disease (OR 0.49, 95% CI 0.30-0.80). The majority of these patients (77 percent) had received chemotherapy alone, while the remainder underwent chemoradiotherapy.",
"      <br/>",
"      <br/>",
"      Similarly, a significant benefit for any adjuvant therapy was shown for patients with margin-positive disease (OR 0.36, 95% CI 0.19-0.68). Nearly two-thirds of the treated patients with margin-positive (R1) disease (63 percent) had received RT alone as a component of adjuvant therapy, while the majority of studies of margin-negative disease (R0 resection) used chemoradiotherapy and most included node-positive patients.",
"     </li>",
"     <li>",
"      There were only limited data to address the benefit of chemotherapy in patients with node-negative disease, limiting the conclusions that could be reached in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this analysis supports current practice (ie, adjuvant therapy for high-risk subgroups with bile duct cancer), it does not resolve the question as to the best treatment strategy for high-risk patients or adequately address the benefit of adjuvant therapy for patients with low-risk (ie, node-negative) disease. Randomized trials are desperately needed in this area, several of which are ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary and guidelines from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with resected cholangiocarcinoma should be encouraged to enroll on randomized trials testing various adjuvant therapy strategies, if available. For patients who are treated off protocol, we suggest adjuvant therapy for patients with resected high-risk cholangiocarcinoma (lymph node",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    margin positive). Given the negative results of the two randomized trials testing the value of chemotherapy alone, we suggest chemoradiotherapy rather than chemotherapy alone following either a margin-positive or node-positive resection.",
"   </p>",
"   <p>",
"    These recommendations are consistent with consensus-based guidelines for adjuvant therapy after resection of bile duct cancer, which are available from two expert groups:",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggests the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrahepatic cholangiocarcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with resected, margin-negative extrahepatic cholangiocarcinoma with negative regional nodes, observation, fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemotherapy or fluoropyrimidine-based chemoradiotherapy are acceptable options.",
"     </li>",
"     <li>",
"      For patients with carcinoma in situ at the margins or positive margins with invasive disease, fluoropyrimidine-based chemoradiotherapy followed by additional fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      chemotherapy; for positive regional lymph nodes, fluoropyrimidine or gemcitabine-based chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrahepatic cholangiocarcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For no residual local disease, no adjuvant therapy recommendations are made.",
"     </li>",
"     <li>",
"      For patients with positive margins, options include reresection, ablation, fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemoradiotherapy, or fluoropyrimidine or gemcitabine-based chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the European Society of Medical Oncology (ESMO) for treatment of either intrahepatic or extrahepatic cholangiocarcinoma suggest supportive care or palliative chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy after a noncurative resection, and consideration of postoperative chemoradiotherapy as an option after complete surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEOADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant therapy is usually not an option for patients with cholangiocarcinoma, the majority of whom are jaundiced and have a poor functional status at presentation. However, the potential benefit of this approach for selected patients has been suggested by the following small reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early series of nine (out of a total of 91) patients with extrahepatic cholangiocarcinoma who underwent preoperative chemoradiotherapy prior to exploration, three had a pathologic complete response while the remainder showed different degrees of histologic response to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/112\">",
"       112",
"      </a>",
"      ]. Margin-negative resections were possible in all nine patients as compared to only one-half of those who did not receive neoadjuvant therapy.",
"     </li>",
"     <li>",
"      Benefit for neoadjuvant chemoradiotherapy was also suggested in a report of 45 patients undergoing concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma, of whom 12 were treated neoadjuvantly [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/100\">",
"       100",
"      </a>",
"      ]. Three had a complete pathologic response, and 11 were able to undergo a complete (R0) resection. Despite having more advanced disease at presentation, patients who received neoadjuvant chemoradiotherapy had longer five-year survival (53 versus 23 percent) and rates of grade 2 to 3 surgical morbidity were no higher (16 versus 33 percent) compared with those treated in the postoperative setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results are promising and support the need for randomized trials testing this strategy, preoperative chemoradiotherapy cannot yet be considered a standard approach to treatment. Rarely, patients with large, locally advanced unresectable tumors who are treated with chemoradiotherapy are converted to potentially resectable disease, and resection could be considered in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ORTHOTOPIC LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplantation (OLT) has been evaluated as a treatment for intrahepatic and central cholangiocarcinomas with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/113-126\">",
"     113-126",
"    </a>",
"    ]. In many cases, the patients were transplanted for primary sclerosing cholangitis (PSC), and they were found to have incidental cholangiocarcinomas in their native liver.",
"   </p>",
"   <p>",
"    Interest in OLT as a treatment for cholangiocarcinoma was revived by the published experience of the Mayo Clinic, which reported a five-year survival rate of 82 percent in a series of patients with initially unresectable cholangiocarcinoma arising in the setting of PSC who were treated with preoperative chemoradiotherapy followed by exploratory laparotomy to exclude metastatic disease before transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/114\">",
"     114",
"    </a>",
"    ]. Of concern, however, 7 of the 16 explants that contained no viable tumor after chemoradiotherapy did not have a pretreatment cytologic diagnosis, raising questions as to incorrect diagnosis in these patients. Furthermore, these results do not reflect an \"intention to treat\" analysis.",
"   </p>",
"   <p>",
"    A more recent report of the Mayo experience using an intent to treat analysis (of all patients who were enrolled into the protocol regardless of whether they were transplanted or not) revealed one, three, and five-year survival rates 82, 63, and 55 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/123\">",
"     123",
"    </a>",
"    ]. Similarly, a retrospective review of the experience with neoadjuvant chemoradiotherapy followed by OLT for localized cholangiocarcinoma at 12 US centers (with 193 of the 287 patients coming from the Mayo Clinic) demonstrated two- and five-year survival rates of 68 and 53 percent, respectively, in an intent to treat analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the highly selected nature of these patients, the poor sensitivity of noninvasive staging for cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/125\">",
"     125",
"    </a>",
"    ], and issues with donor allocation, OLT cannot be considered a standard form of therapy for locally unresectable cholangiocarcinoma at present. The following represents the conclusions of a systematic review of published reports of OLT for cholangiocarcinoma performed on behalf of the Agency for Healthcare Research and Quality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/128\">",
"     128",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median patient survival was 11.8 months when combining all studies that included a minimum of 10 patients. Overall one-,three- and five-year patient survival rates were 63, 46, and 22 percent, respectively. For comparison, one-, three-, and five-year patient survival following liver transplantation for chronic hepatitis C is 79, 79, and 66 percent, respectively.",
"     </li>",
"     <li>",
"      Recurrence was reported in 52 percent of patients when combining all studies that included a minimum of 10 patients (total 543 patients). The mean follow-up was 53 months. Overall one-, three-, and five-year disease-free survival rates for all patients were 58, 22, and 13 percent, respectively.",
"     </li>",
"     <li>",
"      There were insufficient data to make firm conclusions regarding patient, tumor, or transplant characteristics that were associated with a favorable prognosis. However, limited data suggested that one-year patient survival was better in patients with tumors diagnosed incidentally compared with those in whom it was diagnosed preoperatively. Prognosis was also better in those with negative lymph nodes and no residual disease after surgery.",
"     </li>",
"     <li>",
"      Adjuvant and neoadjuvant chemotherapy did not appear to improve survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as described above, in a large report from the Mayo Clinic that was not included in the systematic review, a five-year survival rate of 82 percent was reported for patients with initially unresectable disease or cholangiocarcinoma arising in the setting of PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/114\">",
"     114",
"    </a>",
"    ]. All patients underwent preoperative chemoradiotherapy followed by exploratory laparotomy to exclude metastatic disease before transplantation.",
"   </p>",
"   <p>",
"    Whether the prognosis is better in patients with underlying primary sclerosing cholangitis (PSC) is unclear. Outcomes in patients with cholangiocarcinoma in the setting of PSC were described in 13 reports with a total of 91 patients. When combining results of the largest four studies, 53 percent recurred. A study of patients with an incidental cholangiocarcinoma found in the setting of PSC (published after the systematic review) found one-, three- and five-year patients survival rates of 65, 35, and 35 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Organ allocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allocation of organs for patients with cholangiocarcinoma is based on the MELD score, and no priority or exception is given unless a center submits a written protocol detailing its selection criteria, administration of neoadjuvant therapy before transplantation, and operative staging to exclude patients outside of transplant criteria to the",
"    <span class=\"nowrap\">",
"     OPTN/UNOS",
"    </span>",
"    (Organ Procurement and Transplantation",
"    <span class=\"nowrap\">",
"     Network/United",
"    </span>",
"    Network for Organ Sharing) Liver and Intestinal Organ Transplantation Committee [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/129\">",
"     129",
"    </a>",
"    ]. UNOS has established criteria for MELD exception for liver transplantation candidates with early unresectable hilar cholangiocarcinoma who complete an approved protocol that includes neoadjuvant therapy, with strict inclusion and exclusion criteria (policy 3.6.4.5.2 Liver Candidates with Cholangiocarcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/129\">",
"     129",
"    </a>",
"    ]. The MELD exception score was set to 22, equal to the current standard assigned score for hepatocellular carcinoma, with eligibility for an increased score every three months if the criteria are still met. Information on how many centers in the US are actively transplanting these patients, what type of neoadjuvant therapy is being used, and outcomes are currently unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplantation cannot be considered a standard form of therapy for localized cholangiocarcinoma at present. It should only be considered for selected patients with early stage unresectable hilar disease who have successfully completed rigorous staging and neoadjuvant therapy. Such clinical protocols are available at only a few transplant centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with cholangiocarcinoma require individualized management. The following general treatment principles are applicable to patients whose disease appears to be localized and potentially resectable. Often, true resectability can only be determined at the time of exploration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend surgical exploration for all patients with suspected cholangiocarcinoma unless they have unresectable adjacent organ invasion, intrahepatic or extrahepatic metastases or other evidence of disseminated disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). At exploration, the finding of nodal metastases beyond the hepatoduodenal ligament (ie, celiac or periaortic nodes) precludes resection.",
"      <br/>",
"      <br/>",
"      We suggest not exploring for attempted resection if there is radiographic evidence of invasion of the main portal vein or main hepatic artery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); others disagree. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Criteria for resectability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with obstructive jaundice, whether preoperative biliary drainage should be accomplished prior to laparotomy is controversial. We suggest selective nonoperative biliary drainage in patients with a serum bilirubin level over 10",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      deferring definitive operative intervention until the serum bilirubin is less than 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Others disagree with this approach, instead proceeding directly to surgery in all patients regardless of the serum bilirubin level. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoperative biliary decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest portal vein embolization (PVE) to induce lobar hypertrophy prior to resection in patients with a predicted postoperative liver remnant volume of &lt;25 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative portal vein embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest postoperative adjuvant therapy for all patients with intrahepatic or extrahepatic cholangiocarcinoma who have microscopically positive resection margins, as well as for those with a complete (margin-negative) resection if they have node-positive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.) For patients with node-positive or margin-positive disease, we suggest chemoradiotherapy rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Some centers prefer infusional 5-FU (225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five weeks) during RT, but increasingly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (825",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily during the five weeks of RT) is used because of its convenience. The doses selected are extrapolated from the experience with capecitabine-based chemoradiotherapy in rectal cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H11#H11\">",
"       \"Adjuvant therapy for resected rectal cancer\", section on 'Orally active fluoropyrimidines'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Following chemoradiotherapy, we administer an additional four months of chemotherapy to all of these patients. We use capecitabine alone (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days) for most patients, and for those with more aggressive tumors or multiple positive nodes, we prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=see_link&amp;anchor=H15#H15\">",
"       \"Systemic therapy for advanced cholangiocarcinoma\", section on 'Oxaliplatin plus gemcitabine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Others prefer the regimen as is used in the adjuvant setting for pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?24/33/25114/abstract/130\">",
"       130",
"      </a>",
"      ], which includes three weeks of gemcitabine alone followed by concurrent fluorouracil-based chemoradiotherapy, and three additional months of gemcitabine chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef81436 \" href=\"UTD.htm?26/2/26669\">",
"       table 5",
"      </a>",
"      ). In our view, either regimen is acceptable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=see_link\">",
"       \"Treatment protocols for hepatobiliary cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not recommend orthotopic liver transplantation as a standard form of therapy for cholangiocarcinoma outside of the context of a clinical research protocol (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Orthotopic liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/1\">",
"      Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/2\">",
"      Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/3\">",
"      Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998; 227:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/4\">",
"      Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000; 232:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/5\">",
"      Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park) 2004; 18:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/6\">",
"      Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003; 238:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/7\">",
"      Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/8\">",
"      Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 2000; 7:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/9\">",
"      Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/10\">",
"      Laurent A, Tayar C, Cherqui D. Cholangiocarcinoma: preoperative biliary drainage (Con). HPB (Oxford) 2008; 10:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/11\">",
"      Nimura Y. Preoperative biliary drainage before resection for cholangiocarcinoma (Pro). HPB (Oxford) 2008; 10:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/12\">",
"      Heslin MJ, Brooks AD, Hochwald SN, et al. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. Arch Surg 1998; 133:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/13\">",
"      Motte S, Deviere J, Dumonceau JM, et al. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology 1991; 101:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/14\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 2000; 4:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/15\">",
"      Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985; 201:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/16\">",
"      Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994; 81:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/17\">",
"      Cherqui D, Benoist S, Malassagne B, et al. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 2000; 135:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/18\">",
"      Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/19\">",
"      Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/20\">",
"      Kloek JJ, van der Gaag NA, Aziz Y, et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg 2010; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/21\">",
"      Hodul P, Creech S, Pickleman J, Aranha GV. The effect of preoperative biliary stenting on postoperative complications after pancreaticoduodenectomy. Am J Surg 2003; 186:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/22\">",
"      Madoff DC, Hicks ME, Abdalla EK, et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness--study in 26 patients. Radiology 2003; 227:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/23\">",
"      Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/24\">",
"      Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/25\">",
"      Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/26\">",
"      Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/27\">",
"      Di Stefano DR, de Baere T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005; 234:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/28\">",
"      Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993; 128:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/29\">",
"      Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg 1996; 83:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/30\">",
"      Lieser MJ, Barry MK, Rowland C, et al. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998; 5:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/31\">",
"      Valverde A, Bonhomme N, Farges O, et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/32\">",
"      Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998; 187:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/33\">",
"      Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990; 159:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/34\">",
"      Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/35\">",
"      Nagino M, Nimura Y, Kamiya J, et al. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998; 45:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/36\">",
"      Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/37\">",
"      Hadjis NS, Blenkharn JI, Alexander N, et al. Outcome of radical surgery in hilar cholangiocarcinoma. Surgery 1990; 107:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/38\">",
"      Pichlmayr R, Weimann A, Klempnauer J, et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/39\">",
"      Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230:663.",
"     </a>",
"    </li>",
"    <li>",
"     Adams RB, Beecherl E, Taylor BR, et al. Proximal cholangiocarcinoma: More extensive resection is associated with improved survival. Data presented at the 86th Annual Clinical Congress of the American College of Surgeons, Chicago IL, Oct, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/41\">",
"      Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997; 15:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/42\">",
"      Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004; 139:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/43\">",
"      Tamandl D, Kaczirek K, Gruenberger B, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009; 96:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/44\">",
"      Wakai T, Shirai Y, Moroda T, et al. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005; 103:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/45\">",
"      Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J Hepatobiliary Pancreat Surg 2000; 7:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/46\">",
"      Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002; 132:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/47\">",
"      Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/48\">",
"      Shirabe K, Mano Y, Taketomi A, et al. Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol 2010; 17:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/49\">",
"      Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/50\">",
"      Kaya M, de Groen PC, Angulo P, et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol 2001; 96:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/51\">",
"      Nakayama F, Miyazaki K, Nagafuchi K. Radical surgery for middle and distal thirds bile duct cancer. World J Surg 1988; 12:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/52\">",
"      Bortolasi L, Burgart LJ, Tsiotos GG, et al. Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 2000; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/53\">",
"      DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/54\">",
"      Murakami Y, Uemura K, Hayashidani Y, et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg 2007; 31:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/55\">",
"      Cheng Q, Luo X, Zhang B, et al. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol 2007; 14:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/56\">",
"      Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002; 137:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/57\">",
"      Hong SM, Pawlik TM, Cho H, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009; 146:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/58\">",
"      Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg 2010; 251:675.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/60\">",
"      Sasaki A, Aramaki M, Kawano K, et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br J Surg 1998; 85:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/61\">",
"      Puhalla H, Schuell B, Pokorny H, et al. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005; 189:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/62\">",
"      Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/63\">",
"      Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/64\">",
"      Paik KY, Jung JC, Heo JS, et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008; 23:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/65\">",
"      Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/66\">",
"      Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/67\">",
"      Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006; 41:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/68\">",
"      Jan YY, Yeh CN, Yeh TS, et al. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005; 29:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/69\">",
"      Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/70\">",
"      Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 2008; 207:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/71\">",
"      Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92:2374.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/73\">",
"      Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/74\">",
"      Nimura Y, Kamiya J, Nagino M, et al. Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 1998; 5:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/75\">",
"      Miyazaki M, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery 1998; 123:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/76\">",
"      Iida S, Tsuzuki T, Ogata Y, et al. The long-term survival of patients with carcinoma of the main hepatic duct junction. Cancer 1987; 60:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/77\">",
"      Langer JC, Langer B, Taylor BR, et al. Carcinoma of the extrahepatic bile ducts: results of an aggressive surgical approach. Surgery 1985; 98:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/78\">",
"      Fortner JG, Vitelli CE, Maclean BJ. Proximal extrahepatic bile duct tumors. Analysis of a series of 52 consecutive patients treated over a period of 13 years. Arch Surg 1989; 124:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/79\">",
"      Klempnauer J, Ridder GJ, Werner M, et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997; 79:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/80\">",
"      Johnson SR, Kelly BS, Pennington LJ, Hanto DW. A single center experience with extrahepatic cholangiocarcinomas. Surgery 2001; 130:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/81\">",
"      Neuhaus P, Thelen A, Jonas S, et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 2012; 19:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/82\">",
"      Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/83\">",
"      Matsuo K, Rocha FG, Ito K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012; 215:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/84\">",
"      Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 2000; 7:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/85\">",
"      Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012; 147:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/86\">",
"      Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 2007; 31:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/87\">",
"      Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/88\">",
"      Hawkins WG, DeMatteo RP, Cohen MS, et al. Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg 2005; 200:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/89\">",
"      Kelley ST, Bloomston M, Serafini F, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004; 70:743.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/91\">",
"      Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/92\">",
"      Kraybill WG, Lee H, Picus J, et al. Multidisciplinary treatment of biliary tract cancers. J Surg Oncol 1994; 55:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/93\">",
"      Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000; 46:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/94\">",
"      Gonz&aacute;lez Gonz&aacute;lez D, Gouma DJ, Rauws EA, et al. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 1999; 10 Suppl 4:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/95\">",
"      Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995; 221:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/96\">",
"      Vern-Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys 2011; 81:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/97\">",
"      Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008; 15:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/98\">",
"      Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002; 54:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/99\">",
"      Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007; 68:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/100\">",
"      Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009; 73:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/101\">",
"      Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/102\">",
"      Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 2009; 13:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/103\">",
"      Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000; 47:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/104\">",
"      Yubin L, Chihua F, Zhixiang J, et al. Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol 2008; 15:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/105\">",
"      Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009; 250:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/106\">",
"      Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/107\">",
"      Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/108\">",
"      Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30:1934.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/results?term=00363584 (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/results?term=01313377 (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/111\">",
"      Eckel F, Jelic S, ESMO Guidelines Working Group. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/112\">",
"      McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/113\">",
"      Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/114\">",
"      Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/115\">",
"      Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/116\">",
"      Brandsaeter B, Isoniemi H, Broom&eacute; U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/117\">",
"      Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993; 166:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/118\">",
"      Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/119\">",
"      Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/120\">",
"      Nashan B, Schlitt HJ, Tusch G, et al. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology 1996; 23:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/121\">",
"      Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/122\">",
"      Robles R, Mar&iacute;n C, Pastor P, et al. Liver transplantation for Klatskin's tumor: contraindicated, palliative, or indicated? Transplant Proc 2007; 39:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/123\">",
"      Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/124\">",
"      Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/125\">",
"      Panjala C, Nguyen JH, Al-Hajjaj AN, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl 2012; 18:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/126\">",
"      Becker NS, Rodriguez JA, Barshes NR, et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/127\">",
"      Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143:88.",
"     </a>",
"    </li>",
"    <li>",
"     Beavers KL, Bonis PAL, Lau J. Liver transplantation for patients with hepatobiliary malignancies other than hepatocellular carcinoma. Available online at www.cms.hhs.gov/mcd/viewtechassess.asp?id=47 (Accessed on May 18, 2011).",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on February 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/33/25114/abstract/130\">",
"      Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2467 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25114=[""].join("\n");
var outline_f24_33_25114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL MANAGEMENT FOR CURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Criteria for resectability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Preoperative biliary decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Preoperative portal vein embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical treatment and outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Distal cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Intrahepatic cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Perihilar cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary and guidelines from expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEOADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ORTHOTOPIC LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Organ allocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2467|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/12/19651\" title=\"figure 1\">",
"      Anatomic classification biliary cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/8/29824\" title=\"figure 2\">",
"      SEER surv intrahep cholang",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/9/43166\" title=\"figure 3\">",
"      Nomogram for survival intrahepatic cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/36/582\" title=\"figure 4\">",
"      Bismuth-Corlette classification of biliary tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/39/44668\" title=\"table 1\">",
"      TNM distal cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/62/44012\" title=\"table 2\">",
"      TNM intrahep cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/11/4285\" title=\"table 3\">",
"      TNM perihilar cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/48/17164\" title=\"table 4\">",
"      Surgery hilar cholangioCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/2/26669\" title=\"table 5\">",
"      Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=related_link\">",
"      Ampullary carcinoma: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21978?source=related_link\">",
"      Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=related_link\">",
"      Treatment protocols for hepatobiliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_33_25115="Circadian rhythm disorders PI";
var content_f24_33_25115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Circadian rhythm disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Circadian rhythms are changes in body functions, such as temperature regulation and sleep cycles, which occur during a 24-hour period. People with circadian rhythm disorders may experience insomnia and daytime sleepiness because their circadian rhythms follow an abnormal pattern.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Shift work sleep disorder",
"        </strong>",
"        - People who work late night shifts can have difficulty sleeping during the daytime. This is especially true for people who work rotating or permanent night shifts, who often revert to sleeping at night on days off to maintain contact with their family. Treatment often includes adopting a consistent daily sleep routine seven days per week.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Delayed sleep phase syndrome",
"        </strong>",
"        - Some people have a sleep-wake rhythm that is longer than 24 hours. These people want to go to bed at a later time and sleep later every morning. However, this is usually not practical because of school or work requirements. Treatment usually includes trying to wake at an earlier, consistent time each day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Advanced sleep phase syndrome",
"        </strong>",
"        - This is the opposite of delayed sleep phase syndrome, and is more common in middle age and elderly adults. A person with this disorder may go to sleep in the early evening and wake much earlier than they wish. Attempts to stay up later do not always allow the person to wake later in the morning. Sleep can be normal if the person is willing to accept the early bedtime and wake time.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25115=[""].join("\n");
var outline_f24_33_25115=null;
var title_f24_33_25116="Acupuncture adverse events";
var content_f24_33_25116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adverse events that have been associated with acupuncture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Serious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac trauma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocarditis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"            <sup>",
"             &bull;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumothorax",
"            <sup>",
"             &Delta;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal injury*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septicemia*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal cord injury*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Potentially serious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bleeding, ~3 percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drowsiness, ~1 percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Perichondritis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peripheral nerve damage*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retained needle*",
"            <sup>",
"             &loz;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syncope*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Non-serious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Contact dermatitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Local pain, ~1 percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aggravation of presenting symptom",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Incidence rates are probably low (percent figures refer to incidence rates where known).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     About 200 cases reported in literature.",
"     <br/>",
"     &Delta; About 100 cases reported in literature.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     More common with Japanese-style acupuncture.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25116=[""].join("\n");
var outline_f24_33_25116=null;
var title_f24_33_25117="Noninfectious mimics of pediatric pneumonia";
var content_f24_33_25117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninfectious condititions that can mimic pneumonia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anatomical considerations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prominent thymus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breast shadows",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchogenic cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vascular ring",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary sequestration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital lobar emphysema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atelectasis (due to a foreign body or mucus plug)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Aspiration of gastric contents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroesophageal reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tracheoesophageal fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cleft palate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuromuscular disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Chronic pulmonary disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asthma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchiectasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchopulmonary dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alpha1-antitrypsin deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary hemosiderosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alveolar proteinosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Desquamative interstitial pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histiocytosis X",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs and chemical exposures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrofurantoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bleomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytotoxic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Smoke inhalation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lipoid pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vasculitic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Others",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypersensitivity pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neoplasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary edema due to heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute respiratory distress syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graft-versus-host disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poor inspiratory film",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Near drowning event",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Underpenetrated film",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Klein JO. Bacterial pneumonias. In: Textbook of Pediatric Infectious Diseases, 5th ed, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004. p.299.",
"       </li>",
"       <li>",
"        McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"       </li>",
"       <li>",
"        Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.",
"       </li>",
"       <li>",
"        Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, 5th ed, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004. p.286.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25117=[""].join("\n");
var outline_f24_33_25117=null;
var title_f24_33_25118="Survival by histology";
var content_f24_33_25118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57100%7EONC%2F66398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57100%7EONC%2F66398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival of paranasal sinus cancer according to tumor site and histologic type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tumor site",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Ethmoid sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       PNS",
"       <sup>",
"        [3]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Characteristic",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 399)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 650)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 305)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       N (n = 650)",
"      </td>",
"      <td class=\"subtitle2_left\">",
"       5-year OS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"9\">",
"       Histology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Adenocarcinoma",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       53.8",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       47.7",
"      </td>",
"      <td>",
"       153",
"      </td>",
"      <td>",
"       43.6",
"      </td>",
"      <td>",
"       107",
"      </td>",
"      <td>",
"       44.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Esthesioneuroblastoma",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       81.7",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Adenoid cystic carcinoma",
"      </td>",
"      <td>",
"       91",
"      </td>",
"      <td>",
"       53.1",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       57.5",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       64.1",
"      </td>",
"      <td>",
"       32*",
"      </td>",
"      <td>",
"       65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Melanoma",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       25.9",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Sarcoma",
"      </td>",
"      <td>",
"       59",
"      </td>",
"      <td>",
"       48.7",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       44.8",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       18&bull;",
"      </td>",
"      <td>",
"       46.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Squamous cell carcinoma",
"      </td>",
"      <td>",
"       156",
"      </td>",
"      <td>",
"       45.2",
"      </td>",
"      <td>",
"       401",
"      </td>",
"      <td>",
"       29.2",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       18.7",
"      </td>",
"      <td>",
"       101",
"      </td>",
"      <td>",
"       43",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Undifferentiated carcinoma",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       30.5",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       14",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Mucoepidermoid carcinoma",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       61.9",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       35.9",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Other",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       35.8",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       38.7",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       32.1",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       92.3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: number of patients; NA: not available; NE: not estimated; OS: overall survival; PNS: paranasal sinuses (including maxillary, ethmoid, sphenoid, and frontal sinuses; esthesioneuroblastoma excluded).",
"     <br>",
"      * Minor salivary malignancies, including adenoid cystic carcinoma.",
"      <br>",
"       &bull; High-grade sarcomas only.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Cantu, G, et al. Arch Otolaryngol Head Neck Surg 2008; 134:170.",
"      <br>",
"       2. Bhattacharyya, N. J Oral Maxillofac Surg 2003; 61:1016.",
"       <br>",
"        3. Ganly, I, et al. Head Neck 2005; 27:575.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival of paranasal sinus cancer according to tumor site and T and N stage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tumor site",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Maxillary sinus",
"       <sup>",
"        [2]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Ethmoid sinus",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Characteristic",
"      </td>",
"      <td class=\"subtitle2\">",
"       N (n = 399)",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2\">",
"       N (n = 650)",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year OS",
"      </td>",
"      <td class=\"subtitle2\">",
"       N (n = 704)",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year OS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"7\">",
"       AJCC-UICC 2002 classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T1",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       51.6",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       53.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T2",
"      </td>",
"      <td>",
"       156",
"      </td>",
"      <td>",
"       61.7",
"      </td>",
"      <td>",
"       63",
"      </td>",
"      <td>",
"       41.8",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       60.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T3",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       50.5",
"      </td>",
"      <td>",
"       169",
"      </td>",
"      <td>",
"       39.8",
"      </td>",
"      <td>",
"       85",
"      </td>",
"      <td>",
"       48.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       T4a/b",
"      </td>",
"      <td>",
"       206",
"      </td>",
"      <td>",
"       35.9",
"      </td>",
"      <td>",
"       335",
"      </td>",
"      <td>",
"       28.9",
"      </td>",
"      <td>",
"       147",
"      </td>",
"      <td>",
"       35.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Not assigned",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"7\">",
"       Nodal status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N0",
"      </td>",
"      <td>",
"       366",
"      </td>",
"      <td>",
"       50.6",
"      </td>",
"      <td>",
"       323",
"      </td>",
"      <td>",
"       40.1",
"      </td>",
"      <td>",
"       300",
"      </td>",
"      <td>",
"       45.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N+",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       16.8",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N1",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       35.7",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N2",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       N3",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Not assigned",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       279",
"      </td>",
"      <td>",
"       NE",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N: number of patients; NE: not estimated; OS: overall survival; PNS: paranasal sinuses (including maxillary, ethmoid, sphenoid, and frontal sinuses; esthesioneuroblastoma excluded).",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Cantu, G, et al. Arch Otolaryngol Head Neck Surg 2008; 134:170.",
"      <br>",
"       2. Bhattacharyya, N. J Oral Maxillofac Surg 2003; 61:1016.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_33_25118=[""].join("\n");
var outline_f24_33_25118=null;
var title_f24_33_25119="Contents: Hospital nephrology";
var content_f24_33_25119=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital nephrology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital nephrology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29589\">",
"           Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31432\">",
"           Approach to the adult with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36570\">",
"           Assessment of kidney function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40646\">",
"           Bicarbonate therapy in lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35190\">",
"           Calculation of the creatinine clearance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33882\">",
"           Causes and evaluation of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13220\">",
"           Causes and treatment of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5402\">",
"           Causes of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/41/15000\">",
"           Causes of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/30/3562\">",
"           Causes of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15767\">",
"           Causes of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/44/3781\">",
"           Causes of lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/22/8551\">",
"           Causes of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21545\">",
"           Clinical manifestations and causes of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/43/27318\">",
"           Clinical manifestations and diagnosis of analgesic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/38/25190\">",
"           Diagnosis of urinary tract obstruction and hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39479\">",
"           Clinical manifestations and evaluation of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/2/9258\">",
"           Clinical manifestations and treatment of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44069\">",
"           Clinical manifestations of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/44/32451\">",
"           Complications of mannitol therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38516\">",
"           Continuous renal replacement therapies: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/40/28295\">",
"           Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42773\">",
"           Definition of acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2167\">",
"           Diagnosis and treatment of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24312\">",
"           Diagnosis of polyuria and diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35785\">",
"           Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27130\">",
"           Differential diagnosis and evaluation of glomerular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39332\">",
"           Electrolyte disturbances with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38260\">",
"           Estimation of the sodium deficit in patients with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/54/12138\">",
"           Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36857\">",
"           Etiology and evaluation of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24457\">",
"           Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/63/11254\">",
"           Evaluation and treatment of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11288\">",
"           Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9366\">",
"           Evaluation of the patient with hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21832\">",
"           Evaluation of the patient with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6613\">",
"           Alcoholic and fasting ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/1/34839\">",
"           Investigational biomarkers and the evaluation of acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/48/40710\">",
"           Loop diuretics: Maximum effective dose and major side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32966\">",
"           Major side effects and safety of calcium channel blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18473\">",
"           Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28246\">",
"           Management of severe asymptomatic hypertension (hypertensive urgencies)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27079\">",
"           Management of ureteral calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20215\">",
"           Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/58/23464\">",
"           Manifestations of hyponatremia and hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31082\">",
"           Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/28/2501\">",
"           Nonoliguric versus oliguric acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/57/38803\">",
"           NSAIDs: Electrolyte complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13527\">",
"           Overview of the causes and treatment of hyperphosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4170\">",
"           Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18072\">",
"           Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10457\">",
"           Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/34/36393\">",
"           Pathophysiology and etiology of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33046\">",
"           Perioperative management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/10/42154\">",
"           Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35498\">",
"           Prevention of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4553\">",
"           Renal and patient outcomes after acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36533\">",
"           Serum anion gap in conditions other than metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/57/32659\">",
"           Signs and symptoms of hypophosphatemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42580\">",
"           Signs and symptoms of magnesium depletion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32914\">",
"           Symptoms of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/1/21526\">",
"           The anion gap/HCO3 ratio in patients with a high anion gap metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/54/17258\">",
"           Treatment and prevention of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/52/24393\">",
"           Treatment of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21210\">",
"           Treatment of hypertension in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17306\">",
"           Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14568\">",
"           Treatment of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35256\">",
"           Treatment of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36456\">",
"           Urine output and residual renal function in renal failure",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-40F6A26D80-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f24_33_25119=[""].join("\n");
var outline_f24_33_25119=null;
